AU2000276225B2

AU2000276225B2 - High affinity small molecule C5A receptor modulators

Info

Publication number: AU2000276225B2
Application number: AU2000276225A
Authority: AU
Inventors: Xia-Shu He; George Maynard; Robert Ohliger; John Peterson; Andrew Thurkauf; Xiaoyan Zhang; He Zhao
Original assignee: Neurogen Corp
Current assignee: Neurogen Corp
Priority date: 1999-09-28
Filing date: 2000-09-29
Publication date: 2008-07-10
Anticipated expiration: 2020-09-29

Description

WO 02/49993 PCT/US00/26816 Title: HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS

BACKGROUND

Field of the Invention This invention relates to low molecular weight, non-peptidic, nonpeptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a recptor ligands. The invention also relates to such ligands that act as antagonists (including inverse agonists) of complement C5a receptors, preferably human C5a receptors.

This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

Background of the Invention a 74 amino acid peptide, is generated in the complement cascade by the cleavage of the complement protein C5 by the complement C5 convertase enzyme.

has both anaphylatoxic bronchoconstricting and vascular spasmogenic) and chemotactic effects. Therefore, it is active in engendering both the vascular and cellular phases of inflammatory responses. Because it is a plasma protein and, therefore, generally almost instantly available at a site of an inciting stimulus, it is a key mediator in terms of initiating the complex series of events that results in augmentation and amplification of an initial inflammatory stimulus. The anaphylatoxic and chemotactic effects of the C5a peptide are believed to be mediated through its interation with the C5a receptor (CD88 antigen), a 52 kD membrane bound G-protein coupled receptor (GPCR). C5a is a potent chemoattractant for polymorphonuclear leukocytes, bringing neutrophils, basophils, eosinophils and monocytes to sites of inflammation and/or cellular injury. C5a is one of the most potent chemotactic agents known for a wide variety of inflammatory cell types. C5a also "primes" or prepares neutrophils for various antibacterial functions, phagocytosis.

Additionally, C5a stimulates the release of inflammatory mediators histamines, TNF-a, IL-1, IL-6, IL-8, protaglandines, and leukotrienes) and the release of lysosomal enzymes and other cytotoxic components from granulocytes. Among its other actions, C5a also promotes the production of activated oxygen radicals and the contraction of smooth muscle.

Considerable experimental evidence implicates increased levels of C5a in a number of autoimmune diseases and inflammatory and related disorders.

Antagonists that block the binding of C5a to its receptor or other agents, including inverse agonists, which modulate signal transduction associated with interactions, can inhibit the pathogenic events, including chemotaxis, associated with anaphylatoxin activity contributing to such inflammatory and autoimmune conditions. Despite many attempts, no one has previously been able to provide any small molecule (less than 700 Daltons MW, or amu) non-peptide, non-peptidomimetic, non-peptoid, C5a antagonist that is essentially free of agonist activity at the C5a receptor and that exhibits a binding affinity for the C5a receptor of less than 1 micromolar, and preferably less than 100 nanomolar.

Description of Related Art Certain modified C5a peptides modifications of C5a) have been identified as partial C5a antagonists and have been shown to block a number of C5a mediated actions including neutrophil chemotaxis, neutropenia and superoxide formation. Various peptidomimetic compounds have also been reported as modulating C5a activity, including cyclic peptoids (a peptoid is a peptidomimetic compound comprising an oligoferic assemblage of naturally occurring amino acids that have been N-substituted). Typically these C5a modulatory compounds exhibit a molecular weight greater than 500 Daltons. and generally greater than 700 Daltons.

Definition In the specification the term "comprising" shall be understood to have a broad meaning similar to the term "including" and will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. This definition also applies to variations on the term "comprising" such as "comprise" and "comprises".

WO 02/49993 PCT/US00/26816 SUMMARY OF THE INVENTION The present invention provides novel compounds that are small molecule receptor antagonists that are non-peptide, non-peptidomimetic, and are preferably free of C5a receptor agonist activity, which compounds exhibit high affinity for the C5a receptor, an affinity constant for binding to the C5a receptor of less than 1 micromolar. Highly preferred compounds exhibit very high affinity for the C5a receptor, an affinity constant for binding to the C5a receptor of less than 100 nanomolar. Preferred compounds are C5a receptor antagonists (including inverse agonists). Preferred antagonists exhibit an antagonist ECso (which as usd herein includes ICso) of less than 1 micromolar, preferably less than 100 nanomolar, in an assay of C5a mediated chemotaxis. Preferred C5a receptors are mammalian, preferably primate receptors, including human C5a receptors, and may either be cloned, recombinantly expressed receptors or naturally expressed receptors. In certain preferred embodiments, compounds of the invention exhibit an affinity for human C5a receptors that is higher than for rodent C5a receptors, preferably at least five times higher, more preferably ten times higher.

The compounds of the present invention do not interact with dopamine receptors with even moderate affinity, they do not bind to dopamine receptors with Ki values of less than 100 micromolar. Preferred compounds of the invention do not bind to any naturally occurring receptors other than C5a receptors with high affinity, and preferably they do not bind to any naturally occurring receptors other than C5a receptors with even moderate affinity.

In certain embodiments these compounds also possess one or more, and preferably two or more, three or more, four or more, or all of the following properties in that they are: 1) multi-aryl in structure (having a plurality of un-fused or fused aryl groups), 2) heteroaryl in structure, 3) orally available in vivo (such that a sublethal or preferably a pharmaceutically acceptable oral dose can provide a detectable in vivo effect such as a reduction of C5a-induced neutropenia), 4) comprised of fewer than four, preferably fewer than three, or fewer than two, or no amide bonds, and WO 02/49993 PCT/US00/26816 capable of inhibiting leukocyte chemotaxis at nanomolar concentrations and preferably at sub-nanomolar concentrations.

In a highly preferred aspect, the invention provides non-peptidic, nonpeptidomimetic, low molecular weight compounds that act as high affinity antagonists of the human C5a receptor. Specifically exemplified representative compounds include, but are not limited to optionally substituted arylimidazoles (i.e.

imidazoles having one or more ring substituents of optionally substituted carbocyclic aryl or optionally substituted heteroaryl), optionally substituted arylpyridyls (i.e.pyridyls having one or more ring substituents of optionally substituted carbocyclic aryl or optionally substituted heteroaryl), optionally substituted aryl-substituted cycloalkylimidazoles (i.e.cycloalkylimidazoles having one or more ring substituents of optionally substituted carbocyclic aryl or optionally substituted heteroaryl), optionally substituted arylpyrazoles (i.e.pyrazoles having one or more ring substituents of optionally substituted carbocyclic aryl or optionally substituted heteroaryl), optionally substituted benzimidazoles, optionally substituted aryl-substituted tetrahydroisoquinolines (i.e.tetrahydroisoquinolines having one or more ring substituents of optionally substituted carbocyclic aryl or optionally substituted heteroaryl), and optionally substituted biaryl carboxamides a carboxamide that has one or more optionally substituted bi-carboxylic aryl or heteroaryl substituents). Novel intermediates useful for synthesizing compounds of the invention are also provided.

Preferred compounds of the invention are compounds of Formula I, shown below, that bind specifically, and preferably with high affinity, to C5a receptors.

The invention also provides pharmaceutical compositions comprising compounds of the invention, including those of Formula I, including otppinally substituted arylimidazoles, optionally substituted arylpyridyls, optionally substituted aryl-substituted cycloalkylimidazoles, optionally substituted arylpyrazoles, optionally substituted benzimidazoles, optionally substituted arylsubstituted tetrahydroisoquinolines, and optionally substituted biaryl carboxamides.

The C5a receptor antagonist compounds described herein are particularly useful in WO 02/49993 PCT/US00/26816 the treatment of C5a-mediated inflammation, inflammation associated with various inflammatory and immune system disorders. The invention further comprises a method of treating a patient in need of such anti-inflammatory treatment or immune treatment an effective amount of a compound of the invention, e.g. an amount of a compound of the invention sufficient to yield a plasma concentration of the compound (or its active metabolite, if a pro-drug) high enough to inhibit white blood cell neutrophil) chemotaxis in vitro. Treatment of humans, domesticated companion animals (pets) or livestock animals suffering such conditions with an effective amount of a compound of the invention is contemplated by the invention. For treating non-human animals of any particular species, a compound exhibiting high affinity for the C5a receptor of that particular species is preferred.

In a separate aspect, the invention provides methods of using compounds of the invention as positive controls in assays for receptor activity and using appropriately labeled compounds of the invention as probes for the localization of receptors, particularly C5a receptors, in tissue sections via autoradiography) or in vivo via positron emission tomography, PET, or single positron emission computed tomography, SPECT, scanning and imaging).

The invention provides compounds and compositions that are useful as inhibitors of C5a-mediated chemotaxis they may be used as standards in assays of such chemotaxis). The invention additionally comprises methods of inhibiting C5a-mediated cellular chemotaxis, preferably leukocyte neutrophil) chemotaxis. These methods comprise contacting white blood cells, particularly primate white blood cells, especially human white blood cells, with one or more compounds of the invention. Preferably the concentration is sufficient to inhibit chemotaxis of white blood cells in an in vitro chemotaxis assay, so that the levels of chemotaxis observed in a control assay one to which a compound of the invention has not been added) are significantly higher (significantly here measured as p:O.05 using a conventional parametric statistical analysis method such as a WO 02/49993 PCT/US00/26816 student's T-test) than the levels observed in an assay to which a compound of the invention has been added.

Accordingly, a broad aspect of the invention is directed to non-peptidic organic (carbon-containing) molecules, having a molecular mass of less than 700 amu, that exhibit C5a antagonist activity or C5a inverse agonist activity with an ECso of less than 500 nM in an assay of C5a mediated leukocyte chemotaxis.

More particularly the invention includes compounds of Formula I,

A

AR1 AR2

LIP

Formula I wherein: AR1 and AR2 are independently carbocyclic aryl or heteroaryl; LIP represents an alkyl, carbocyclic aryl, heteroaryl, or arylalkyl; A is oxygen or nitrogen; di represents the distance between A and the geometric center of AR1 and is between 3 and 6 angstroms in at least one energetically accessible conformer of the compound; d 2 represents the distance between A and the geometric center of AR2 and is between 5 and 10 angstroms in at least one energetically accessible conformer of the compound; and d 3 represents the distance between A and the nearest atom of LIP and is between 3 and 6 angstroms in at least one energetically accessible conformer of the compound. Preferred compounds of Formula I exhibit antagonist (including inverse agonist) activity at C5a Receptors, and essentially no or little agonist activity at this receptor. Preferably such compounds contain one or more heteroaryl rings.

Preferred compounds of the invention exhibit good activity in standard in vitro C5 receptor mediated chemotaxis assay, specifically the assay as specified in WO 02/49993 PCT/US00/26816 Example 12, which follows and is defined below. Alternative preferred assays include the calcium mobilization assay. Preferred compounds of the invention exhibit an ECso of about 500 nM or less in such a standard C5a mediated chemotaxis assay, more preferably an ECso of about 200 nM or less in such a standard C5a mediated chemotaxis assay, still more preferably an ECso of about 100, 50, 25 and 10 nM in such a standard C5a mediated chemotaxis assay, even more preferably an ECso of about 5 nM in such a standard C5a mediated chemotaxis assay.

The invention includes additional methods such as methods for localizing recerptors in tissue section samples, comprising cotacting a tissue sample with detectably labelled one or more compounds of the invention that are preferably detectably labeled, optionally washing the contacted tissue sample, and detecting the bound compound associated with the tissue sample. Suitable detectable labels include e.g.1251, tritium, 32P, 99Tc or the like. A variety of detection methods could be employed include single emission photono computed tomography ("SPECT").

Other aspects of the invention are discussed infra.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is the sequence of SEQ ID NO-1.

DETAILED DESCRIPTION OF THE INVENTION Preferred compounds of the invention include carbon-containing molecules that comprise: i) having a molecular mass of less than 700 amu; ii) that is nonpeptidic; iii) that exhibits C5a antagonist activity or C5a inverse agonist activity with an EC 5 o of less than 500 nM in an assay of C5a mediated leukocyte chemotaxis; and iv) exhibits less than 10% intrinsic agonist activity in an assay of leukocyte chemotaxis.

WO 02/49993 PCT/US00/26816 Among such compounds, particularly preferred are those that contain one or more heteroaryl and/or carbocyclic rings. For example, preferred are compounds of the following formula:

A

d l \d2 AR1 AR2

LIP

AR1 and AR2 are independently optionally substituted carbocyclic aryl or optionally substituted heteroaryl; LIP represents an optionally substituted alkyl, optionally substituted carbocyclic aryl, optionally substituted heteroaryl, or optionally substituted arylalkyl; A is oxygen or nitrogen; di represents the distance between A and the geometric center of AR1 and is between 3 and 6 angstroms in at least one energetically accessible conformer of the compound; d 2 represents the distance between A and the geometric center of AR2 and is between 5 and 10 angstroms in at least one energetically accessible conformer of the compound; and da represents the distance between A and the nearest atom of LIP and is between 3 and 6 angstroms in at least one energetically accessible conformer of the compound.

Preferred compounds of the invention also include heterocycles of the following formula II

II

R,

R R S n R R6 -R 4 Ar" X- Y

R

2

R

3 R3A Ar 2 WO 02/49993 PCT/US00/26816 or a pharmaceutically acceptable salt thereof, wherein the compound exhibits an

EC

5 o of luM or less in an assay of C5a mediated chemotaxis, wherein: the ring system represented by N )n is a 5 to 7 membered heterocycle that may be either aromatic or partially unsaturated; X is N, C, or CR 7 wherein R 7 is hydrogen, hydroxy, halogen, amino, cyano, nitro, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted (cycloalkyl)alkyl; Y is N or CH; n is 0, 1, or 2; m is 0, 1, or 2; R and R 1 are independently chosen from hydrogen, hydroxy, halogen, amino, cyano, nitro, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms;

R

2

R

a R3A, Rs, and R 6 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, optionally substituted haloalkyl, optionally substituted alkoxy, optionally substituted mono- or dialkylamino, optionally substituted WO 02/49993 PCT/US00/26816 alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl)alkyl; When n is 0, R 1 and Rs may be joined to form a cycloalkyl or heterocycloalkyl ring, each of which may be optionally substituted; When n is 1, R and R 3 may be joined to form a cycloalkyl or heterocycloalkyl ring, each of which may be optionally substituted;

R

4 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl each of which may be optionally substituted; or

R

4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Arl and Ar 2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Preferred compounds of the above Formula II include those compounds wherein: R and R 1 are independendently selected from i) hydrogen, halogen, hydroxy, amino, alkoxy, mono- or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl)alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or dialkylamino, iii) phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, WO 02/49993 PCT/USOO/26816 nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino;

R

2

R

3 RSA, R5, and R 6 are independently selected from i) hydrogen, halogen, hydroxy, amino, alkoxy, mono- or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cyeloalkyl)alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or dialkylamino;

R

7 is hydrogen, hydroxy, halogen, amino, cyano, nitro, or haloalkyl, or

R

7 is alkoxy, mono- or dialkylamino, alkyl, alkenyl, alkynyl or (cycloalkyl)alkyl, each of which may be unsubstitutod or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or dialkylamino; When n is 0, R 1 and R 3 may be joined to form a cycloalkyl or heterocycloalkyl ring, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono- or dialkylamino; When n is 1, R and R 3 may be joined to form a cycloalkyl or heterocycloalkyl ring, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino;

R

4 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino; or WO 02/49993 PCT/USOO/26816

R

4 is phenyl? phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b~thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[dlisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono- or dialkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N-alkylsulfonylaminocarbonyl, 1-azetidinyl, 1 -pyrrolidinyl, and 1-piperidyl; or

R

4 is a bicyclic oxygen-containing group of the formula: 0-

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino; and Ar 1 and Ar 2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, beno[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl., quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono- or dialkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, WO 02/49993 PCT/USOO/26816 mono or dialkylaminocarbonyl, N-alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, and 1-piperidyl, and ii) bicyclic oxygen-containing groups of the formula: 0 N

SRB

wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino.

Additional preferred compounds of the above formula II include those wherein R and R, are independently selected from i) hydrogen, halogen, hydroxy, amino, CI-C 6 alkoxy, mono- or di(Ci-

C

6 )alkylamino, cyano, nitro, haloalkyl, and ii) C 1 -Cg alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 3 -CS cycloalkyl, and (C 3 C8)cycloalkyl) Cl-C 3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or di(Cl- C6)alkylamino, iii) phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyt, hydroxy, acetoxy, Ci-C 8 alkyl, C 2

-C

6 alkenyl, C2-C6 alkynyl, C 1 -Cr, alkoxy, amino, and mono- or di(C1-C6)alkylamino; When n is 0, Ri and R 3 may be joined to form a C 3 -C8 cycloalkyl or 3C heterocycloalkyl ring, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, WO 02/49993 PCT/USOO/26816 trifluoromethyl, trifluoromethoxy, haloalkyl, hyciroxy, acetoxy, C I-C 6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, Cl-C 6 alkoxy, amino, mono- or di(Cl-

C

6 alkylamino; When n is 1, R and R3 may be joined to form a C3-C 8 cycloalkyl or C3-C 8 heterocycloalkyl ring, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, Ci-Cr, alkoxy, amino, and mono- or di(Cl- Cs)alkyltamino;

R

2 R3, R3A, and R 6 are independently selected from i) hydrogen, halogen, hydroxy, amino, C 1

-C

6 alkoxy, mono- or di(Ci- C6)alkylamino, cyano, nitro, haloalkyl, and ii) Ci-C3 alkyl, C 2 -C6 alkenyl, C 2 -C6 alkynyl, Cs-Cs cycloalkyl, and (Cs-Cs cycloalkyl) Cl-C 3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkoxy, amino, mono- or di(Ci-

C

6 alylamino;

R

7 is hydrogen, hydroxy, halogen, amino, cyano, nitro, or haloalkyl,

R

7 is alkoxy, mono- or di(CI-C6)alkylaniino, Cl-C 6 alkyl, C 2 -Csalkenyl, C 2 -C6 alkynYl or (C3-Cscycloalyl) Ci-Osalkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkoxy, amino, and mono- or di(Cl-C 6 )alkylamino;

R

4 is Cl-Cg alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C3-Cg cycloalkyl, (Cs-Cs cycloalkyl)

C

1 -C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl,

C

2

-C

6 alkenyl, C 2 -C6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Ci- Cs)alkylamino; or WO 02/49993 PCT/USOO/26816

R

4 is phenyl, phenyl(C-C 4 )alkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C-C6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, CI-C 6 alkoxy, amino, mono- or di(Ci-C 6 )alklylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(CI-C6)alkylaminocarbonyl, Cl-C6)alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, and 1piperidyl; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1 -C6 alkoxy, amino, and mono- or di(Ci-

C

6 )alkylamino; and Ar 1 and Ar2 are independently chosen from phenyl, phenyl(Ci-C 4 )alkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, WO 02/49993 PCT/USOO/26816 hydroxy, acetoxy, CI-C 6 alkyl, C2-C6 alkenyl, C 2

-C

6 alkynyl, CI-C 6 alkoxy, amino, mono- or di(CI-C 6 )alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Ci-C 6 alkylaminocarbonyl, N- (C 1 C6)alkylsulfonylaminocarbonyl, 1-azetidinyl, 1 -pyrrolidinyl, and 1 -piperidyl; and ii) bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Ci- C6)alkylamino.

Still additional preferred compounds of the aboveformula II include those compounds of the following fomula: and additionally include those compounds of the following formula: Aj_ N K_ Ar Nr m is 0, 1, or 2;R 2 R Ar

R

1 i chosen from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, WO 02/49993 PCT/US00/26816 optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms;

R

2 Ra, R3A, Rs, and R 6 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl)alkyl;

R

4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Ar and Ar 2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Additional preferred compounds of the above formula II include those compounds of the following formula: R R4 Ar N N Ar 2 R2 R3 wherein:

R

1 is hydrogen, Ci-C7 alkyl, halogen or phenyl optionally substituted with C 1

-C

6 alkyl, C 1

-C

6 alkoxy, halogen, hydroxy, amino, or mono- or di(Ci-Cs)alkylamino; R2 is Ci-Cs alkyl or Cs-Cs cycloalkyl; and RS is hydrogen or C 1

-C

7 alkyl.

WO 02/49993 PCT/USOO/26816 Additional preferred compounds of the above formula II include those compounds of the following formula: R, R Ar<K NN_ Ar~ hnl hnllkl hey, Ar 2 Arlis henl, henlaRI, hieylimidazolyl, pyridyl, pyrimidyl, benizodioxinyl, benzodioxolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl,

C

2

-C

5 j alkenyl, C2-Cf, alkynyl, 0 1

-C

6 alkoxy, amino, mono- or di(Ci- C6)alkylamino; Ar2 is defined as in Claim 2;

R

1 is hydrogen, CI-C 7 alkyl, halogen or phenyl optionally substituted with CI-C 6 alkyl, Cl-C 6 alkoxy, halogen, hydroxy, amino, or mono- or di(Cl-C6)alkylamino;

R

2 is CI-C8 alkyl or C 3

-C

8 cycloalkyl; and

R

3 is hydrogen or 01-07 alkyl; and

R

4 is Cl-Cs alkyl, C 3 -Cg cycloalkyl, or (Cs-Cs cycloalkyl) Ci-C 3 alkyl, each of which may be unsubstit-uted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 ailkyl, C2-C6 alkenyl, 02-06 alkynyl, CI-CG alkoxy, amino, and mono- or di(Cl-Cr,)alkylamino.

Additional preferred compounds of the above formula 11 include those compounds of the following formula: RI R N K Ar<K N ;N Ar 2 WO 02/49993 PCT/US00/26816 wherein: Ar 1 is phenyl, phenylalkyl, thienyl, imidazolyl, pyridyl, pyrimidyl, benzodioxinyl, benzodioxolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(Ci- C6)alkylamino; Ar2 is defined as in Claim 4; Ri is hydrogen, Ca-C7 alkyl, halogen or phenyl optionally substituted with C-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, amino, or mono- or di(C1-C 6 )alkylamino;

R

2 is C1-Os alkyl or C3-Cs cycloalkyl; and

R

3 is hydrogen or C1-C7 alkyl; and R4 is phenyl, phenyl(C1-C4)alkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C 2 -Cs alkenyl, C2-Cs alkynyl, C1-Cs alkoxy, amino, mono- or di(Ci-C 6 )alkylamino; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, 0 1

-C

6 alkoxy, amino, and mono- or di(Ci- Cs)alkylamino.

WO 02/49993 PCT/US00/26816 Additional preferred compounds of the above formula II include those compounds of the following formula: R R4 NN Ar N Ar2 I Ar R2 R3 wherein: Anr is phenyl, phenylalkyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-C 6 alkyl, C 2

-C

6 alkenyl, C 2 -Cs alkynyl, CI-C6 alkoxy, amino, mono- or di(CI-C6)alkylamino; Ar2 is defined as in formula II;

R

1 is hydrogen, methyl, ethyl, or optionally substituted phenyl;

R

2 is C 3 -Cs alkyl or C 3 -Cs cycloalkyl; and R3 is hydrogen or methyl; and

R

4 is CI-Cs alkyl, C 3 -Cs cycloalkyl, or (C 3

-C

8 cycloalkyl) Ci-C 3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-C 6 alkyl, C 2

-C

6 alkenyl, C 2 -Cs alkynyl, C1-C 6 alkoxy, amino, and mono- or di(Ci-Cs)alkylamino.

Additional preferred compounds of the above formula II include those of the following formula: R R4 N\

N

ArK Nr I R Ar 2 R Rwherein: wherein: WO 02/49993 PCT/US00/26816 Ar is phenyl, phenylalkyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C 6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(C1-C 6 )alkylamino; Ar 2 is defined as in Claim 4;

R

1 is hydrogen, methyl, ethyl, or phenyl;

R

2 is C 3 -Cs alkyl or C 3 -Cs cycloalkyl; and

R

3 is hydrogen or methyl; and

R

4 is phenyl, phenyl(Cl-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2 -Cs alkenyl, C 2

C

6 alkynyl, C1-C 6 alkoxy, amino, mono- or di(C1-Cs)alkylamino; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

-C

6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1

-C

6 alkoxy, amino, and mono- or di(C1- Cs)alkylamino.

Still additional preferred compounds of the above formula Ii include of the following formula: WO 02/49993 WO 0249993PCT/USOO/26816 Ar( 4 jl

N

RN\ 3 Ar 2 wherein: Ar 1 is phenyl, phenylalkyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-06 all, 02-06 alkenyl, C 2 -CCi alkynYl, 01-06 alkoxy) amino, mono- or di(Ci -Cf)alkylamino; Ar 2 is chosen from phenyl, phenyl(CI-0 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[djisoxazolyl, quinolinyl, isoquinolinyl, and quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, 02-06, alkenyl, 02- 06 alkynyl, 01-06, alkoxy, amino, mono- or di(Cl-C 6 )alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Cl- C6)alkylaminocarbonyl, N-(CI-C 6 )alkylsulfonylaminocarbonyl, 1-azetidinyl, 1pyrrolidinyl, and 1 -piperidyl; or Ar 2 is a bicyclic oxygen-containing groups of the formula: wherein R13 represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, 02-06 alkenyl, 02-06 alkynyl, 01-06 alkoxy, amino, and mono- or di(Ci-

C

6 )alkylamino; R, is hydrogen, methyl, ethyl, or phenyl;

R

2 is 03-08 alkyl or 03-08 cycloalcyl; and WO 02/49993 PCT/US00/26816

R

3 is hydrogen or methyl; and

R

4 is C1-Cs alkyl, Ca-Cs cycloalkyl, or (C 3 -Cs cycloalkyl) C 1

-C

3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C 6 alkyl, C2-Cs alkenyl, C2-C alkynyl, Ci-Cs alkoxy, amino, and mono- or di(Ci-Cs)alkylamino.

Still further preferred compounds of the above formula II include those of the following formula: Ri R4 AriNK N is\ Ar 2 R2 R3 wherein: Arl is phenyl, phenyl(Ci-C 4 )alkyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cr-Ce alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(CI-Cs)alkylamino; Ar 2 is chosen from phenyl, phenyl(Ci-C4)alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[dlisoxazolyl, quinolinyl, isoquinolinyl, and quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C-C 6 alkyl, C 2

-C

6 alkenyl, C 2

C

6 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(C 1 -Cs)alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Ci- C)alkylaminocarbonyl, N-(C1-Cs)alkylsulfonylaminocarbonyl, 1-azetidinyl, 1pyrrolidinyl, and 1-piperidyl; or Ar2 is a bicyclic oxygen-containing groups of the formula: WO 02/49993 WO 0249993PCT/USOO/26816 0 wherein RB3 represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cj-C 6 alkyl, C2-C6,alkenyl, C 2 -Cr, alkynyl, 01-06 alkoxy, amino, and mono- or di(Ci- 06)alkylarnino; R, is hydrogen, methyl, ethyl, or phenyl;

R

2 is C 3

-C

8 alkyl or C 3

-C

8 cycloalkyl; and

R

3 is hydrogen or methyl; and R4 is phenyl, phenyl(Cl-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, benzodioxinyl, benzodioxolyl, benzld]isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, C 2

-C

6 alkenyl, C2- 06 alkynyl, 01-06, alkoxy, amino, mono- or di(CI-06)alkylamnino; or

R

4 is a bicyclic oxygen-containing group of the formula: 0

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl,

C

2 -CG alkenyl, C 2

-C

6 alkynyl, Ct-C 6 alkoxy, amino, and mono- or di(Ci- C6)alkylamino.

Preferred compounds of the invention also include those of the following formula III: WO 02/49993 WO 0249993PCT/USOO/26816 N R3 or apharmaceutically acceptable salt thereof, wherein: An, is phenyl, phenyl(CI-C 4 )alkyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C i-C6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, CI-C 6 alkoxy, amino, mono- or di(CI-C 6 )alkylamino; Ar 2 is a bicyclic oxygen-containing groups of the formula:

)RB"

wherein Ria represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, Cl-C 6 alkoxy, amino, and mono- or di(Ci-

C

6 )alkyllamfiflo; R, is selected from i) hydrogen, halogen, hydroxy, amino, CI-C 6 alkoxy, mono- or di(Cl- C6)alkylamino, cyano, nitro, haloalkyl, and ii) Cj-C 8 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 3

-C

8 cycloalkyl., and (C 3 C8)cycloalkyl) Cl-C 3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluorornethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or di(Ci- C6)alkylamino; or R, is selected from phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, WO 02/49993 WO 0249993PCT/USOO/26816 pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 8 alkyl,

C

2

-C

6 alkenyl, C 2 -C6 alkynyl, CI-C 6 5 alkoxy, amino, and mono- or di(Ci- C6)alkylamino;

R

2 and R3 are independently selected from i) hydrogen, halogen, hydroxy, amino, Cl-C 6 alkoxy, mono- or di(Ci- C6)alkylamino, cyano, nitro, haloalkyl, and ii) Cl-Cs alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C3-Cs cycloalkyl, and (C.3-C8 cycloalkyl) CI-Cq alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalktyl, hydroxy, acetoxy, C 1

-C

6 alkoxy, amino, mono- or di(Ci- C6)alkylamino; and

R

4 is Cj-C8 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 3

-C

8 cycloalkyl, (C3-Cs cycloalkyl) C 1

C

3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Ci- CG)alkylamino; or

R

4 is phenyl, phenyl(CI-C 4 )alkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[dlisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2

-C

6 alkenyl, C 2 -Cc 5 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(CI-C6)alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Cl-C6)alkylaininocarbonyl, WO 02/49993 PCT/USOO/26816 Cl-C6)alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, and 1piperidyl; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkvl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1 -C6 alkoxy, amino, and mono- or di(Cl-Cs)alkylamino.

Preferred compounds of the above formula III include those wherein: R, is hydrogen, methyl, ethyl, or phenyl;

R

2 is C 3

-C

8 alkyl or C 3

-C

8 cycloalkyl;

R

3 is hydrogen or methyl; and

R

4 is Cl-C 8 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 3 -Cs cycloalkyl, (C3-C8 cycloall) Ci-

C

3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluorornethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2

-C

6 alkenyl, C 2

C

6 alkynyl, C 1

-C

6 alkoxy, amino, and mono- or di(Cl-C6)alkylamino.

Additional preferred compounds of formula III include those wherein:

R

1 is hydrogen, methyl, ethyl, or phenyl;

R

2 is C 3 -Cs alkyl. or C3-C 8 cycloalkyl;

R

3 is hydrogen or methyl; and

R

4 is Cl-Ca alkYl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, Ca-Cs cycloalkyl, (C3-C 8 cycloalkyl) C 1

C

3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2 -C6 alkenyl, C 2

C

6 alkynyl, Cl-C 6 alkoxy, amino, and mono- or di(CI-C 6 )alkylamino.

WO 02/49993 PCT/USOO/26816 Still additional preferred compounds of formula III above include those wherein: Ri is hydrogen, methyl, ethyl, or phenyl;

R

2 is Cs-Cs alkyl or Cs-C8 cycloalkyl; R3 is hydrogen or methyl; and phenyl, phenyl(C1-C4)alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, benzodioxinyl, benzodioxolyl, benz[dlisoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(CI-C6)alkylamino.

Preferred compounds of formula III above also include those wherein: Ri is hydrogen, methyl, ethyl, or phenyl; R2 is C 3 -Cs alkyl or C 3 -Ca cycloalkyl;

R

3 is hydrogen or methyl; and

R

4 is a bicyclic oxygen-containing group of the formula:

RA

-C

6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1

-C

6 alkoxy, amino, and mono- or di(Ci- Cr,)alkylamino.

The invention also includes compounds of the following formula IV: WO 02/49993 PCT/US00/26816 N 'CRsaR 6 a R7 Ar N NI R2 R4 Ar 2

IV

or a pharmaceutically acceptable salt thereof, wherein: n is an integer from 0 to 3; and

R

2 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, or haloalkyl, each or which may be substituted or unsubstituted;

R

4 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, each or which may be substituted or unsubstituted; or

R

4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms, Ra and RA are the same or different and represent hydrogen or alkyl; or

R

3 and R3A, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; Rs and R 6 are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; or Rs and R 6 taken together with the carbon atom to which they are attached form a cycloalkyl ring; Rsa and R6a are the same or different, and are independently selected at each occurrence from hydrogen, halogen, hydroxy, alkyl, and alkoxy;

R

7 represents hydrogen or alkyl; WO 02/49993 PCT/US00/26816 Ar and Ar 2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, or an optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms.

Also preferred are compounds of that formula IV above (such preferred compounds referred to as compounds of formula IV-A) wherein n, Ra, R3A, Rs, R 6 Rsa, Rsa, and R 7 are as defined in that formula IV, and

R

2 is hydrogen or alkcyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, or haloalkyl, each or which unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluormethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or dialkylamino;

R

4 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino and mono- or dialkylamino,

R

4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono- or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N- WO 02/49993 PCT/US00/26816 alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl and

XR

3 wherein X and RB are as defined below; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

wherein RA represents O to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino; Ar and Ar 2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono- or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, Nalkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl and

XR

2 wherein X and RD are as defined below;, and ii) bicyclic oxygen-containing groups of the formula: 0 Re wherein R 5 represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino; WO 02/49993 PCT/US00/26816 X is independently selected at each occurrence from the group consisting of -CH 2 CHRc-, -NRc-, -S(O)mNH-, -S(O)mNRc-, -NHS(O)m-, and -NRcS(0)m- (where m is 0, 1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of: hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(alkyl), -NH(alkyl), -N(alkyl)(alkyl), -NHC(O)(alkyl), -N(alkyl)C(0)(alkyl), -NHS(O)x(alkyl), -S(O)x(alkyl), S(0)xNH(alkyl), -S(0),N(alkyl)(alkyl), (where x is 0, 1, or 2).

Also preferred are compounds of formula IV above wherein (such preferred compounds referred to as compounds of formula IV-B) n is defined as in formula IV above, and

R

3 and R3A are the same or different and represent hydrogen or

C

1

-C

6 alkyl; or

R

3 and R3A, taken together with the carbon atom to which they are attached, form a C3-s cycloalkyl ring; Rs and R 6 are the same or different and represent hydrogen, halogen, hydroxy, Ci-C6 alkyl, or Ci-Co alkoxy; or Rs and R 6 taken together with the carbon atom to which they are attached form a

C

3 -8 cycloalkyl ring; Rsa and R5b are the same or different, and are independently selected at each occurrence from hydrogen, halogen, hydroxy, Ci-C 6 alkyl, and C 1

-C

6 alkoxy;

R

2 is hydrogen or Ci-s alkyl, C2-8 alkenyl, C2-s alkynyl, C3-s cycloalkyl, (C3-8 cycloalkyl) C1-3 alkyl, or Ci- Co haloalkyl, each or which unsubstituted or substituted by one or more of WO 02/49993 PCT/US00/26816 halogen, nitro, cyano, trifluormethyl, trifluoromethoxy, CO-3 haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or di(Ci-Cs)alkylamino;

R

4 is hydrogen or Ci-s alkyl, C2-8 alkenyl, C2-8 alkynyl, Cs.acycloalkyl, (C3-8 cycloalkyl)CI-4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino and mono- or di(Ci-Cs)alkylamino,

R

4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino, mono- or di(CI-C)alkylamino, amino(C1-Cs)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(C1-Cs)alkylaminocarbonyl, N-( C1-C6)alkysulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, XRB, wherein X and RB are as defined below; or

R

4 is a bicyclic oxygen-containing group of the formula: (0K

RA

wherein RA represents O to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 0 v-Co alkyl, C26 alkenyl, C2-6 alkynyl, C1-C6 alkoxy, amino, and mono- or di(C- Cs)alkylamino; Ar 1 and Ar 2 are independently chosen from WO 02/49993 WO 0249993PCT/USOO/26816 i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl., or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-C6 alkoxy, amino, mono- or di(Ci-Cti)alkylamino, amino(C,-C 6 )alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Cl-C6)alkylaminocarbonyl, N-( C1-C6)alkylsulfonylaminocarbonyl, 1-azetidinyl, 1 -pyrrolidinyl, 1 -piperidyl, and -XRB, wherein X and RB are as defined below; and ii) bicyclic oxygen-containing groups of the formula: 0

RB

wherein RB3 represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C6 alkyl,

C

2 6 alkenyl, 026c alkynyl, C1-C06 alkoxy, amino, and mono- or di(Cl- C6)alkylamino; X is independently selected at each occurrence from the group consisting of -CH 2 CHRc-, -NRc-, -S(0)mNH, -S(0)mNRc-, -NRcC(0)-, -NHS(O)m-, and -NRcS(O).- (where m is 0, 1, or 2); and R13 and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of:.

hydrogen, straight, branched, or cyclic alklI groups, which may contain one or more double or triple bonds, each of which may unsubstituted or WO 02/49993 WO 0249993PCT/USOO/26816 substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(Cl-C 6 alkyl), -NH(Cl-C 6 alkyl), -N(Cl-C 6 alkyl) (01-06 alkyl), -NHC(O) (01-06 alkyl), -N(C 1

-C

6 alkyl)C(O)(Cl-6 alkyl), -NHS(O)x(CI-C 6 alkyl), -S(O).(Cl-C 6 alkyl), S(O).NH(Ca-C 6 alkyl), -S(O)xN(Ci-C 6 alkyl)( 01-06 alkyl.), (where x is 0, 1, or 2).

Also preferred are compounds of formula TV above (such preferred referred to as compounds of formula P1-C) wherein n, R 2

R

3 R3A, Rs, R 6 R5a, R~a, and R 7 are as defined in formula IV above,

R

4 is hydrogen or 01-08 alkyl, 02-08 alkenyl, 02-08 alkvnyl, 0; 3 -Cacycloalkyl, (Ca-C 8 cycloalkyl) Cl-O4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, 02-06 alkenyl, 02-06 alkynyl, 01-06 alkoxy, amino and mono- or di(0i- C6)alkylarnino,

R

4 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, 02-06 alkenyl, 02-06 alkynyl, 01-06 alkoxy, amino, mono- or di(0I-C 6 )alkylamino, amino(C1-C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Cl-C6)alkylaminocarbonyl, Cl- C6)alkylsulfonylaminocarbonyl, 1-azetidinyl, 1 -pyrrolidinyl, 1 -piperidyl, XRB, wherein X and RB are as defined below; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

WO 02/49993 WO 0249993PCT/USOO/26816 wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C I-C6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1 -Cr, alkoxy, amino, and mono- or di(Ci- C6)alkylamino; Ar 1 is phenyl, thienyl, or pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which is unsubstituted or substituted with up to four substituents independently selected from: halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-0 6 alkyl, C 2 -Cc) alkenyl, C 2 -Cr, alkynyl, Ct-C6 alkoxy, amino, mono- or di(Cj-Cr&)alkylamino, amino(CI-C 6 )alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Ci- C6)alkylanlinocarbonyl, CI-C6,)alkylsulfonylaminocarbonyl, 1azetidinyl, I1-pyrrolidinyl, I1-piperidyl, and -XRB, wherein X and RB3 are as defined below; Ar 2 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-Cr, alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(CI-C6)alkylamino, amnino(Cl-C 6 )alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(C1-C6)alkylarninocarbonyl, C 1 C6)alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and XRB, wherein X and RB3 are as defined below; or Ar 2 is a bicyclic oxygen-containing group of the formula:

'N

wherein RA' represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, WO 02/49993 PCT/US00/26816

C

2

-C

6 alkenyl, C 2 -C6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Ci- Cs)alkylamino; X is independently selected at each occurrence from the group consisting of -CH 2 CHRc-, -NRc-, -S(O)mNH-, -S(O)mNRc-, -NHS(0)m-, and -NRcS(0)m- (where m is 0, 1, or 2); and RB and Re, which may be the same or different, are independently selected at each occurrence from the group consisting of: hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(Ci-C 6 alkyl), -NH(Ci-C 6 alkyl),

-N(C

1

-C

6 alkyl)(Ci-C 6 alkyl), -NHC(0)(C 1

-C

6 alkyl), -N(C 1

-C

6 alkyl)C(0)(Ci-C 6 alkyl), -NHS(0)x(Ci-C 6 alkyl), -S(0)x(Ci-C 6 alkyl), S(O)xNH(C 1

-C

6 alkyl), -S(0)xN(C 1

-C

6 alkyl)(Ci-C 6 alkyl), (where x is 0, 1, or 2).

Further preferred are compounds of the above formula IV-C wherein:

R

3 and R 4 are the same or different and represent hydrogen or methyl;

R

5 and R 6 are the same or different and represent hydrogen or methyl; and Rsa and Rea are the same or different, and are independently selected at each occurrence from hydrogen and methyl.

Further preferred are compounds of the above formula IV-C wherein:

R

3 and R 4 are hydrogen; Rs and R 6 are the same or different and represent hydrogen or methyl; and Rsa and R6a are the same or different, and are independently selected at each occurrence from hydrogen and methyl.

WO 02/49993 PCT/USOO/26816 Further preferred are compounds of the above formula IV-C wherein:

R

6 N (C 5aR6a)n N N

K

2

K

R -XR 4 Ar 2 or a pharmaceutically acceptable salt thereof, wherein: n is an integer from 0 to 3; and R9, is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, or haloalkyl, each or which may be substituted or unsubstituted;

R

4 is hydrogen or

C

1

-C

8 alkyl, C 2

-C

8 alkenyl, C 2

-C

8 alkynyl, C 3 -Cscycloalkyl, (Ca-Cacycloalkyl) Cl-C4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl,

C

2 -0 6 alkenyl, C 2

-C

6 alkynyl, CI-C 6 alkoxy, amino and mono- or di(Ci-

C

6 )alkylamino,

R

4 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, Cl-C 6 alkoxy, amino, mono- or di(C1-06)alkylamino, anaino(C1-C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Ci-C6)alkylaminocarbonyl, Cl- C6)alkylsulfonylarninocarbonyl, 1-azetidinyl, 1 -pyrrolidinyl, 1 -piperidyl, XRB, wherein X and RB3 are as defined below; or

R

4 is a bicyclic oxygen-containing group of the formula: WO 02/49993 WO 0249993PCT/USOO/26816

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1 -C6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, Cl-Os alkoxy, amino, and mono- or di(Ci- C6)alkylamino; Ar 2 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy,

C

1 -C6 alkyl, Cl-Cs alkenyl, C 2

-C

6 alkynyl, Cl-C6 alkoxy, amino, mono- or di(Ci-C6)alkylamino, amino(CL-C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(CI-Cs)alkylaminocarbonyl, Cj- C6)alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and

XR

0 wherein X and RB are as defined below; or Ar2 is a bicyclic oxygen-containing group of the formula: 0 wherein RA' represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl,

C

2

-C

6 alkenyl, C 2 -C6 alknyl, Cl-C 6 alkoxy, amino, and mono- or di(Ci- C6)alkylamino; X is independently selected at each occurrence from the group consisting of -CH 2 CHRc-, -NRc-, -S(O)mNH-, -S(O)mNRc-, -NRcC(0O)-, -NHS(C)m-, -C(0)NHS(O)m-, and -NRcS(O)m- (where m is 0, 1, or 2); and WO 02/49993 PCT/US00/26816 RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of: hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(Ci-C 6 alkyl), -NH(C 1

-C

6 alkyl),

-N(CI-C

6 alkyl)(Ci-C 6 alkyl), -NHC(O)(C 1

-C

6 alkyl), -N(Ci-C 6 alkyl)C(O)(Ci-Cs alkyl), -NHS(O)x(Ci-C 6 alkyl), -S(O)(Ci-C 6 alkyl), S(O)xNH(Ci-C6 alkyl), -S(O)xN(CI-C6 alkyl)(Ci-C6 alkyl), (where x is 0, 1, or 2).

Rs and R 6 are the same or different and represent hydrogen or methyl; Rsa and Rea are the same or different, and are independently chosen at each occurrence from hydrogen and methyl; and Rx represents up to four substituents independently chosen from hydrogen, halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-Cs alkyl, C 2

-C

6 alkenyl, C2-C 6 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(Ci-C 6 )alkylamino, and amino(Ci-C6)alkoxy.

Further preferred are compounds of the above formula IV-C wherein: Rs N

N

rR 6 NC (SaRa) R2 Rx R 4 Ar 2 or a pharmaceutically acceptable salt thereof, wherein: n is an integer from 0 to 3; and

R

4 is hydrogen or WO 02/49993 WO 0249993PCT/USOO/26816 Cl-0 8 alkl, C2-08 alkenyl, 02-Cs alkynyl, C 3 -Cscycloalkyl, (C3-Cacycloalkyl) CI-C~ialkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, 01-06, alkoxy, amino and mono- or di(Ci- C6)alkylamino, R4 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy,

CI-C

6 alkyl, C 2 -C6 alkenyl, C2-06 alkynyl, Cl-C6 alkoxy, amino, mono- or di(Cl-Crj)alkylamino, amino(CI-Cs,)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Cl-Crs)alkylaminocarbonyl, Cl- C6)alkylsulfonylaminocarbonyl, 1-azetidinyl, 1 -pyrrolidinyl, 1 -piperidyl, XRB, wherein X and RB are as defined below; or R4 is a bicyclic oxygen-containing group of the formula: R0 wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, 02-06 alkenyl, 02-C6 alkynyl, 0i-06 alkoxy, amino, and mono- or di(Ci- Os)alkylamino; Ar2 is phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, 02-06 alkenyl, 02-06 alkynyl, Cj-C6 alkoxy, amino, mono- or di(Cl-C6)alkylamino, amino(CI-C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(CI-Cr,)alkylaminocarbonyl, Ci- WO 02/49993 WO 0249993PCT/USOO/26816

C

6 )alkylsulfontylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and XRB, wherein X and RB are as defined below; or Ar 2 is a bicyclic oxygen-containing group of the formula:

RA'

wherein RA' represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydr'X'y, acetoxy, CI-C 6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, Cl-C 6 alkoxy, amino, and mono- or di(Ci-

C

6 )alkylamnino; X is independently selected at each occurrence from the group consisting of -CH 2 CHRc-, -NRc-, -C(0)NRc-, -S(O)mNH-, -S(O)mNRc-, -NRcC( -NHS(O)m-, -C(0)NHS(O)m-, and -NRcS(O)m- (where mn is 0, 1, or and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of:.

hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(C 1

-C

6 alkyl), -NH(C 1

-C

6 alkyl), -N(Cl-C 6 alkyl) (Cl-C 6 alkyl), -NHC(O) (CI-C 6 alkyl), -N(CI-C 6 alkyl) C(O) (CI-C 6 alk~yl), -NHS(O).(CI-C 6 alkyl), 6 alkyl), S(O),,NH(Cl-C 6 alk~yl), -S(O),N(C 1

-C

6 alkyl)(Cl-C 6 alkyl), (where x is 0, 1, or 2).

R

2 is C 3

-C

8 straight or branched chain alkyl, C 2

-C

8 alkenyl, or C 2

-C

8 alkynyl;

R

5 and R 6 are the same or different and represent hydrogen or methyl; and R 6 are the same or different, and are independently chosen at each occurrence from hydrogen and methyl; and WO 02/49993 PCT/US00/26816 Rx represents up to four substituents independently chosen from hydrogen, halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1 -C5 alkyl, C 2 -Cs alkenyl, C 2 -Cs alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(Ci-Cs)alkylamino, and amino(C1-Cs)alkoxy.

Further preferred are compounds of the above formula IV-C wherein: Ar2, Rx, and n are as defined in formula IV-C, or a pharmaceutically acceptable salt thereof, wherein:

R

2 is Ca-C 8 straight or branched chain alkyl, C 2

-C

8 alkenyl, or C 2 -Cs alkynyl; and

R

4 is C 1

-C

8 straight or branched chain alkyl, C 2

-C

8 alkenyl, or C 2 -Cs alkynyl.

Further preferred are compounds of the above formula IV-C, or a pharmaceutically acceptable salt thereof, wherein:

R

2 is C 3 -C straight or branched chain alkyl, C 2 -Cs alkenyl, or C 2 -Cs alkynyl;

R

4 is phenyl, which may be unsubstituted or substituted with: C1-C 6 alkyl, C 2 -C6 alkenyl, C 2

-C

6 alkynyl, C 3 -C cycloalkyl, (C 3 -Cs cycloalkyl)C1-C 4 alkyl, haloalkyl, Ci-C 6 alkoxy, halogen, hydroxy, amino, or mono- or di(Cl-Cs)alkylamino; or

R

4 is a bicyclic oxygen containing group of the formula: 00 o o r

)R

R A RA wherein RA is hydrogen, C 1

-C

6 alkyl, C 2

-C

6 alkenyl, C 2 -C alkynyl, C 3

-C

8 cycloalkyl, (Cs-Cscycloalkyl) C1-C 4 alkyl, haloalkyl, alkoxy, halogen, hydroxy, amino, or mono- or di(Ci-C 6 )alkylamino; Ar 2 is phenyl which is unsubstituted or optionally substituted or substituted with up to four groups independently selected from: halogen, C 1

-C

7 alkyl, C 1

-C

7 alkoxy, cyano, amino, mono- or di(C 1 C6)alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, N- WO 02/49993 PCT/US00/26816 alkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidyl, 1-morpholino, nitro, hydroxy, acetoxy, trifluoromethyl, and trifluoromethoxy or -XRB, wherein X and RB are as defined for formula IV-C; or Ar 2 is a bicyclic oxygen-containing group of the formula: 0- KI or wherein RA, RA', and n are as defined in formula IV-C.

Also preferred are compounds of formula IV-C as specified above, wherein: n is an integer from 0 to 3;

R

2 is C 3 -C8 straight or branched chain alkyl, C 2

-C

8 alkenyl, or C 2 -Cs alkynyl; R4 is C 1 -Cs straight or branched chain alkyl, C 2 -C8 alkenyl, or C 2 -Cs alkynyl; Ar 2 is a bicyclic oxygen containing group of the formula: or 0 RA' wherein RA' represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-C 6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1 -C alkoxy, amino, and mono- or di(Ci-

C

6 )alkylamino.

Additional preferred compounds include those of the following formula V: WO 02/49993 PCT/US00/26816

R

3

R

3

R

6 MeO RSA n R6A Br o wherein: n is an integer from 0 to 3;

R

3 and R3A are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; or

R

3 and R3A, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; Rs and R 6 are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; or Rs and R 6 taken together with the carbon atom to which they are attached form a cycloalkyl ring; and and R6A are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy.

Preferred compounds of formula V include those compounds wherein:

R

3 and R3A are the same or different and represent hydrogen or Ci-C 6 alkyl; or

R

3 and R3A, taken together with the carbon atom to which they are attached, form a cycloalkyl ring of from three to six carbon atoms; Rs and R 6 are the same or different and represent hydrogen, halogen, hydroxy, C 1

-C

6 alkyl, or Ci-C 6 alkoxy; or Rs and R 6 taken together with the carbon atom to which they are attached form a cycloalkyl ring of from three to six carbon atoms; and and R6A are the same or different and represent hydrogen, halogen, hydroxy, C1-

C

6 alkyl, or C 1

-C

6 alkoxy.

Preferred compounds of formula V include thosae compounds wherein: WO 02/49993 PCT/US00/26816

R

3 and R 4 are hydrogen; and Rs, R 6 R5A, and R6A are the same or different and represent hydrogen or methyl.

The invention also includes compounds of the following formula VI:

R

3 R3A N RA Ar N\ RA R2

VI

wherein: n is an integer from 0 to 3;

R

2 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, or haloalkyl, each of which may be substituted or unsubstituted;

R

3 and R 4 are the same or different and represent hydrogen or alkyl; or Rs and R 3 a, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; Rs and R 6 are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; or

R

5 and R 6 taken together with the carbon atom to which they are attached, form a cycloalkyl ring; and R6A are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; and Arn is unsubstituted or substituted carbocyclic aryl, unsubstituted or substituted arylalkyl, or a unsubstituted or substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms.

Preferred compounds of formula VI include those compounds wherein:

R

2 is C 1 -Cs straight or branched chain alkyl, C 2 -Cs alkenyl, C 2 -Cs alkynyl, C 3

-C

8 cycloalkyl, C 2 -Cg (cycloalkyl)C1-C 4 alkyl, or Ci-Cs haloalkyl; WO 02/49993 PCT/US00/26816 Ra and Rsa are the same or different and represent hydrogen or CI-C 6 alkyl; or

R

3 and R3a, taken together with the carbon atom to which they are attached, form a cycloalkyl ring of from three to six carbon atoms; and Rs and R 6 are the same or different and represent hydrogen, halogen, hydroxy, C 1

-C

6 alkyl, or Ci-C 6 alkoxy; or Rs and R 6 taken together with the carbon atom to which they are attached form a cycloalkyl ring of from three to six carbon atoms; and R6A are the same or different and represent hydrogen, halogen, hydroxy, Cz-

C

6 alkyl, or Ci-C 6 alkoxy; Arl is phenyl, thienyl, or pyridyl, pyrimidyl, dihydrobenzofuranyl, furanyl, benzodioxanyl, indolyl, each of which is unsubstituted or substituted with up to four substituents independently selected from: halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-C 6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C1-C 6 alkoxy, amino, mono- or di(Ci-C 6 )alkylamino, amino(Ci-C 6 )alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Ci- C6)alkylaminocarbonyl, C1-C6)alkylsulfonylaminocarbonyl, 1azetidinyl, 1-pyrrolidinyl, 1-piperidyl, and -XRB, wherein X and RB are as defined below; X is independently selected at each occurrence from the group consisting of-CH 2 CHRc-, -NRc-, -S(O)mNH-, S(O)mNRc-, -NHS(O)m-, and NRcS(O)m- (where m is 0, 1, or and RB and Re, which may be the same or different, are independently selected at each occurrence from the group consisting of: hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(Ci-C 6 alkyl), -NH(Ci-C 6 alkyl), WO 02/49993 WO 0249993PCT/USOO/26816 -N(Cl-C 6 alkyl)(C-C 6 alkyl), -NI{C(O)(Cl-C6 alkyl), -N(Cl-C 6 alkYl)C(O)(CI-C6 alkyl), -NHS(O).(CI-C 6 alkyl), -S(O),(GI-C 6 alkyl), S(O).NH(Ci-Ci alkyl), -S(O).N(Cl-C 6 alkyl)(Ci-C6, alkyl), (where x is 0, 1, or 2).

Preferred compounds of the above formula VI include those of the following formula: 6 N R6A Nn RxR wherein: n is 0, 1, or 2:

R

2 is G 3

-C

8 straight or branched chain alkyl, 02-08 alkenyl, or 02-08 alkynyl;

R

5

R

6 R5A, and R6A are the same or different and represent hydrogen or methyl; and Rx represents up to four substituents independently chosen from hydrogen, halogen, nitro, cyano, trifluoremethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C5 alkyl, C 2

-C

8 alkenyl, C 2

-C

8 alkynyl, Cl-C 6 alkoxy, amino, mono- or di(Ca-C 6 )alkylamino, and amino (C1I-C6) alkoxy.

The invention also includes compounds of the following formula VII:

R

3

AR

N R3 IR Ar 1 "IQ N HO R 7

II

wherein: WO 02/49993 PCT/US00/26816 n is an integer from 0 to 3; and

R

2 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, each or which may be substituted or unsubstituted; Rs and R3A are the same or different and represent hydrogen or alkyl; or

R

3 and R 3 a, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; Rs and R 6 are the same or different and represent hydrogen or alkyl; or Rs and R 6 taken together with the carbon atom to which they are attached, form a cycloalkyl ring; Rsa and R6a are the same or different, and are independently selected at each occurrence from hydrogen, halogen, hydroxy, alkyl, and alkoxy;

R

7 represents hydrogen or alkyl; and Arl is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, or an optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms.

Preferred compounds of formula VII include those of the following formula:

R

5

R

6 Rsa R6a N o n Rx OH Rx R2 wherein: n is an integer from 0 to 3;

R

2 is C3-Cs straight or branched chain alkyl, C 2 -Cs alkenyl, or C2-Cs alkynyl; Rs, R6, RsA, and R6A are the same or different and represent hydrogen or methyl; and WO 02/49993 PCT/US00/26816 Rx represents up to four substituents independently chosen from hydrogen, halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2 -Cs alkenyl, C 2

-C

8 alkynyl, C 1 -Cs alkoxy, amino, mono- or di(C1-C6)alkylamino, and amino(Ci-C6)alkoxy.

The invention also includes methods of syntesis of compounds of the invention. In particular, the invention includes methods to synthesis compounds of the following formula VIII: R3A R6 R2 Ar R KN

R

4 Ar 2 VIII wherein: n is an integer from 0 to 3; and

R

4 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, each or which may be substituted or unsubstituted; or R4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms,

R

3 and RSA are the same or different and represent hydrogen or alkyl; or

R

3 and R3A, taken together with the carbon atom to which they are attached, form a cycloalkyl ring; Rs and R 6 are the same or different and represent hydrogen, halogen, hydroxy, alkyl, or alkoxy; or WO 02/49993 PCT/US00/26816 Rs and R 6 taken together with the carbon atom to which they are attached form a cycloalkyl ring; Rsa and R6a are the same or different, and are independently selected at each occurrence from hydrogen, halogen, hydroxy, alkyl, and alkoxy;

R

7 represents hydrogen or alkyl; Ari and Ar 2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, or an optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 hetero atoms.

the process comprising: reacting a compound of the formula:

R

3

ARS

R3 R6 Ar N Y R7 R2 wherein Y is halogen or sulfonate ester, in a suitable solvent in the presence of a suitable base, with a secondary amine of the formula: R4 Ar 2 In that synthetic method, preferred are compounds (referred to as compounds of formula VIII-A) wherein n and Y are as defined above for formula VIII;

R

3 and R3A are the same or different and represent hydrogen or

CI-C

6 alkyl; or WO 02/49993 WO 0249993PCT/USOO/26816

R

3 and R3A, taken together with the carbon atom to which they are attached, form a C3-8 cycloalkl ring;

R

5 and Rr, are the same or different and represent hydrogen, halogen, hydroxy, C 1

-CG

alkyl, or C i-C 6 alkoxy; or

R

5 and R 6 taken together with the carbon atom to which they are attached form a C3.8 cycloalkyl ring; and R6a are the same or different, and are independently selected at each occurrence from hydrogen, halogen, hydroxy, Cl-C 6 alkyl, and 0 1

-C

6 alkoxy;

R

2 is hydrogen or 01-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, (C 3 8 cycloalkyl) CI-3 alkyl, or Ci- 06 haloalkyl, each or which unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluormethyl, trifluoromethoxy, 0C1-3 haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or di(Oi-C 6 )alkylamino;

R

4 is hydrogen or

C

1 8 alkyl, C 2 -a alkenyl, CM 8 alkynyl, C3-8cycloalkyl, (C3-8 cycloalkyl)CI- 4 alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2 6 alkenyl, C2-6 alkynyl, 01-06 alkoxy, amino and mono- or di(Ci-C0&)alkylamino,

R

4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, inridazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, teftrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[diisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetaxy, 01-06 alkyl, C2-6 alkenyl, C 2 6 alkynyl, Ci-Cf, alkoxy, amino, mono- or di(Cl-C6)alkylamino, amino(Cl-C6)alkoxy, carboxylic acid, esters of WO 02/49993 WO 0249993PCT/USOO/26816 Cl-C6)alkylsulfonylaminocarbonyl, 1 -azetidinyl, 1 -pyrrolidinyl, 1-piperidyl, XRB, wherein X and RB are as defined below; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluorornethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl,

C

2 6 alkenyl, C2-6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Ci- CG)alkylamino; Ar 1 and Ar 2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b~thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, C 2 6 alkenyl, C2-6 alkynyl, Cl-C 6 alkoxy, amino, mono- or di(Cl-C 6 )alkylamino, amino (C i-C6) alkoxy, carboxylic acid, esters of carboxylic acids, amiinocarbonyl, mono or di(Cl-C 6 )alkylaminocarbonyl, N-( Cl-C6)alkcylsulfonylaminocarbonyl, 1-azetidinyl, 1 -pyrrolidinyl, 1 -piperidyl, and -XRB, wherein X and R13 are as defined below; and ii) bicyclic oxygen-containing groups of the formula: 0

RB

wherein R]3 represents 0 to 3 groups selected from halogen, nitro, cyano,

C

2 6 alkenyl, C 2 -6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Cl- C6)alkylamilno; X is independently selected at each occurrence from the group consisting of -Cl- 2 CIIRc-, -NRc-, -C(0)NRc-, -S(0)mNH-, -S(O)mNRc-, -N1S(0)rn-, and -NRcS(O)m- (where m. is 0, 1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of: hydrogen; straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(C 1

-C

6 alkyl), -NH(CI-C 6 alkyl),

-N(CI-C

6 alkyl)(Cl-C6 alkyl), -NHC(0)(Cl-0 6 alkyl), -N(Ci-C 6 alkyl)C(0)(Cl-6 alkyl),

NHS(O),(C

1

-C

6 alkyl), -s(o)x4cj-c 6 ailkyl), -s(O)xNH(C1-Cr, alkyl), -S(Q),N(C1-C 6 alkyl)( Cl-C 6 alkyl), (where x is 0, 1, or 2).

The invention also includes compounds of the above formula VII and VIII-A, and pharmaceutically acceptable salts of such compounds.

The invention also provides compounds of the following formula IX: R2 R R3AAr 2

IX

or a pharmaceutically acceptable salt thereof, wherein: m is 0, 1, or 2; R is hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, WO 02/49993 PCT/US00/26816 optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl; or R is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms;

R

1

R

2

R

3 R3A, Rs, and R 6 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl)alkyl;

R

4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Ari and Ar 2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Preferred compounds of formula IX include those of the following formula IX-

A:

R1 N R R4 ArN R2

R

3 Ar 2 IX-A wherein Arl, Ar 2 R, R 1

R

2

R

3 and R4 are for formula IX above.

Preferred compounds of formula IX-A above include those wherein: WO 02/49993 WO 0249993PCT/USOO/26816 i) hydrogen, halogen, hydroxy, amino, alkoxy, mono- or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl)alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or dialkylamino; or R is selected from phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluorornethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino; and RI, R 2 and R 3 are independently selected from i) hydrogen, halogen, hydroxy, amino, alkoxy, mono- or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl)alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or dialkylamino;

R

4 is hydrogen or alkyl, alkenlyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino and mono- or dialkylamino,

R

4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, cxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrinhidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, WO 02/49993 WO 0249993PCT/USOO/26816 benzodioxinyl, benzodioxolyl, benz[dlisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono- or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, Nalkylsulfonylaminocarbonyl, l-azetidinyl, 1 -pyrrolidinyl, 1-piperidyl, -XR]3, wherein X and RB are as defined below; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino; Anl and Ar2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzofbjthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[djisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl., alkynyl, alkoxy, amino, mono- or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, Nalkylsulfonylaminocarbonyl, 1-azetidinyl, 1-pyrrolidinyl, I-piperidyl, and WO 02/49993 PCT/US00/26816 ii) bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino; X is independently selected at each occurrence from the group consisting of -CH 2 CHRc-, -NRc-, -S(O)mNH-, -S(0)mNRc-, -NHS(0)m-, and -NRcS(O)m- (where m is 0, 1, or 2); and RD and Re, which may be the same or different, are independently selected at each occurrence from the group consisting of: hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(alkyl), -NH(alkyl), -N(alkyl)(alkyl), -NHC(0)(alkyl), -N(alkyl)C(0)(alky1), -NHS(0)x(CI-C6 alkyl), -S(O).(alkyl), -S(0)xNH(alkyl), -S(0)xN(alkyl)(alkyl), (where x is 0, 1, or 2).

Additional preferred compounds of formula IX-A include those wherein:

R

1

R

2 and R 3 are independently selected from i) hydrogen, halogen, hydroxy, amino, C 1

-C

6 alkoxy, mono- or di(Ci- Cs)alkylamino, cyano, nitro, haloalkyl, and ii) C 1 -C8 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 3 -C cycloalkyl, and (C 3

-C

cycloalkyl) C 1

-C

3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, WO 02/49993 WO 0249993PCT/USOO/26816 haloalkyl, hydroxy, acetoxy, CI-C 6 alkoxy, amino, mono- or di(Ci- C6) alkylamino; R is selected from i) hydrogen, halogen, hydroxy, amino, Cl-C 6 alkoxy, mono- or di(Ci- C6)alkylamino, cyano, nitro, haloalkyl, and ii) Cl-C8 alkyl, C 2

-C

5 alkenyl, C 2

-C

6 alkynyl, C 3 -CS cycloalkyl, and (C 3 C8)cycloahLyl) Cj-C3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or di(Ci- C6)alkylaminc; or R is selected from phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-08 alkyl, 02-C6 alkenyl, C 2 -C6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Cl- C6)alkylarnino;

R

4 is hydrogen or C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8cycloalkyl, (C3-8 cycloalkl)Cj4alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2 -6 alkenyl, C2-6 alkynyl, Cl-C6 alkoxy, amino and mono- or di(Cl-Cs)alkylaiino,

R

4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, iinidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [blthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[djisoxazolyl, quinolinyl, isoquinolinyl, WO 02/49993 WO 0249993PCT/USOO/26816 substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoroniethoxy, haloalkyl, hydroxy, acetoxy, Cr-C6 all, C 2 6 alkenyl, C 2 -6 alkynyl, C 1 -0 6 alkoxy, amino, mono- or di(Cl-C6)alkylamnino, amino(Ci-C 6 )alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Ci-Cr,)alkylaminocarbonyl, N-( Cl-C 6 )alkylsulfonylaminocarbonyl, 1 -azetidinyl, 1 -pyrrolidinyl, 1-piperidyl, XRB, wherein X and RB are as defined below; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl,

C

2 6 alkenyl, C 2 6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Ci- C6)alkylamino; and Arn and Ar 2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[blthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl., each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1 -C6 alkyl, C 2 6 alkenyl, C 2 alkynyl, CI-C 6 alkoxy, amino, miono- or di(Cl-C6)alkylamino, amino(CI-C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Cl-C6)alkcylaminocarbonyl, N-( Cl-C6)alkylsulfonylaminocarbonyl, 1 -azetidinyl, 1 -pyrrolidinyl, 1-piperidyl, and -XRB, wherein X and RB are as defined below; and WO 02/49993 WO 0249993PCT/USOO/26816 wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl,

C

2 6 alkenyl, C 2 6 alkynyl, C 1

-C

6 alkoxy, amino, and mono- or di(Ci- C6)alkylamino; X is independently selected at each occurrence from the group consisting of -Cl- 2 CHRc-, -NRc-, -S(O)mNH-, -S(O)mNRc-, -NRcC(0O)-, -NHS(O)m-, and -NRcS(O)m- (where rn is 0, 1, or 2); and Ri 0 and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of: hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(C 1

C

6 alkyl), -NH(Cl-C 6 alkyl),

-N(C

1

-C

6 alkyl)(Cl-Cr, alkyl), -NHC(O) (C 1 -Cr, alkyl), -N(Cl-Cr 6 alkyl) C(O) (Cr1 6 alkyl), -NHS(O)x(Cl-C 6 alkyl), -S(O),,(Cj-Cr 5 alkyl), S(O),NH(Gi-C 6 alkyl), -S(O).N(C 1

-C

6 alkyl)( Cl-C 6 alkyl), (where x is 0, 1, or 2).

Additional preferred compounds of formula IX-A above include those wherein: R is hydrogen, halogen, Cl-C 8 alkyl, C 2

-C

8 alkenyl, C 2 -C8 alkynyl, Cj-C 8 cycloalkyl, (C3-Cscycloalkyl)Ci-C 3 alkyl, C 1

-C

8 alkoxy, or C 1

-C

8 haloalkyl, or R is a phenyl. which may be substituted by up to five substituents independently chosen from Cr-C8 alkyl, C 2

-C

8 alkenyl, C2-C 8 alkynyl, Cj-C8 alkoxy, halogen, cyano, carboxylic acid, hydroxy, acetoxy, nitro, amino, mono or di(Cl- WO 02/49993 WO 0249993PCT/USOO/26816 C6)alkylamino, aminocarbonyl, sulfonamido, mono or di(Cs-C6)alkylsulfonamido, 3,4-methylenedioxy, 3 ,4-(l1,2-ethylene)dioxy, trifluoromethyl or trifluoromethoxy; R, is hydrogen, Cj-C8 alkyl, C 2 -C8 alkenyl, C 2

-C

8 alkynyl, Cs-Ca cycloalkyl (C 3 Cacycloalkyl)C1-Csalkyl or Cl-C 8 haloalkyl;

R

2 is CI-C8 alk~yl, C 2 -C8 alkenyl, C2-CS alkynyl, CI-CB cycloalkyl or (C3- Cacycloalkyl)Ci-Caalkyl or CI-C 8 haloaLkyl.;

R

3 is hydrogen, CI-Cs alkyl, C 2 -C8 alkenyl, or C 2 -C8 alkynyl; R?4 is C 1 -C8 alkyl, C 3 -C8 cycloalkyl, or (C 3 -Cs cycloalkyl) CI-C3 alkyl, each of which may be umsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, halcalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkyriyl, Cl-C 6 alkoxy, amino, and mono- or di(CI-C 6 )alkylamino; or

R

4 is phenyl, phenyl(CI-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl., each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluorornethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C.

2

-C

6 alkenyl, C 2 Ca alkynyl, Cl-C 6 alkoxy, amino, mono- or di(Cl-C6)alkylamino, or

R

4 is a bicyclic oxygen-containing group of the formula: Co

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C6 alkyl, C 2

-C

6 alkenyl, C 2 -C6 alkynyl, Ci-C6 alkoxy, amino, and mono- or di(Cl-C6)alkylamino; and Arl and Ar2 are independently chosen from phenyl., phenyl(Cl-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, bcnzotb]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[dlisoxazolyl, quinolinyl, WO 02/49993 WO 0249993PCT/USOO/26816 isoquinolinyl, and quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethox-y, haloalkyl, hydroxy, acetoxy,

C

1

-C

6 alkyl, C 2 -C6 alkenyl, C2-C 6 alkYnyl, Ci-C6 alkoxy, amino, mono- or di(Cl-C6)alkylamnino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Cl-C6)alkylamninocarbonyl, N-(C l- C6)alkylsulfonylaminocarbonyl, I -azetidinyl, 1 -pyrrolidinyl, and I -piperidyl, and bicyclic oxygen-containing groups of the formula: 0

RES.

wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoroinethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Ci- CG)alkylamino.

Still additional preferred compounds of formula IX-A include those compounds wherein: R is hydrogen, halogen, Cj-Cs alkyl, C 2

-C

8 alkenyl, C 2

-C

8 alkynyl, Cl-Cs cycloalkyl, (C3-Cacycloalkyl)Ci-Caalkyl, Cj-C 8 alkoxy, or Cj-C 8 haloalkyl, or is a phenyl which may be substituted by up to five substituents independently chosen from C 1 -Ca alkyl, C 2 -C8 alkenyl, C 2

-C

8 alkynyl, Cl-Cs alkoxy, halogen, cyano, carboxylic acid, hydroxy, acetoxy, nitro, amino, mono or di(Ci- C6)alkylamino, aminocarbonyl, sulfonamido, mono or di(Cl-C6)alkylsulfonanlido, 3 ,4-methylenedioxy, 3, 1,2-ethylene)dioxy, trifluoromethyl or trifluoromethoxy; R, is hydrogen, Cl-C 8 alkyl, C 2 -C8 alkenyl, C 2

-C

8 alkynyl, C 3

-C

8 cycloalkyl. (C3- Cscycloalkyl)Ca-Caalkyl or Ca-Cs haloalkyl;

R

2 is CI-C 8 alkyl, C 2 -C8 alkenyl, C 2

-C

8 alkynyl, Cl-C8 cycloalkyl or (C3-C 8 cycloalkyljCI-Csalkyl or Ci-Cs haloalkyl; WO 02/49993 WO 0249993PCT/USOO/26816

R

3 is hydrogen, C 1 -Cs alkyl, C2-Cs9 alkenyl, or C 2 -Cs alkynyl;

R

4 is Cl-C 8 alkyl, C 3 -C8 cycloalkyl, or (C 3 -C8 cycloalkyl) Ci-C 3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Cl-C 6 )alkylamino; or

R

4 is phenyl, phenyl(Ci-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, benzodioxinyl, benzodioxolyl, benz[dlisoxazolyl, quinolinyl., isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-Cr, alkyl, C 2 -CG alkenyl, 02-

C

6 alkynyl, CI-C 6 alkoxy, amino, mono- or di(Cl-C6)alkylamino; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, C2-C6 alkenyl, C 2 -0 6 alkynyl, C 1

-C

6 alkoxy, amino, and mono- or di(Cl-Cri)alkylamino; Arl is phenyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2

-C

6 alkenyl, 02-C6 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(Ci- C6)alkylamino; and Ar 2 is phenyl, phenyl(Cl-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, and quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, WO 02/49993 PCT/USOO/26816 trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2

-C

6 alkenyl, C 2

C

6 alkynyl, CI-C 6 alkoxy, amino, mono- or di(Cl-Ca)alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyt, mono or di(Cl- C6)alky3laniinocarbonyl, N-(CI-C6)alkylsulfonylamninocarbonyl, I -azetidinyl, 1pyrrolidinyl, and 1-piperidyl, or An2 is a bicyclic oxygen-containing group of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl,

C

2

-C

6 alkenyl, C2-C6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Cl- C6)alkylamino.

Still further preferred compounds of formula IX above include those wherein R is hydrogen, halogen, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, or phenyl;

R

1 is hydrogen, mnethyl. or ethyl;

R

2 is C 3

-C

6 all;

R

3 is hydrogen, methyl or ethyl;

R

4 is C 1 -Cs alkyl, C 3

-C

8 cycloalkyl, or (Ca-Ca cycloalkyl) Cl-Cs alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C 6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1

-C

6 alkoxy, amino, and mono- or di(Cl-C6)alkylamino; or

R

4 is phenyl, phenyl(CI-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[blthiophenyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, WO 02/49993 PCT/USOO/26816 trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2

-C

6 alkenyl, C 2

C

6 alkynyl, Ci-C 6 alkoxy, amino, mono- or di(CI-C 6 )alkylamino; or

R

4 is a bicyclic oxygen-containing group of the formula:

K

0 or RA 0RA wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynYl, CI-C 6 alkoxy, amino, and mono- or di(CI-C 6 )alkylamino; Arl is phenyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, Cl-C 6 alkoxy, amino, mono- or di(Cl- C6)alkylamino; and Ar2 is phenyl, phenyl(Cl-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[bjthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, and quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2

-C

6 alkenyl, C 2

C

6 alkynyl, Cl-C 6 alkoxy, amino, mono- or di(Cl-C6)alkylamino; Ar 2 is a bicyclic oxygen-containing group of the formula: Ki or RB 0O RB wherein R]3 represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-C 6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1

-C

6 alkoxy, amino, and mono- or di(Cl-C 6 )alkylamino.

The invention also include compounds of the following formula X: WO 02/49993 PCT/US00/26816

RR

N N R RS R R 4 Ar mN

R

2

R

3 R3A

X

Ar2

X

wherein: m is 0, 1, or 2; R is hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl; or R is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; RI, R 2

R

3 R3A, R 5 and Rg are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl)alkyl;

R

4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Art and Ar 2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

WO 02/49993 WO 0249993PCT/USOO/26816 Preferred compounds of formula X include those of the following formula X-

A:

N R R 4

NH

Arl

R

2

R

3

X-A

wherein Arl, R, RI, R 2 R3, R 4 are as defined for formula X above.

Additional preferred compounds of formula X include those wherein: RI, R 2 and R 3 are independently selected from i) hydrogen, halogen, hydroxy, amino, Cl-C 6 alkoxy, mono- or di(Ci- C6)alkylamino, cyano, nitro, haloalkyl, and ii) Cl-C8 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C3-CS cycloalkyl, and (C3-Cs cycloalkyl) C 1

-C

3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cs-C 6 alkoxy, amino, mono- or di(Cl-

C

6 )alkylamino; is selected from i) hydrogen, halogen, hydroxy, amino, C 1

-C

6 alkoxy; mono- or di(Q. C6)alkylIamino, cyano, nitro, haloalkyl, and ii) Ci-C8 alkyl, C2-C 6 alkenyl, C 2

-C

6 alkynyl, Cs-Cs cyoloalkyl, and (C3- C8)cycloalkyl) CI-C3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or di(Ci- C6)alkylamino; or R is selected from phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with WO 02/49993 WO 0249993PCT/USOO/26816 up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C8 alkyl,

C

2

-C

6 alkenyl, C 2

-C

6 alkynyl, Cl-C6 alkoxy, amino, and mono- or di(Ci- C6)alkylamino;

R

4 is hydrogen or 01-8 alkyl, C 2 8 alkenyl, C2-8 alkynyl, C3-8cycloalkyl, (C 3 8 cycloalkyl)Cli 4 alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C2-6 alkenyl, alkynyl., 01-06 alkoxy, amino and mono- or di(Cl-C6)alkylamino,

R

4 is phenyl, phenylalyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[blthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, C2-6 alkenyl, C2-6 alkynyl, 01-06 alkoxy, amino, mono- or di(CI-C 6 )alkylamino, amino(C1-C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(C1-C6)alkylaminocarbonyl, N-( Ci-C 6 )alkylsulfonylaminocarbonyl, 1 -azetidinyl, 1 -pyrrolidinyl, 1 -piperidyl, XRB, wherein X and RB are as defined below; or

R

4 is a bicyclic oxygen-containing group of the formula:

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06, alkyl, WO 02/49993 PCT/USOO/26816

C

2 -6 alkenyl, C 2 _6 alkynyl, Cl-C 6 alkoxy, amino, and mono- or di(Ci- C6,)alkylamino; and Arn and Ar 2 are independently chosen from 1) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl., benzodioxinyl, benzodioxolyl, benz[dlisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2 6 alkenyl, C 2 -6 alkynyl, Cl-C 6 alkoxy, amino, mono- or di(Ci-C 6 )alkylamino, amino(Ci-C 6 )alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Ci-C 6 )alkylamninocarbonyl, N-( Cl-C6)alkylsulfonylaminocarbonyl, 1 -azetidinyl, 1-pyrrolidinyl, 1 -piperidyl, and -XRB, wherein X and RE3 are as defined below; and ii) bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, frifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1 -Cr, alkyl,

C

2 6 alkenyl, C2-6 alkynyl, C 1

-C

6 alkoxy, amino, and mono- or di(Ci- C6)alkylarnino; X is independently selected at each occurrence from the group consisting of -CH 2 CHRc-, -NRc-, -C(0)NRc-, -S(0)mNH-, -S(0)mNRc-, -NHC(= -NRcC(0)-, -NHS(O)m-, -C(0)NHS(0)m-, and -NRcS(O)m- (where m is 0, 1, or 2); and WO 02/49993 PCT/US00/26816 RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of: hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(C1-C6 alkyl), -NH(C 1 -C6 alkyl),

-N(CI-C

6 alyl)(01-06 alkyl), -NHC(O)(C 1

-C

6 alkyl), -N(C 1

-C

6 alkyl)C(O)(C 1 6 alkyl), NHS(O).(C1-C6 alkyl), -S(O)x(C1-C6 alkyl), -S(O)xNH(C1-C6 alkyl), -S(0)xN(CI-C6 alkyl)( C 1 -Cs alkyl), (where x is 0, 1, or 2).

Additional preferred compounds of formula X above include those wherein: R is hydrogen, halogen, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, or phenyl;

R

1 is hydrogen, methyl or ethyl;

R

2 is C3-C6 alkyl;

R

3 is hydrogen, methyl or ethyl;

R

4 is C 1 -C alkyl, C3-C cycloalkyl, or (C3-C8 cycloalkyl) Ci-C 3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-06 alkynyl, 01-06 alkoxy, amino, and mono- or di(Ci-C 6 )alkylamino; or

R

4 is phenyl, phenyl(C-C 4 )alkyl1, thienyl, pyridyl, pyrimidyl, pyrazinyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1-C alkyl, C2-C6 alkenyl, C2- C6 alkynyl, C1-C6 alkoxy, amino, mono- or di(Ci-C 6 )alkylamino; or

R

4 is a bicyclic oxygen-containing group of the formula: WO 02/49993 PCT/US00/26816 or A RoA 0 A wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1 -Cs alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1

-C

6 alkoxy, amino, and mono- or di(Ci-C 6 )alkylamino; and Arl is phenyl, thienyl, or pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(Ci- Ce)alkylamino.

The invention also includes compounds of the following formula XI:

R

5 Re Ar R R 3 R3A Arg

XI

or pharmaceutically acceptable salt thereof, wherein: n is 0, 1, or 2; R is chosen from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms;

R

2 Ra, R3A, Rs, and R 6 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally WO 02/49993 PCT/US00/26816 substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl) alkyl; R and R 3 may be joined to form an optionally substituted saturated carbocylic ring of from 5 to 8 members or an optionally substituted heterocyclic ring of from to 8 members;

R

The invention further includes compounds of the following formula XII:

R

SR

3 Ar 2 R2

XII

or a pharmaceutically acceptable salt thereof, wherein: R is chosen from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; WO 02/49993 PCT/US00/26816

R

2 and R 3 are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl)alkyl; R and R 3 may be joined to form an optionally substituted carbocylic ring of from 5 to 8 members or an optionally substituted heterocyclic ring of from 5 ro 8 members;

R

Preferred compounds of formula XII above include wherein R and R 3 are not joined.

Also preferred are compounds of formula XII wherein: R is selected from i) hydrogen, halogen, hydroxy, amino, alkoxy, mono- or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl)alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or dialkylamino, iii) phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, WO 02/49993 WO 0249993PCT/USOO/26816 pyrimidyl, pyrazinyl, each of which may be substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino;

R

2 and R 3 are independently selected from i) hydrogen, halogen, hydroxy, amino, alkoxy, mono- or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl)alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or dialkylamino;

R

4 is hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl., trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino and mono- or dialkylamino,

R

4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[blthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d~isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinvl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono- or dialkylamino, aminoalkoxy, carboxylic: acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, Nalkylsulfonylaminocarbonyl, 1-azetidinyl, 1 -pyrrolidinyl, 1-piperidyl and XRE3, wherein X and RB are as defined below; or WO 02/49993 PCT/US00/26816 R4 is a bicyclic oxygen-containing group of the formula:

RA

wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino; Arj and Ar 2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d]isoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, mono- or dialkylamino, aminoalkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or dialkylaminocarbonyl, Nalkylsulfonylaminocarbonyl, 1 -azetidinyl, 1 -pyrrolidinyl, 1 -piperidyl and

XR

3 wherein X and Ra are as defined below;, and ii) bicyclic oxygen-containing groups of the formula:

RB

wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkyl, alkenyl, alkynyl, alkoxy, amino, and mono- or dialkylamino; WO 02/49993 PCT/USOO/26816 X is independently selected at each occurrence from the group consisting of -CH 2 CHRc-, S9(O)mn, -NRc-, -S(O)inNRc-, -NRcC(0O)-, -NHS(O)m-, -C(0)NHS(O)m, and -NRcS(O)m- (where m is 0, 1, or 2); and RB and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of.

hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(alkyl), -NH(alkyl), -N(alkyl) (alkyl), -NHC(O) (alkyl), -N(alkyl,)C(O)(alkyl), -NHS(O)x(alkyl), -S(O).(alkyl), S(O)xNH(alkyl), -S(O).N(alkyl)(alkyl), (where x is 0, 1, or 2).

Additional preferred compounds of formula XII include those wherein: R is selected from i) hydrogen, halogen, hydroxy, amino, Cl-C 6 alkoxy, mono- or di(Cl- Cs)alkylamino, cyano, nitro, haloalkyl, and ii) C 1

-C

8 alkyl, 02-06 alkenyl, C 2

-C

6 alkynyl, 03-08 cycloalkyl, and (C3- C8)cycloalkyl) 01-03 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, triftuoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or di(Cl- C6)alkvlaznino, iii) phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-08 alkyl, 02-06 alkenyl, 02-06 alkynyl, Cl-C6 alkoxy, amino, and mono- or di(Ci-Cr,)alIylamino; WO 02/49993 PCT/USOO/26816

R

2 and R 3 are independently selected from i) hydrogen, halogen, hydroxy, amino, Cl-C 6 alkoxy, mono- or di(Ci- C6)alkylamino, cyano, nitro, haloalkyl, and ii) C 1 -C8 alkyl, C 2 -CG alkenyl, C 2 -CG alkynyl, C 3

-C

8 cycloalkyl, and (C3-C8 cycloalkyl) Cl-C 3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, frifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkoxy, amino, mono- or di(Cl- C6)alkylaniino;

R

4 is hydrogen or C1.8 alkyl, C2-8 alkenyl, C 2 -8 alkynyl, C3-scycloalkyl, (C 3 8 cycloalkyl)CI- 4 alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trif'luoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, 02_6 alkenyl, C2-6 alkynyl, Cl-C 6 alkoxy, amino and mono- or di(Ci-C6)alkylamino,

R

4 is phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo [bithiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[dlisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 01-06, alkoxy, amino, mono- or di(C1-C6)alkylamino, amino(Cl-C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Ci-C6)alkylarninocarbonyl, N-( Cl-C6)alkylsulfonylaminocarbonyl, 1 -azetidinyl, 1 -pyrrolidinyl, 1-piperidyl, XR13, wherein X and R13 are as defined below; or

R

4 is a bicyclic oxygen-containing group of the formula: WO 02/49993 WO 0249993PCT/USOO/26816 wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C2-6 alkenyl, C 2 -6 alkynyl, 01-06 alkoxy, amino, and mono- or di(Cl- 06) alkylamino; Ar, and Ar 2 are independently chosen from i) phenyl, phenylalkyl, chromanyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, zriazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzimidazolyl, naphthyl, indolyl, indanyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzo[blthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[djisoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, or quinoxalinyl, each of which may be optionally substituted or substituted with uip to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, C2-6 alkenyl, 02-6 alkynyl, 01-06 alkoxy, amino, mono- or di(CI-C6)alkylamino, amino (Cl-C 6 )alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(0l-C6)alkylaminocarbonyl, N-( Cl-06)alkylsulfonylaminocarbonyl, 1 -azetidinyl, 1-pyrrolidinyl, 1 -piperidyl, and -XRB, wherein X and RB are as defined below; and ii) bicyclic oxygen-containing groups of the formufla: 0 wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 01-06, alkoxy, amino, and mono- or di(Ci- C6)alky3lamino; WO 02/49993 PCT/USOO/26816 X is independently selected at each occurrence from the group consisting of -CH 2 CURc-, -S(O)m -NRc-, -S(O)mNH-, -S(O)MNRc-,

-NIIC(=O)-,

-NRcC( -NHS(O)m-, -C(=O)NHS(O)m and -NRcS(O)m- (where m is 0, 1, or 2); and RB3 and Rc, which may be the same or different, are independently selected at each occurrence from the group consisting of:.

hydrogen, straight, branched, or cyclic alkyl groups, which may contain one or more double or triple bonds, each of which may unsubstituted or substituted with one or more substituent(s) selected from: oxo, hydroxy, -O(CI-C 6 alkyl), -NH(C 1

-C

6 alkyl),

-N(CI-C

6 alk-yl)(Cl-C6 alkyl), -NHC(O)(Cl-C 6 alkyl), -N(Cl-C 6 alkyl)C(O)(C 1 6 alkyl), -NHS(O),(CI-C 6 alkyl), -S(O).(Ci-C6 alkyl)l,

S(O),,NH(C

1

-C

6 alk~yl), -S(O),N(CI-C 6 alkyl)( C 1

-C

6 alkcyl), (where x is 0, 1, or 2).

Also preferred are compounds of formula XII wherein: R is hydrogen, halogen, hydroxy, Cl-C 6 alkoxy, haloalkyl, Cl-Cs alkyl, C 2

-C

5 alkenyl,

C

2

-C

6 alkynyl, C 3 -C8 cycloalkyl, and (C 3 -C8)cycloalkyl) Cj-C 3 alkcyl, or R is phenyl substituted with up to five groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy,

C

1 -CS alkyl, C 2

-C

6 alkenyl, C 2 -Cr, alkynyl, CI-C 6 alkoxy, amino, and mono- or di(C1-Cs)alkylamino, aminocarbonyl, sufonamido, mono or di(Ci- C6)alkvylsulfonamido, 3,4-methylenedioxy, and 3 1,2-ethylene)dioxy;

R

2 is selected from CI-C8 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C3-C8 cycloalkyl, (C3-Cs cycloalkyl) C 1

-C

3 all and haloalkyl;

R

3 is hydrogen Cl-Cs alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl;

R

4 is C 1 -8 alkyl, C 2 -8 alkenyl, C 2 -8 alkynyl, C3-8cycloalkyl, (C 3 8 cycloalkyl)CI- 4 alkyl, haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, WO 02/49993 PCT/USOO/26816 trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cj-C 6 alkyl, C2-6 alkenyl, C2-r alkynyl, C 1

-C

6 alkoxy, amino and mono- or di(Cl-C6)alkylamino,

R

4 is phenyl, phenyl(Ci-C4)alk-yl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo[blthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[d~isoxazolyl, each of which may be substituted with up to five groups independently selected from halogen, nitro, cyano, frifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 01-06 alkoxy, amino, mono- or di(Cl-.Os)alkylamino, amino(CI-Cr,)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(C1-C6)alkylaminocarbonyl, C 1 C6)alkylsulfonylatninocarbonyl, l-azetidinyl, 1 -pyrrolidinyl, 1-piperidyl,

R

4 is a bicyclic oxygen-containing group of the formula:

RA

C

2 -6 alkenyl, C2-6 alkynyl, 01-06 alkoxy, amino, and mono- or di(Cl- C6)alkylamino;- Ar 1 and Ar 2 are independently chosen from i) phenyl, phenyl(CI-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenizofuranyl, naphthyl, indolyl, indanyl, benzo[bithiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, and benzfd]isoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C0I-C6 alkyl, C2-6 alkenyl,, C2-6 alkynyl, 01-06 alkoxy, amino, mono- or di(Cl-Cr 6 )alkylaxnino, amino(Cl- C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Cl-Cr 6 )alklaminocarbonyl, Cl-C6)alkylsulfonylaminocarbonyl, 1azetidinyl, 1-pyrrolidinyl, 1 -piperidyl; or WO 02/49993 PCT/USOO/26816 ii) bicyclic oxygen-containing groups of the formula: 0~ wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 0 1

-C

6 alkyl, C 2 6 alkenyl, C 2 6 alkynyl, Ci-C 6 alkoxy, amino, and mono- or di(Ci-C 6 )alkylamino.

Also preferred are compounds of formula XII wherein: R, R 2

R

3

R

4 and Ar 2 are as defined in formula XII; Ar 1 is phenyl with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hvdroxy, acetoxy, Cl-C 6 alkyl, C 2 -6 alkenyl, C2- alkynyl, Cl-C 6 alkoxy, amino, mono- or di(Ci-

C

6 )alkylamino, and amino (C 1-C 6 )alkoxy.

Also preferred are compounds of formula XII wherein: R, R 2 and R3 are as defined in formula XII; Ar 1 is phenyl with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, C 2 6 alkenyl, C 2 -r alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(Cl- C6)alkylamino, and amino(Cl-C6)alkoxy; R4 is C3-C8 alkyl, C 2

-C

8 alkenyl, C 2 -C8 alkynyl, C3-Cscycloalkyl, (C3-8 cycloalkyl)CI-

C

4 alkyI, Cj-C8 haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl,

C

2 6 alkenyl, C 2 6 alkynyl, CI-C 6 alkoxy, amino and mono- or di(Ci-

C

6 )alkylamino,

R

4 is phenyl, phenyl(Cl-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzolb]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[djisoxazolyl, each of which WO 02/49993 PCT/USOO/26816 may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxyV, C 1

-C

6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 01-06 alkoxy, amino, mono- or di(C1-C6)alkylamino, amino(Cv- C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(CI-C6)alkylaminocarbonyl, Oa-C6)alkylsulfonylaminocarbonyl, 1azetidinyl, 1-pyrrolidinyl, 1 -piperidyl; Ar2 is phenyl, phenyl(CI-0 4 )alkyl, thienyl, pyridyl., pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo[blthiophenyl, beuzodioxanyl, benzodioxinyl, benzodioxolyl, or benzjisoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C i-C 6 alkyl, C2-6 alkenyl, 02-6 alkynyl, CI-C 6 alkoxy, amino, mono- or di(Ca-C6)alkylamino, amino(Cl- C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Cl-C6)alkylaminocarbonyl, Cl-C 6 )alkylsulfonylaminocarbonyl, 1azetidinyl, 1-pyrrolidinyl, 1 -piperidyl; or Ar2 is bicyclic oxygen-containing groups of the formula: 0

I-

wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluorotuethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, C2-6 al'kenyl, C2-6 alkynyl, 01-06 alkoxy, amino, and mono- or di(CI-C 6 )alkylamino.

Also preferred are compounds of formula XII wherein: R is hydrogen, 01-08 alkyl, 02-06 alkenyl, 02-06 alkynyl, 03-08 cycloalkyl, or (03- Cs)cycloalkyl) 01-03 alkyl, or R is phenyl substituted with up to five groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, WO 02/49993 WO 0249993PCT/USOO/26816

CI-C

8 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, CI-C 6 alkoxy, amino, and mono- or di(Ci-C 6 )alkylamino, aminocarbonyl, sufonamido, mono or di(Cl- C6)alkylsulfonainido, 3,4-methylenedioxy, and 3,4-(1 ,2-ethylene)dioxy; R?2 is C 3

-C

6 alkyl;

R

3 is hydrogen, methyl, or ethyl;

R

4 is C 3

-C

8 alkyl, C 2

-C

8 alkenyl, C 2

-C

8 alkynyl, C3aCscycloalkyl, (C 3 8 cycloalkyl)CI

C

4 alkyl, C 1

-C

8 haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 01-C6 alkoxy, amino and mono- or di(Ci- Cr)alkylamino,

R

4 is phenyl, phenyl(Cl-C4alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz[dlisoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-06 alkyl, C 2 6 alkenyl, C2-6 alkynyl, C 1

-C

6 alkoxy, amino, mono- or di(CI-Cri)alkylamino, amino(Ci- Cri)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(CI-C6)alkylaminocarbonyl, Ci-Cr)alkylsulfonylaminocarbonyl, 1azetidinyl, 1-pyrrolidinyl, 1 -piperidyl; Ar 1 is phenyl with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-Cri alkYl, C2-6i alkenyl, C2-6 alkynyl, Cj-Cri alkoxy, amino, mono- or di(Cl- Cr)alkylamino, and amino (Cl- C6)alkoxy; Ar2 is phenyl, phenyl(Cl-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo[blthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, or benz[djisoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, WO 02/49993 PCT/USOO/26816 trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-C 6 alkyl, C 2 -6 alkenyl, C 2 6 alkynyl, CI-C 6 alkoxy, amino, mono- or di(Ci-Cri)alkylamino, amino(Ci-

C

6 )alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(C l-C6)alkylarninocarbonyl, Cl-C 6 ,)alkylsulfonylaminocarbonyl, 1azetidinyl, 1-pyrrolidinyl, 1-piperidyl; or Arn is bicyclic oxygen-containing groups of the formula: wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2 6 alkenyl, C 2 6 alkynyl, Ci-C 6 alkoxy, amino, and mono- or di(Cl-C6)alkylamino.

Also preferred are compounds of formula XII wherein: R is hydrogen, Cj-C 8 alkyl, C 2 -C6 alkenyl, C 2

-C

6 alkynyl, C3-C 8 cycloalkyl, or (Cs- C8)cycloalkyl) Cl-C3 alkyl, or phenyl; R2 is C 3

-C

6 alkyl; R3 is hydrogen, methyl, or ethyl;

R

4 is CsC8 alkyl, C 2

-C

8 alkenyl, C2sCB alkynyl, C3-Cscycloalkyl, (C 3 8 cycloalkyl)Cl-

C

4 alkyl, C 1 -C3 haloalkyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyaria, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci-C 6 alkyl,

C

2 6 alkenyl, C 2 6 alkynyl, Cj-C 6 alkoxy, amino and mono- or di(Ci-

C

6 )alkylamino; Ar 1 is phenyl. with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2 6 alkenyl, C 2 6 alkynyl, Ci-C 6 alkoxy, amino, mono- or di(Ci-

C

6 )alkvlansino, and amino (Ci-C 6 )alkoxy; and Ar 2 is phenyl, phenyl(C 1 alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo[b]thiophenyl, WO 02/49993 PCT/USOO/26816 benzodioxanyl, benzodioxinyl, benzodioxolyl, or benz[dlisoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 0 1

-C

6 alkyl, C2-C6 alkenyl, 02- 06 alkynyl, Cl-C 6 alkoxy, amino, mono- or di(CI-C 6 )alkylamino, arnino(Oi- C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Cl-C6)alkylaminocarbonyl, 01-06) alkylsulfonylaminocarbonyl, 1azetidinyl, 1 -pyrrolidinyl, 1 -piperidyl; or Ar 2 is bicyclic oxygen-containing groups of the formula: 0 wherein RB3 represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 01-06 alkoxy, amino, and mono- or di(Cl-C 6 )alkylamino.

Also preferred are compounds of formula XLI wherein: R is hydrogen, 01-08 alkyl, C 2

-C

6 alkenyl, 02-06, alkynyl, C3-C8 cycloalkyl, or (C 3 C8)cycloalkyl) 01-03 alkyl, or phenyl;

R

2 is 03-06 alkyl;

R

3 is hydrogen, methyl, or ethyl;

R

4 is phenyl, phenyl(CI-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzofblthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, benz~djisoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 0 1

-C

6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 01-06 alkoxy, amino, mono- or di(Cl-C6)alkylamino, amino(Ci-

C

6 )alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono WO 02/49993 WO 0249993PCT/USOO/26816 or di(CI-C 6 )alkylaminocarbonyl, C1-C6)alkylsulfonylaminocarbonyl, 1Iazetidinyl, 1-pyrrolidinyl, 1 -piperidyl; Arl is phenyl with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-0 6 alkyl, C 2 6 alkenyl, C 2 6 alkynyl, Cl-C 6 alkoxy, amino, mono- or di(Ci-

C

6 )alkylamino, and amino (Cl-C6)alkoxy; Ar 2 is phenyl, phenyl(Gi-C 4 )alkyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, chromanyl, dihydrobenzofuranyl, naphthyl, indolyl, indanyl, benzo[bjthiophenyl, benzodioxanyl, benzodioxinyl, benzodioxolyl, or benz[dlisoxazolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, C 2 -6 alkenyl, C 2 .6 alkynyl, 01-06 alkoxy, amino, mono- or di(CI-0&)alkylamino, amino(Cl-

C

6 )alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(C l-C6)aHlyaminocarbonyl, C1-C6alkylsulfonylaminocarbonyl, 1azetidinyl, I-pyrrolidinyl, 1-piperidyl; or Ar 2 is bicyclic oxygen-containing groups of the formula: 0 wherein RB represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, 02-6 alkenyl, C2-6 alkynYl, C 1

-C

6 alkoxy, amino, and mono- or di(C1-C6)alkylamino.

The invention also includes compounds of the following formula XIII: Ar 3

'N

m Ar 2 Arl X11 or a pharmaceutically acceptable salt thereof, wherein: WO 02/49993 PCT/US00/26816 n is 1, 2, or 3 M represents a carbon chain that may be substituted with hydrogen, halogen, cyano, nitro amino, mono or dialkyl amino, alkenyl, alkynyl, alkoxy, trifluoromethyl, trifluoromethoxy, straight or branched chain alkyl, or cycloalkyl, and n is 1, 2, or 3; Arl, Ar2, and Ar 3 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and

R

1 represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, alkoxy, acetoxy, mono- or dialkylamino, cyano, nitro, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH 2 mono or dialkylaminocarbonyl, sulfonamido, and mono or dialkylsulfonamido.

Also preferred are compounds of formula XIII wherein n, m, and R 1 are defined as for formula XIII above; Ar 1 and Ar 3 are independently chosen from phenyl, pyridyl, and pyrimidinyl each of which is optionally optionally substituted or substituted with up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, C 1

-C

6 alkoxy, acetoxy, mono- or di(Ci-C)alkylamino, cyano, nitro, CI-C 6 haloalkyl, Ci-Cr, alkyl, C 2 -Cs alkenyl, C 2 -C6 alkynyl, C 3

-C

8 cycloalkyl, (C 3 -Cscycloalkyl) Ci-Csalkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH 2 mono or di(Cl-Cs)alkylaminocarbonyl, sulfonamido, 3,4-methylenedioxy, ethylenedioxy, and mono or di(C1-Cs)alkylsulfonamido; and Ar 2 represents suberanyl, indanyl, tetrhydronaphtyl, or indolyl, each of which is optionally optionally substituted or substituted with up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, C 1

-C

6 alkoxy, acetoxy, mono- or di(Ci-Cs)alkylamino, cyano, nitro, Cl-C 6 haloalkyl, WO 02/49993 PCT/USOO/26816 Ci-C 6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C 3 -C8 cycloalkyl, (C 3 -Cgcycloalkyl)

CI-C

3 alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH 2 mono or di(CI-C6)alkylaminocarbonyl, sulfonamido, 3,4-methylenedioxy, ethylenedioxy, and mono or di(Cl-C6)alkylsulfonamido.

Also preferred are compounds of formula XIII above wherein: Ri, R 3 and Rs each represent up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, Cl-C 6 alkoxy, acetoxy, mono- or di(Cl-C 6 )alkylamino, cyano, nitro, CI-C 6 haloalkyl, Ci-C 6 alkyl, C 2 -C6 alkenyl, C 2

-C

6 alkynyl, C3-C 8 cycloalkyl, (C3-Cacycloalkyl) Cl-Caalkyl, hydroxy carbonyl (COOH), aminocarbonyl

(CONH

2 mono or di(Cl-C6)alkylaminocarbonyl, sulfonamido, and mono or di(Ci- C6)alkylsulfonamido; and represents suberanyl, indanyl, tetrhydronaphtyl, or indolyl, each of which is optionally optionally substituted or substituted with up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, CI-C 6 alkoxy, acetoxy, mono- or di(Cl-C6)alkylamino, cyano, nitro, Cl-C 6 haloalkyl, Cl-C 6 alkyl, C2-C 6 alkenyl, C 2

-C

6 alkynyl, C3-CS cycloalkyl, (C 3 -Cscycloalkyl) CI-Csalkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH 2 mono or di(CI-C 6 )alkylaminocarbonyl, sulfonamido, 3,4methylenedioxy, ethylenedioxy, and mono or di(Cl-C6)alkylsulfonamido.

The invention also includes compounds of the followinf formula XIV: WO 02/49993 PCT/US00/26816 inrl L or a pharmaceutically acceptable salt, thereof, wherein: R represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, alkoxy, acetoxy, mono- or dialkylamrnino, cyano, nitro, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH2), mono or di(C-C)alkylaminocarbonyl, sulfonamido, 3,4-methylenedioxy, ethylenedioxy, and mono or dialkylsulfonamido;

R

1 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl each of which may be optionally substituted; or

R

1 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkyl, or an optionally substituted heteroalicyclic or heteroalicyclicalkyl group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; and Anrl and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or an optionally substituted heteroalicyclic or heteroalicyclicalkyl group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Preferred compounds of formula XIV include those (referred to herein as compounds of formula XIV-A) wherein R represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, C 1 -Cs alkoxy, acetoxy, mono- or di(CI-C6)alkylamino, cyano, nitro, C1- C6 haloalkyl, C 1 -Cs alkyl, C2-C6 alkenyl, C 2

-C

6 alkynyl, C3-C8 cycloalkyl, (C3- C8 cycloalkyl) C 1

-C

3 alkyl, hydroxy carbonyl (COOH), aminocarbonyl (CONH2), WO 02/49993 PCT/USOO/26816 mono or di(CI-C6)alkylaminocarbonyl, sulfonamido, 3,4-inethylenedioxy, ethylenedioxy, and mono or di(Cl-C6)alkylsulfonarnido;

R

1 is CI-8 alkyl, C2.8 alkenyl, C2-8 alkynyl, C3-8cycIoalky, (C3-8 CYCIOalkyl)CI.

4 alktyl, each or which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, C 2 6 alkenyl, C2-6 alkynyl, 0 1

-C

6 alkoxy, amino and mono- or di(Cl-C 6 )alkylamino, or

R

1 is phenyl, phenylalkyl, chromanyl, chromanylalkyl, imidazolyl, imidazolylalkyl, pyridyl., pyridylalkyl, pyrimidyl, pyrimdylalkyl, pyrazinyl, pyrazinylalkyl, indolyl., indolylalkyl, indanyl, indanylalkyl, benzodioxolylalkyl, or benzodioxolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, C2- 6 alkenyl, C 2 6 alkynyl, 01-06 alkoxy, amino, mono- or di(CI-C 6 )alkylamino, amino(C 1-C6) alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(CI-C6)alkylarninocarbonyl, Cl- C6)alkylsulfonylaminocarbonyl, 1 -azetidinyl, 1 -pyrrolidinyl, and 1-piperidyl; Ar 1 is chosen from phenyl, pyrrolyl, imidazolyl., pyrazolyl, triazolyl, thiophenyl, and pyridyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Cl-C 6 alkyl, 02-6 alkenyl, C2-6 alkynyl, 01-06 alkoxy, amino, mono- or di(CI-C6)alkylamino, amino(CI-C6)alkoxy, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(C1-C6)alkylaminocarbonyl, and N-(Cl- C6,)alkylsulfonylaminocarbonyl; and Ar 2 is chosen from phenyl, phenylalkyl, chromanyl, chromanylalkyl, pyrrolyl, pyrrolylalkyl, furanyl, furanylalkyl, thienyl, thienylalkyl, pyridyl, pyridylalkyl, pyrimidyl, pyrimidylalkyl, pyrazinyl, pyrazinylalkyl, benzimTidazolyl, benzimidazolylalkyl, imidazopyrdinyl, imidazopyrdinylalkyl, naphthyl, napthylalkyl, indolyl, indolylalkyl, indanyl, indanylalkyl, benzofuranyl, WO 02/49993 PCT/USOO/26816 benzofuranylalkyl, benzodioxinyl, benzodioxinylalkyl, benzodioxolyl, benzodioxolylalkyl, quinolinyl, quinolinylalkyl, isoquinolinyl, isoquinolinylalkyl, each of which may be optionally substituted or substituted with up to four groups independently selected from: halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, 01-06 alkyl, C 2 6 alkenyl, CM, alkynyl, 01-06 alkoxy, amino, mono- or di(Ci-C 6 )alkylamino, mono- or di(CI-C6)alkylamino(Cl- C6)alkyl, amino(CI-C6)alkoxy, Ci-C6 alkoxyCl-C6 alkyl, 0i-Cr, alkoxyCI-C 6 alkoxy, carboxylic acid, esters of carboxylic acids, arninocarbonyl, mono or di(Ci-C 6 alkylaminocarbonyl, N-(C 1- 06) alkylsulfonylaminocarbonyl, benzyl (which may be unsubstituted or substituted with one or more substituents independently chosen from halogen, Cl-C6alkyl, and Cj-

C

6 alkoxy), -01-06 alkylNR 2 R3 or -CI-C 6 alkoxy NR 2

R

3 wherein the point of attachment to Ar 2 is at the C1-06 alkyl or 01-06 alkoxy, and R 2 and R 3 are hydrogen, or straight or branched chain alkyl and are optionally substituted with halogen, hydroxy, or 01-06 alkoxy and R 2 and R 3 may be taken together with the nitrogen to which they are attached to form a heterocycloalkyl group.

Preferred compopunds of formula XLV-A include those wherein: -xi Nr WO 02/49993 PCT/USOO/26816 wherein: Ar2 is as defined in Claim in formula XIV-A; Rx represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, C 1

-C

6 alkoxy, acetoxy, mono- or di(Cl-C 6 jalkylamino, cyano, nitro, CI-C 6 haloalkyl, Cl-C 6 alkyl, C 2

-C

6 alkenyl, and C 2

-C

6 alkynyl; and RI is Ci-Ccalkyl, C 3 Cscycloalkyl, (C 3

-C

8 cycloalkyl)C1pC 4 alkyl, phenyl, phenylCi-

C

6 alkyl, chromanyl, chromanylCl-C 6 alkyl, inidazolyl, imidazolylCI-C 6 alkyl ,pyridyl, PYridYlCi-C 6 alkyl, pyrimidyl, pyrimnidylCI-C 6 alkyl,pyrazinyl, pyrazinylCl-C6alyl, indolyl, indolylCI-C 6 alkyl, indanyl, indanylCl-C 6 alkyl, benzodioxolyl, or benzodioxoyC 1

-C

6 alkyl each or which may be unsubstituted or substituted with up to 4 substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2 _f alkenyl, C 2 alkynyl, Ci-Cr, alkoxy, amino and mono- or di(Cl-C6)alkylamino.

Additional preferred compounds of formula XIV-A includes those of the following formula: Ar 2 Rxg0 wherein: Rx represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, Cl-C 6 alkoxy substituted with 0-2 R 2 acetoxy, mono- or di(C1-C6)alkylamino, cyano, nitro, Cl-C6 haloalkyl, Cl-C 6 alkyl, C 2

-C

6 alkenyl, and C 2

-C

6 alkynyl; WO 02/49993 PCT/USOO/26816 Ri is phenyl, phenylCI-C 6 alkyl, 03-08 cycloalkl, 0 3

-C

8 cycloalky(C1-C4 alkyl), naphthyl, napthylCi-C 6 alkyl, indanyl, indanyl~l-06 alkyl, benzodioxolanyl, or benzodioxolanylCI-C 6 alkl, each of which may be substituted by up to 4 groups chosen from halogen, hydroxy, amino, 01-06 alkoxy, acetoxy, monoor di(Cl-C 6 )alkylamino, cyano, nitro, 01-06 haloalkyl, 01-06 alkyl; and Ar 2 represents phenyl, benzyl, indanyl, indanyl-CH 2 benzodioxolanyl, or benzodioxolariyl-CH2-; each of which is substituted by up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, Cl-C 6 alkoxy, aectoxy, mono- or di(Cl-06)alkylamino, cyano, nitro, 01-06, haloalkyl, 01-06 alkyl, 02-06 alkenlyl, and 02-06 alkynyl.

Additional preferred compounds of formula XIV includes those wherein: Ar 2 is as defined for formula XIV; R represents up to 4 groups independently chosen from hydrogen, halogen, amino, 01-06, alkoxy, 01-06 alklI, trifluoromethyl, and trifluoromethoxy; Ri is phenyl, benzyl, C3-CB cycloalkyl, C3-Os cycloalkyl(CI-C 4 alkyl), naphthyl, naphthyl-011 2 indanyl, indandyl-CH2-, benzodioxolalyl-CH2-, or benzodioxolanyl, each of which may be substituted by up to 4 groups chosen from halogen, hydroxy, amino, 01-06 alkoxy, acetoxy, mono- or di(Cl- CG)alky3lamino, cyano, nitro, 01-06 haloalkyl, 01-06 alkyl; and Arl is chosen from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thiophenyl, each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, trifluoromethyl, trifluoromethoxy, 01-06 alkoxy, 01-06 alkyl, and amino.

Also preferred are compounds of the formula XIV above wherein: R represents up to 4 groups independently chosen from hydrogen, halogen, amino, 01-06 alkoxy, C1-06, alkyl, trifluorometbyl, and trifluoromethoxy; WO 02/49993 WO 0249993PCT/USOO/26816 Ri is benzyl which is unsubstituted or substituted by up to 4 groups chosen from halogen, hydroxy, amino, 0 1

-C

6 alkoxy, acetoxy, mono- or di(Ci- C6)alkylalnino, cyano, nitro, C 1

-C

6 haloalkyl, Cl-C6 alkyl.; Ar 1 is chosen from pyrrolyl, irnidazolyl, pyrazolyl, triazolyl, thiophenyl., each of which may be optionally substituted or substituted with up to four groups independently selected from halogen, trifluoromethyl, trifluoromethoxy, Cl-C6 alkoxy, CI-C6 alkyl, and amino; and Ar 2 is chosen from phenyl, benzyl, indolyl, indolyl-CH 2 indanyl, indanyl-CH 2 chromanyl, chromanyl-CH 2 benzofuranyl, benzofuranyl-CH 2 benzodioxinyl, benzodioxinyl-CH 2 benzodioxolyl-CH 2 and benzodioxolyl, each of which may be optionally substituted or substituted with up to four groups independently selected from: halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, CI-C 6 alkyl, C 2 6 alkenyl, C2-6 alkynyl, Ci-C 6 alkoxy, amino, and mono- or di(Cl-C6)alkylamino.

Preferred compounds of formula XIV also include thos eof the following formula IV-B: N 0

R

NN

R""

1 Ry wherein: WO 02/49993 PCT/US00/26816 m is 0, 1, 2, or 3, and m represents a carbon chain which is optionally substituted with methyl, ethyl, methoxy, ethoxy, hydoxy, halogen, or amino; R represents up to 4 groups independently chosen from hydrogen, halogen, hydroky, amino, Ci-C 6 alkyl, C 2

-C

6 alkenyl, C 1

-C

6 alkynyl, C-C 6 alkoxy, acetoxy, monoor di(CI-Cs)alkylamino; Rx and Ry each represent up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, C1-C 6 alkoxy, acetoxy, mono- or di(C 1

C

6 )alkylamino, cyano, nitro, C1-C6 haloalkyl, C 1

-C

6 alkyl, C 2

-C

6 alkenyl, and

C

2 -Cs alkynyl; and

R

1 and R 4 are independently selected from Cl-C 6 alkyl, C3-Cscycloalkyl, (C3-Cs cycloalkyl)Ci C 4 alkyl, phenyl, phenylCi-C 6 alkyl, pyridyl, and pyridylCi- C6alkyl, each or which may be unsubstituted or substituted with up to 4 substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C 1

-C

6 alkyl, C 2 6 alkenyl, C 2 -6 alkynyl, C-C 6 alkoxy, amino and mono- or di(CI-C 6 )alkylamino.

The invention also provides compounds of the following formula XV: Arl -N

N-NM

n Ar 2 R2 or a pharmaceutically acceptable salt thereof, wherein; m is 0, 1, 2, or 3, and m represents a carbon chain which is optionally substituted with methyl, ethyl, methoxy, ethoxy, hydoxy, halogen, or amino; WO 02/49993 PCT/US00/26816 n is O, 1, 2, or 3, and n represents a carbon chain which is optionally substituted with methyl, ethyl, methoxy, ethoxy, hydoxy, halogen, or amino; R represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, alkoxy, acetoxy, mono- or dialkylamino, cyano, nitro, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, and(cycloalkyl)alkyl;

R

2 is i) hydrogen, halogen, hydroxy, amino, alkoxy, mono- or dialkylamino, cyano, nitro, haloalkyl, and ii) alkyl, alkenyl, alkynyl, cycloalkyl, and (cycloalkyl) alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, mono- or dialkylamino; and Arl and Ar2 are independently optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkyl, or an optionally substituted heteroalicyclic or heteroalicyclicalkyl group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms.

Preferred compounds of formula XV include those of the following formula: m is 1 and m represents a carbon chain which is unsubstituted; n is 1 and n represents a carbon chain which is unsubstituted; R represents up to 4 groups independently chosen from hydrogen, halogen, hydroxy, amino, C1-C6 alkoxy, acetoxy, mono- or di(Ci-C6)alkylamino, cyano, nitro, Ci-

C

6 haloalkyl, C 1

-C

6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl; C 2

-C

6 cycloalkyl, and(Cs-Cs cycloalkyl) C 1

-C

4 alkyl;

R

2 is C 3 -Cs alkyl or C 3 -Cs cycloalkyl; WO 02/49993 PCT/US00/26816 Ari and Ar2 are independently chosen from phenyl, phenyl(Ci-C 4 )alkyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, and pyrazinyl, each of which may be unsubstituted or optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy,

C

1

-C

6 alkyl, C 2

-C

6 alkenyl, C 2

-C

6 alkynyl, C1-C 6 alkoxy, amino, mono- or di(Ci-C 6 )alkylamino.

Compounds of the invention may have one or more asymmetric centers or planes. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms (racemates), by asymmetric synthesis, or by synthesis from optically active starting materials. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral (enantiomeric and diastereomeric), and racemic forms, as well as all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.

Some compounds of the invention may exist as tautomers. Unless otherwise specified any description or claim of one tautomeric form is intended to encompass the other tautomer.

Specifically preferred compounds include those shown in the FIGS. 1 through 6. In those figures, the substituent X depicts the moiety linkage to the base compound whose strucutre is shown at the top of each Figure.

WO 02/49993 PCT/USOO/26816 Addiional preferred compounds of the invention include the following (compounds structures are shown directly above the compound chemical name in many instances): 1-butyl)-2-phenyl-5-(N, N-di[3,4-methylenedioxyphenyl methyl])aminomethylimidazole; 1-butyl)-2-phenyl-5-( ,4-methylenedioxyphenylmethyl-Nphenylmethyl]arnino)ethylimidazole; 1-Butyl-2-phenyl-4-bromo-5-(N-phenylnethy-N-[ 1-butyll)aminomethylimidazole; 1-(l1-Butyl)-2-phenyl-4-methyl-5-(N-[3,4-methylenedioxyphenyl-methyl]-Nphenylmethyl)aininomethylimidazole; 1-(l1-Butyl)-2-(4-fluorophenyl)-5-(N-[1I,4-benzodioxan-6-yljmethyl-Nphenylmethy) aminomethylimidazole; l-(l1-Butyl)-2-(4-fluorophenyl)-5-(N-[3 ,4-methylenedioxyphenylmethyl-Nphenylmethyl) aminomethylimidazole; l-(l1-Butyl)-2-(4-fluorophenyl)-5-(N-[ 1,4-benzodioxan-6-yl]methyl-Nphenylmethyl) aminomethylimidazole; 0 1 -Butyl)-2-(4-fluoropheny)-5-(N-[3 ,4-methylenedioxyphenylmethyl]-Nphenylmethyl) aminomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1 1-Butyl)-2-(2-fluorophenyl)-5-(N-[ 1,4-benzodioxan-6-ylmethyl]-Nphenylmethyl)amino- methylimidazole; 1 1-Butyl)-2-(2-methoxyphenyl)-5-(N-[naphtha-2-ylmthy]-Nphenylmethyl)amino-methyimidazole; 1 1-Butyl)-2-(2-methoxyphenyl)-5-(N-[3,4-methylenedioxyphenylmethyl-Nphenylmethyl) aminomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1 -Butyl)-2-(2-mnethoxyphenyl)-5-(N,N-di[3,4-methylenedioxyphenylnaethyl]) aminomethylimidazole;

N

1-(l1-Butyl)-2-(2-methoxyphenyl)-5-(N-[4-dimethylaminophenylmethyl]-Nphenylmethyl) aminomethylimidazole;

N

0-I 1-(l1-Buty) -2-(2--methylphenyl)-5-(N-[3,4-rnethylenedioxyphenylmethyl]-Nphenylmethyl) aminomethylimidazole;

F

1-(l1-Butyl)-2-(4-fluorophenyl)-5-(N,N-di[3,4methylenedioxyphenylmethyl])amino- methylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1-Butyl)-2-(2-methylphenyl)-5-(N,N-di[3 ,4methylenedioxyphenylniethyl]) amino- methylimidazole; 1 -iutyl)-2-(3-fluorophenyl)-5-(N-fnaphth-2-ylrnethyJ-Nphenylmethyl)amino m ethyl im idazole;

F

1-(l1-Butyl)-2-(3-fluorophenyl)-5-(N-[3,4-methylenedioxyphenylmethyl-Nphenylmnethyl) aminomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1 -Butyl)-2-(3-fluorophenyl)-5-(N,N-di[3,4methylenedioxyphenylmethyl]) amino- methylimidazole; 1-(l1-Butyl)-2-(3-methoxyphenyl)-5-(N- [3 ,4-methylenedioxyphenylmethyl]-Nphenylmethyl)- aminomethylimidazole; 1 1-Butyl)-.2-phenyl-5-{1 ,4-methylenedioxyphenylmethyl.-Nphenylmethyl) amino) ethylimidazole; WO 02/49993 PCT/USOO/26816 1 -Pentyl)-2-phenyl-5-(N-[indol-5-ylmnethyl]-N-phenylmethyl) aminomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 Bis-benzo[ 1,3]dioxol-5-ylmethyl-(3-butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl)-amine BenzoI 1,3]dioxol-5-ylmethyl-benzyl-[3-butyl-5-(4-methoxy-phenyl)-2-phenyl-3H-imidazol-4-ylmethyl]amine 4-({Benzyl-[1-(3-butyl-2,5-diphenyl-3H-iniidazoI-4-y1)-ethyl]-amino}-methyl)-benzamide WO 02/49993 WO 0249993PCT/USOO/26816 4-{EBenzyl-(3-butyl-2,5-diphenyl-3H-imidazol-4-yhnethyl)-anino]-methyl-3-chlorophenol 4-(E 1-(3-Butyl-2-phenyl-3H-inidazob-4-yl)-pentyl]-cyclohexylmethyl-amino-methyl)phenol 4-ftBenzyl-(3-butyl-2,5-diphenyl-3H-imidazol-4-ymethyl)-anino-niethyl-benzamide

I

N N

HN/

WO 02/49993 WO 0249993PCT/USOO/26816 1 1-Propyl)-2-phenyl-5-(N-[indol-5--ylmethyl]-N-phenylrnethyl) aminoniethylimidazole; 1 1-Butyl)-2-phenyl-5-(N-[ 1 -(S)-phenyethyl]-Nphenylmethyl)aminomethylimidazole; 1 -Butyl)-2-phenyl-5-(N-[l1-(R)-phenylethyl]-Nphenylmethyl)aminomethylimidazole; 1 1-Butyl)-.2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl-N-[3 ,4dichlorophenyllmethyl)aminomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 0 1 -Butyl)-2-phenyl-5-(N,N-di[3,4-methylenelioxyphenylmethyl]) aminomethylimidazole; 1 1-B-ty1)-2-pheny1-5-(N-[3,4-methylenedioxyphenylmethyJ-N-[3,4methoxyphenylmethyl])-aminomethylimidazole; ro 'N

N

I-fluty1)-2-pheny1-5-(N-13,4-methylenedioxyphenylmethyJ-N-[4-{l propyllphenylmethyl]) aminomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1-Butyl)-2-phenyl-5--(N-[3,4-methylenedioxyphenylmethyl]-N-[3,4diclalorophenylethyl]) aminomethylimidazole; N02 1 1-Butyl)-2-.phenyl-5-(N- [3,4-methylenedioxyphenyllmethyl-N-14 nitrophenylmethyl]) aminomethylimidazole; 1 -Butyl)-2-phenyl-5-(N-[3 ,4-methylenedioxyphenylnethyl]-N- 1 propyloxy} phenylmethyl])aminomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1-(l1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl-N-[quinol-6ylmethyl])- aminomethylimidazole; 1-Butyl) -2-phenyl-5-(N-[3 ,4-methylenedioxyphenylmethyl]-N-[2,3dichlorophenylmethyl])-aminomethylimidazole; 1-Butyl) -2-phenyl--5-(N-[3,4-methylenedioxyphenylmethyl-N-[3,4dirnethylphenylmethyl])-aminomethylinidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1-(l1-Butyl)-2-phenyl-5-(N-[3 ,4-methylenedioxyphenyllmethyl-N-[indan-2-yl])aminomethylimidazole; I N 1-(l1-Butyl)-2-phenyl-5-(N-[3 ,4-methylenedioxyphenylmethyl]-N-[2phenylethyl])amino-methylimidazole; <0 1 1-Propyl)-2-phenyl-5-(N-[ 1 ,4-benzodioxan-6-ylmethyl-Nphenyh-nethyl)aminomethyl-imidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1-(l1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl] -Nphenylmethyl)aminomethyl-imidazole; 1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl-Nethyl) aminomethylimidazole; 1 -Butyl)-2-phenyl-5-(N- [3,4-methylenedioxyphenylmethyl-N-1 1propyll)aminornethyl-imidazole; ~N17IJKN 0 1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylnethyl-N- [1butyl])aminomethyl-imidazole; WO 02/49993 WO 0249993PCT/USOO/26816 N N

N

1-Butyl)-2-phenyl1-5-(N-[3 ,4-methylenedioxyphenylmethyl]-Ncycloheptylmethyl)amino-methylimidazole; 1-Butyl)-2-phenyl-5-(N-[3 ,4-methylenedioxyphenymethyl-Nisobutyl)aminomethyl-imidazole; 1 -Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl]-N-[2cyclopentylethyl])amino-methylimidazole; 1 1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl] cyclopentylpropyl])amino-mcthylimidazolc; WO 02/49993 WO 0249993PCT/USOO/26816 rou' 0 1-(1-Butyl)-2-phenlyl-5-(N- [3,4-inethylenedioxyphenylmethyl-N-f 1-noctyll)aminomethyl-imidazole; 1-(l1-Butyl)-2-phenyl-5-(N- [3 ,4-methylenedioxyphenylmethyl]-Ncyclopropylmethyl)amino-methylimidazole; 1 1-Butyl)-2-phenyl-5- (N-[3,4-.methylenedioxyphenylmethyl-Ncyclopentylmethyl)amino-methylimidazole; 1 1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl]-Ncyclohexylmethyl)amino-methylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1-Butyl)-2-phenyl-5-(N-13 ,4-methylenedioxyphenylmethyl]-N-[tamyll)aminomethylimidazole; ~~hIRN I 1 1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl]-N-[1 methyllbutyl)]amino-methylimidazole; -Jo> 1 1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl-N-[l1-{2,2dimethyl~butyll) aminomethyimidazole; Ih NN Me 1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxvyphenylnethyl]-Nmethyl)aminomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 N 0 1-Butyl)-2-phenyl-5-(N-[3 ,4-methylenedioxyphenyhmethyl]-N- [2thiophenylmethyl)amino-methylimidazole; 1 -Butyl)-2-phenyl-5-(N-[3 ,4-methylenedioxyphenymethyl]-N- ylmethyl])amino-methylimidazole; 1 1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl-N-[1 yllmcthyl])am-inomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1-(1-Butyl)-2-phenyl-5-(N-(3,4-methylenedioxyphenyljmethyl-N-[4-hydroxy-2chlirophenyl] -methyl)aminomethylimidazole;

HO

1 1-Butyl)-2-(3-fluorophenyl)-5-(l1-[N-{2-chloro-4-hydroxyphenyllmethyl-Nphenylmethyl]) aminoethylimidazole; 1-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenyljmethyl-N-[2 13- WO 02/49993 PCT/USOO/26816 1 -Butyl-2-(4-fluorophenyl)-5-(l1-[N-{3 ,4-methylenedioxyphenyl~methyl-Nphenyhmethyll-amino)ethylitnidazole; N7KN s N 1 -Butyl)-2-(2-thienyl)-5-(N-[3 ,4-methylenedioxyphenyl]methyl-N-phenylmethyl] amninomethylimidazole;

H

3 CO OCH 3

OCH

3 1-Butyl)-2-phenyl-5-(N-[3,4, methylimidazole; O~OCK3

OCH

3 1-Butyl)-2-phenyl-5-(N-phenylmethyl-N-[3 ,4diinethoxyphenylmethyl])aminomethyl-imidazole; WO 02/49993 WO 0249993PCT/USOO/26816

N(CHS)

2 1-(l1-Butyl)-2-phenyl-5-(N-[4-dimethylaminophenylmethyl-Nphenylmethyl~aminomethy1-imidazole;

N

NHC H 3 1-(l1-Butyl)-2-phenyl-5-(N-[4-methylaminophenylmethyl-Nphenylmethyl)arninomethyl-imidazole;

NH

2 1 -Butyl)-2-phenyl-5-(N-[3-methylA4-aminophenylmethyl]-Nphenylmethyl)aininomethyl-imidazole); WO 02/49993 WO 0249993PCT/USOO/26816 1-(l1-Butyl)-2-phenyl-5-(N-[2,3-dichlorophenylmethyl]-Nphenylmethyljaminomethylimiidazole; 1 1-Butyl)--2-phenyl-5-(N-[3,4-dichlorophenylmethyl]-Nphenylmnethyl)an-inomethylimidazole; 1 -Butyl)-2-phenyl-5-(N- [3,4-difluorophenylmethyl-Nphenylmethyl)amrinomethylimidazole; 1-(l1-Butyl)-2-phenyl-5-(N-(benzofbjthiophen-5-ylmethyl)-Nphenyhnethyl)aminomethyl-imidazole; WO 02/49993 WO 0249993PCT/USOO/26816

ORE

1-(l1-Butyl)-2-phenyl-5-(N-[4-ethoxyphenyhnethyl -Nphenylmethyl)amrinomethylimidazole; N Br 1-(l1-Butyl)-2-phenyl-4-bromo-5-(N-phenylmethyl-N-[1-butyl])aminoniethylimidazole;

N

OMe 1.-(l1-Butyl)-2-phenyl-5- (N-[4-methoxyphenylmethyl]-Nphenylmethyl)aminomethylimidazole;

N

1-Butyl) -2-phenyl-5-(N-16-chloro-3,4-methylenedioxyphenylmethyl-Nphenylmethyl)-arninomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1 1-Butyl)-2.-phenyl-5-(N-[2 ,3-dichlorophenylmethyll-N-[ 1butyl])aminomethylimidazole; 1 1-Butyl)-2-phenyl-5-(N-[3-methoxyphenylmethyl]-Nphenylmethyl)aminomethylimidazole; 1 -Buty1)-2-phenyl-5-(N-12-chloro-4-fluorophenylnethylI-Nphenylmethyl)aminomethyl-inidazole; 1-(l1-Butyl)-2-phenyl-4-bromo)-5-(N-[2,3-dichlorophenylmethyl-N-[ 1butyl])aminomethyl-imidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1-Butyl)-2--phenyl-5-(N-[2 ,6-dichlorophenylmethyl]-Nphenylmethyl)aminomethylimidazole;

OH

1-(1-Butyl)-2-phenyl-5-(N-[2-chloro-4-hydroxyphenylnethyl]-Nphenylmethyl)aminomethyl-imidazole; 1 1-Butyl)-2-phenyl-4-chloro-5-(N-phenylmethyl-N-[l1-butyl])aminornethylirnidazole; WO 02/49993 WO 0249993PCT/USOO/26816 4-{[Benzyl-(3-butyl-2 ,5-diphenyl-3H-imidazol-4-ylmethyl)-aminol-nethyl-2-methylphenol 4-{[(3-Butyl-2,5-diphenyl-3H-imnidazol-4-ylmethyl)-cyclohexylmnethyl-amino-methyl-2methyl-phenol (3-.Butyl-2,5-diphenyl.-3H-imidazol-4-yhmethyl)-(2,6-difluoro-benzyl)-(4-methoxy-benzyl)amine WO 02/49993 WO 0249993PCT/USOO/26816 Benzo[1 ,3]dioxol-5-ylmethylhbuty1-[3-buty1l-2-(2-methoxy-pheny)-5-pheny-3H-imidazo-4-yI methyll-arnine O- N N N-

SO

2

NH

2 4-({Benzyl-[3-butyl-2-(2-methoxy-phenyl)-5-phenyl-3H-imidazol-4-ylmethyl-amino-methyl)benzenesulfonamide Benzo[ 1,3jdioxol-5-ylmethyl-benzyl-[3-butyl-2-(2-methoxyr-phenyl)-5-phenyl-3H-imidazol-4-yl methyl]-amine WO 02/49993 WO 0249993PCT/USOO/26816 4-({Butyl-f3-butyl-2-(3-methoxy-phenyl)-5-phenyl-3H-inidazol-4-ymethyl]-amino-methy )-3-chlorophenol 4-{J(3-Butyl-2,5-diphenyl-3H-imidazol-4-yhnethyl)-(4-methoxy-benzyl)-amino-methyl-benzoic acid phenol WO 02/49993 WO 0249993PCT/USOO/26816 Benzo[1 ,3jdioxol-5-ylmethyl-benzyrl-[1-(3-butyl-2 ,5-diphenyl-3H-irnidazol-4-yl)-pentyrl]-amnine Benzo[ 1 7 3dioxol-5-ylmethyl-benzyl-[ 1-(3-butyl-2,5-diphenyl-3H-imidazol-4-yl)-ethyl]-amine 4-{tButyl-(3-buty1-2,5-dipheny-3H-imidazol-4-ylmethy)-aminol-methyl}-benzamide WO 02/49993 WO 0249993PCT/USOO/26816 Benzo[ 1,3]dioxol-5-ylmethyl-benzyl-[3-butyl-5-(4-fluoro-phenyl)-2-phenyl-3H-iniidazol-4-ylmet hyl]amine N -OH N N 3-{[Benzyl-(3-butyl-2,5-diphenyl-3H-imidazol-4-ylrnethyl)-amino-methyl}-phenoI 4-{[Butyl-(3-butyl-5-tert-butyl-2-phenyl-3H-imidazol-4-ylmethyl)-an-ino-methyl-benzamide WO 02/49993 WO 0249993PCT/USOO/26816 Benzyl-(3-butyl-2,5-diphenyl-3H-rnidazol-4-ylmethyl)-(2,3-dhydro-benzo[ 1,4]dioin-6-ylmethyl)-aniin (3-Butyl-2,5-diphenyl-3H-imiidazol-4-ymethyl)-(2,5-dfluoro-benzyl)-(4-methoxy3-benzyl)-amine (3-Butyl-2,5-cipheny-3{-imidazo-4-yhnethy)-(2,6-dichoro-benzy)-(4-methoxy-benzyi)amine WO 02/49993 WO 0249993PCT/USOO/26816 4-{[BenzyI-(3-butyl-2,5-diphenyI-3H-imidazol-4-ylmethyl).amino]-methyl)-2,6-dimethyk-phenoI 0

N

NN

OH

4-({[3-ButyI-5-(4-methoxy-phenI)-2-pheny-3H-imidazo-4-ylmethy]cycohexylmehy-amino-methy)- 2,6-dimethyl-phenol 0

N

?N

0 [3-Butyl-5-(4-methoxy-phenyi)-2-phenyl-3H-imidazol-4-ylmethyl]-cyclohexylmethyl(2,3dihydro-benzo WO 02/49993 WO 0249993PCT/USOO/26816 4-([Butyl-(3-butyl-2,5-diphenyl-3H-imidazol-4-ylmethyl)-amino-meffiyl}-2,6-dimnethyl-phenoI 4-({Butyl-11-(3 -buty1-2,5-diphenyl-3H-imidazo1-4-y1)-ethy1]-ainino)-methyl)-2,6-dimefiyl-phenoI 4-{[(3-Butyl-2,5-diphenyl-3II-inidazo1-4-ylmethyl)-(4-dimethylamino-benzy)-anino-methy} -benzoic acid WO 02/49993 WO 0249993PCT/USOO/26816 1,3]dioxol-5-ylrnethylbamino)-methyl]-2,4-diphenyl-imidazol- 1-yl}-butyric acid ethyl ester 4-{5-[(Bis-benzo[1 ,3]dioxol-5-ylmethyl-amino)-methyl-2,4-dipheny-imilazol-l1-yI}-butan-1--o (4-{[(3-Butyl-2 ,5-diphenyl-3H-imidazol-4-ylrmethyl)-cyclohexylniethyl-amino]-methyl-phenyl)dimethyl-amine WO 02/49993 WO 0249993PCT/USOO/26816 1 -Butyl)-2-phenyl-5-(N-[4-{1-pyrrolidinyllphenylmethyl -Nphenylmethyl)aminomethyl-imidazole; Ki NK 1 1-Butyl)-2-phenyl-5-(N-[4-diethylaminophenylmethyl]-Nphenylmethyl)aminornethyl-imidazole;, 1-Butyl)-2-phenyl-5-(N-[pyridin-2-ylmethyl]-Nphenylmethyl)aminomethylimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1-Butyl)-2-phenyl-5-(N-[pyridin-3-ymethyl] -Nphenylmethyl)aminomethylimidazole; 1 -Butyl)-2-phenyl-5-(N-[pyridin-4-ylmethyl] -Nphenylmethyl)aininoinethylimidazole; 1 -Butyl)-2-phenyl-5-(N-[2-fluioro-6-chloropheny-nethyl -Nphenylmethyl)aminom'ethyl-inidazole); 1-(l1-Butyl)-2-phenyl-5-(N-[2,4-dichlorophenylmethyl]-N-phenylmethyl)aminomethylimidazole); WO 02/49993 WO 0249993PCT/USOO/26816 1 1-Butyl)-2-phenyl-5-(N-[4-chlorophenylmethyl]-Nphenylmethyl)aminomethylimidazole; 0+

OH

1 -Butyl)-2-phenyl-5-(N- [4-hydroxyphenylmethyl]-Nphenylmethyl)aminomethylimidazole;

OCF

3 1-(1 -Butyl)-2-phenyl-5-(N-[4-trifluoromethoxyphenyhinethyl-Nphenylmethyl)aminomethyl-imidazole); 1-(l1-Butyl)-2-phenyl-5-(N-[2-chloro-3,4-dimethoxyphenyinethyl]-Nphenyhmethyl)amino-methylimidazole); WO 02/49993 WO 0249993PCT/USOO/26816 N0 2 1 1-Butyl)-2-phenyl-5-(N-[4-nitrophenylmethyl-Nphenylmethyl)aminomethylimidazole;

NH

2 1 1-Butyl)-2-phenyl-5-(N-[4--aminophenylmethyl-Nphenylmethyl)aminomethylimidazole; 1 -Butyl)-2, 4-diphenyl-5-(N-phenylmethyl-N-[1 -butyl])aminomethylimidazole; 1-(l1-Butyl)-2-phenyl-5-(N- phenylmethyl)aminonaethyl-imidazole WO 02/49993 WO 0249993PCT/USOO/26816 1-Butyl)-2-phenyl-5-(N-12,3-dihydrobenzo[blfuran-5-ylnethyl-Nphenylmethyl)amino-methylimidazole; 1-Butyl)-2-phenyl-5-(N-[2 -chlOro-4-hydroxyphenylmethyl-N-[1 butyl])aminomethyl-imidazole) 1-(1-ButyL)-2-phenyl-4-methyl-5-(N-phenylmethyl-N-[ 1-butyl])aminomethyliiidazole;

OH

F e WO 02/49993 WO 0249993PCT/USOO/26816 I -(1-Butyl)-2-(4-fluorophenyl)-5-(N-[2-chloro-4-hydroxyphenylmethyl]-Nphenylmethyl)-aminomethyimidazole; 1 -Buty1)-2-(3-fluorophenyl)-5-(N-[2-chloro-4-hydroxyphnylmethy]-Nphenylmethyl)-aminotnethyliinidazole; 1 -Butyl)-2-(3-fluorophenyl)-5-(N- 3-dichlorophenylmethyl-Nphenyhmethyl)amino-methylimidazole; 1-(l1-flutyl)-2-(3-fluorophenyl)-5--(N-[4-dimethylamiriophenylmethyl] -Nphenylmethyl)amino-methyimidazole; WO 02/49993 WO 0249993PCT/USOO/26816 1 -(1-Butyl)--2-(3-fluorophenyl)-5-(N-[4-{1-pyrrolidinyllphenylmethyl-Nphenylmethyl)ainino-methylimidazole; 1-(1-Butyl)-2-(3-chlorophenyl)-5-(l1-[N-{2-chloro-4-hydroxyphenylmethyl-Nphenylmethyll amino) ethylimidazole; N NH N N 1-Butyl)-2-phenyl-5-(N-[indol-5-ylmethyl]-N-phenylmethyl)aminomethylimidazole; N N 0

FN

1-Butyl)-2-(4-fluorophenyl)-5-( 1-N,N-di[3,4methylenedioxyphenylmethyl]amino)ethylimidazole; WO 02/49993 PCT/US00/26816 2-{[5-({Butyl[(1-butyl-2,4-diphenylimidazol-5-yl)methyl]amino}methyl)-2pyridyl]amino}ethan- l-ol; As discussed above, preferred compounds of the invention exhibit good activity in standard in vitro C5 receptor mediated chemotaxis assay, specifically the assay as specified in Example 12, which follows. References herein to "standard in vitro C5 receptor mediated chemotaxis assay" are inteided to refer to that protocol as defined in Example 12 which follows. Preferred compounds of the invention exhibit an ECso of about 100 pM or less in such a standard C5a mediated chemotaxis assay, more preferably an ECso of about 10 [IM or less in such a standard mediated chemotaxis assay, still more preferably an ECso of about 1 pM in such a standard C5a mediated chemotaxis assay, even more preferably an EC5o of about 0.1 iM in such a standard C5a mediated chemotaxis assay.

Additional assays suitable for determining the effects of small molecule compounds on C5a receptor binding and receptor modulatory activity, as well as assays suitable for measuring their effects on C5a-induced neutropenia in vivo, can be found in the published literature, for example in US patent 5,807,824, which is incorporated herein by reference for its disclosure in this regard in Examples 6-9, columns 19-23, as well as for its discussion of complement and inflammation at columns 1-2. Those of skill in the art will recognize that such assays can be readily adapted to the use of cells or animals of different species as deemed appropriate.

WO 02/49993 PCT/US00/26816 In one aspect of the invention, one or more compounds of the invention, preferably in solution in a pharmaceutically acceptable carrier as a pharmaceutical preparation, is used to perfuse a donor organ prior to transplantation of the organ into a recipient patient. Such perfusion is preferably carried out using a solution comprising an concentration of the compound of the invention that is an effective amount sufficient to inhibit C5a mediated effects in vitro or in vivo. Such perfusion preferably reduces the severity or frequency of one or more of the inflammatory sequelae following organ transplantation when compared to that occurring in control (including, without restriction, historical control) transplant recipients who have received transplants of donor organs that have not been so perfused.

Definitions In certain situations, the compounds of of the invention may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g.

asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms. For compounds with two or more asymmetric elements, these WO 02/49993 PCT/US00/26816 compounds can additionally be mixtures of diastereomers. In these situations, the single enantiomers, optically active forms, can be obtained by asymmetric synthesis, synthesis from optically pure precursors or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column.

The term "substituted", as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound. When a substituent is keto then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example, and without limitation, isotopes of hydrogen include tritium and deuterium and isotopes of carbon include 11C, 13C, and 14C.

When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 then said group may optionally be substituted with up to two R* groups and R* at each occurrence is selected independently from the definition of Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As indicated herein, various substituents of the compounds of the present invention and various formulae set forth herein are "optionally substituted", including, Arl, Ar 2 R, R 1

R

2

R

3 R3A, R 4

R

5

R

6

R

7 RA, RA', RB, and Re. When substituted, those substituents may be substituted at one or more of any of the available positions, typically 1, 2, 3, or 4 positions, by one or more suitable groups such as those disclosed herein.

WO 02/49993 PCT/US00/26816 Suitable groups or "substituted" moities of compounds of the invention include halogen such as fluoro, chloro, bromo or iodo; cyano; hydroxyl; nitro; azido; alkanoyl such as a Ci-c alkanoyl group such as acyl and the like; carboxamido; alkyl groups including those groups having 1 to about 12 carbon atoms, or 1, 2, 3, 4, 5, or 6 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 12 carbon, or 2, 3, 4, 5 or 6 carbon atoms; alkoxy groups having those having one or more oxygen linkages and from 1 to about 12 carbon atoms, or 1, 2, 3, 4, 5 or 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those moieties having one or more thioether linkages and from 1 to about 12 carbon atoms, or 1, 2, 3, 4, 5 or 6 carbon atoms; alkylsulfinyl groups including those moieties having one or more sulfinyl linkages and from 1 to about 12 carbon atoms, or 1, 2, 3, 4, 5, or 6 carbon atoms; alkylsulfonyl groups including those moieties having one or more sulfonyl linkages and from 1 to about 12 carbon atoms, or 1, 2, 3, 4, 5, or 6 carbon atoms; aminoalkyl groups such as groups having one or more N atoms and from 1 to about 12 carbon atoms, or 1, 2, 3, 4, 5 or 6 carbon atoms; carbocyclic aryl having 6 or more carbons, particularly phenyl an Ar group being a substituted or unsubstituted biphenyl moiety); arylalkyl having 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms, with benzyl being a preferred group; aralkoxy having 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms, with O-benzyl being a preferred group; or a heteroaromatic or heteroalicyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O or S atoms, e.g. coumarinyl, quinolinyl, pyridyl, pyrazinyl, pyrimidyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholino and pyrrolidinyl.

As used herein, "alkyl" is intended to include both branched and straightchain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, npropyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. Preferred alkyl WO 02/49993 PCT/US00/26816 groups are C 1 -Cs and C1-6 alkyl groups. Especially preferred alkyl groups are methyl, ethyl, propyl, butyl, 3-pentyl. The term C1-6 alkyl as used herein includes alkyl groups consisting of 1 to 6 carbon atoms, which may contain a cyclopropyl moiety.

Suitable examples are methyl or ethyl.

"Cycloalkyl" is intended to include saturated ring groups, having the specified number of carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl and brigded or caged saturated ring groups such as norbornane or adamantane and the like.

In the term "(C3-6 cycloalkyl)C1-4 alkyl", as defined above, the point of attachment is on the alkyl group. This term encompasses, but is not limited to, cyclopropylmethyl, cyclohexylmethyl and cyclohexylethyl.

"Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point along the chain, such as ethenyl and propenyl.

"Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration comprising one or more triple carbon-carbon bonds that may occur in any stable point along the chain, such as ethynyl and propynyl.

"Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -Cv(Xi)wi(H2v+l-z(wi)) where v 1 to 3; X i Cl(i=2), Br(i=3), I(i=4) and Swi<2v+l). Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.

"Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, nhexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.

As used herein, the term "carbocyclic aryl" indicates aromatic groups containing only carbon in the aromatic ring. Such aromatic groups may be further WO 02/49993 PCT/US00/26816 substituted with carbon or non-carbon atoms or groups. Typical carbocyclic aryl groups contain 1 to 3 separate of fused rings and from 6 to about 18 ring atoms, without heteroatoms as ring members. Specifically preferred carbocyclic aryl groups include phenyl, napthyl, including 1-naphthyl and 2-naphthyl, and acenaphthyl.

By the term "energetically accessible conformer" is meant any conformer of a compound that falls within about a 15 Kcal/mol window above the lowest energy conformation (as for example that found in a monte carlo or systematic confirmational search) by using MM2, MM3, or MMFF force fields as implemented in molecular modeling software such as MacroModel® v 7.0, Schr6dinger, Inc., Portland, Oregon United Stats and Jersey City, New Jersey, United States, http:/ /www.schrodinger.com or the like.

Peptidomimetic compounds are generally compounds with "chemical structures derived from bioactive peptides which imitate natural molecules" (Murray Goodman and Seonggu Ro, "Peptidomimetics for Drug Design" chapter twenty in Burger's Medicinal Chemistry and Drug Discovery, Volume 1: Principles and Practice, Manfred E. Wolff, ed. John Wiley Sons, Inc., NY, 1995, pp. 801- 861.) As used herein and in the claims, the term peptidomimetic additionally comprises peptoid compounds, which are compounds that comprise oligomers of Nsubstituted natural amino acids, and the term further comprises any compound having more than two amide bonds.

As used herein, the terms "heteroaryl" and "heteroalicyclic" group are intended to indicate a stable 5-to 7-membered monocyclic or bicyclic or 7-to membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The term heteroaryl indicates that the group contains at least 1 aromatic ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings WO 02/49993 PCT/USOO/26816 described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized.

It is preferred that when the total number of S and 0 atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and 0 atoms in the heterocycle is not more than 1, 2, or 3, more typically 1 or 2. It is preferred that the total number of S and 0 atoms in the aromatic heterocycle is not more than 1.

Examples of heteroaryl groups and other heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, NH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H- 1,5,2-dithiazinyl, dihydrofuro[2,3-bltetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, LH-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1 ,2,3-oxadiazolyl, 1,2 ,4-oxadiazolyl;,- 1,2 ,5oxadiazolyl, 1 ,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathitnyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, qluinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H- 1,2,5-thiadiazinyl, 1,2,3thiadiazolyl, 1,2 ,4-thiadiazolyl, 1 ,2,5-thiadiazolyl, 1 ,3,4thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1 ,2,4-triazolyl, 1 ,2,5-triazolyl, 1 ,3,4-triazolyl, and xanthenyl, Preferred heteroaryl groups include, but are not limited to, pyridinyl, WO 02/49993 PCT/US00/26816 pyrimidinyl, furanyl, and thienyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

The term "halogen" indicates fluorine, chlorine, bromine, or iodine.

The term "pharmaceutically acceptable salts" includes, but is not limited to non-toxic salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrite or salts with an organic acids such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, salicylate and stearate. Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium and ammonium. The present invention also encompasses the prodrugs of the compounds disclosed.

Examples of bicyclic oxygen containing groups of the formula:

RA

(RA may also be indicated R3) include the following: 0

C

O O O A RA RA I R

A

RA

O RA 0 RA 0 RA RA Methods of Treating Patients The present invention provides methods of treating patients suffering from diseases or disorders involving pathologic activation of C5a receptors. Such diseases and disorders may include the following.

Such disorders that may be autoimmune in nature and are suitable for WO 02/49993 PCT/US00/26816 treatment in accordance with the present invention include e.g. rheumatoid arthritis, systemic lupus erythematosus (and associated glomerulonephritis), psoriasis, Crohn's disease, vasculitis, irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma, pemphigus, pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome (and associated glomerulonephritis and pulmonary hemorrhage), and immunovasculitis. Such inflammatory and related conditions include neutropenia, sepsis, septic shock, Alzheimer's disease, stroke, inflammation associated with severe burns, lung injury, myocardial infarction, coronary thrombosis, vascular occlusion, post-surgical vascular reocclusion, artherosclerosis, traumatic central nervous system injury and ischemic heart disease, and ischemiareperfusion injury, as well as acute (adult) respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), tissue graft rejection, and hyperacute rejection of transplanted organs. Also included are pathologic sequellae associated with insulin-dependent diabetes mellitus (including diabetic retinopathy), lupus nephropathy, Heyman nephritis, membranous nephritis and other forms of glomerulonephritis, contact sensitivity responses, and inflammation resulting from contact of blood with artificial surfaces that can cause complement activation, as occurs, for example, during extracorporeal circulation of blood during hemodialysis or via a heartlung machine, for example, in association with vascular surgery such as coronary artery bypass grafting or heart valve replacement) such as extracorporeal postdialysis syndrome, or in association with contact with other artificial vessel or container surfaces ventricular assist devices, artificial heart machines, transfusion tubing, blood storage bags, plasmapheresis, plateletpheresis, and the like).

Treatment methods of the invention include in general administration to a patient a therapeutically effective amount of one or more compounds of the invention. Suitable patients include those subjects suffering from or susceptible to propylactic treatment) a disorder or disease identified herein. Typical patients WO 02/49993 PCT/USOO/26816 for treatment in accordance with the invention include mammals, particularly primates, especially humans. Other suitable subjects include domesticated companion animals such as a dog, cat, horse, and the like, or a livestock animal such as cattle, pig, sheep and the like.

Pharmaceutical Preparations The compounds of the invention may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. Oral administration in the form of a pill, capsule, elixir, syrup, lozenge, troche, or the like is particularly preferred. The term parenteral as used herein includes injections and the like, such as subcutaneous, intradermal, intravascular intravenous), intramuscular, intrasternal, spinal, intrathecal, and like injection or infusion techniques, with subcutaneous, intramuscular and intravascular injections or infusions being preferred. In addition, there is provided a pharmaceutical formulation comprising a compound of the invention and a pharmaceutically acceptable carrier. One or more compounds of the invention may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants and if desired other active ingredients.

The pharmaceutical compositions containing compounds of the invention may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.

Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.

Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These WO 02/49993 PCT/US00/26816 excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

WO 02/49993 PCT/USOO/26816 Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil; olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.

Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

Pharmaceutical compositions of the invention may also be in the form of oilin-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.

Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for WO 02/49993 PCT/USOO/26816 example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the. rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

Compounds of the invention may be administered parenterally, preferably in a sterile non-toxic, pyrogen-free medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.

Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment or preventions of conditions involving pathogenic C5a activity, particularly those disorders list in the "background of the invention" section (about 0.5 mg to about 7 g per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.

Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most disorders, a dosage regimen of 4 times daily, three times daily, or less is preferred, with a dosage regimen of once daily or 2 times daily being particularly preferred.

WO 02/49993 PCT/US00/26816 It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination other drugs being administered to the patient), the severity of the particular disease undergoing therapy, and other factors, including the judgment of the prescribing medical practitioner.

Preferred compounds of the invention will have favorable pharmacological properties. Such properties include, but are not limited to bioavailability oral bioavailibilty, preferably high enough to permit oral administration of doses of less than 2 grams, preferably of less than or equal to one gram), low toxicity, low serum protein binding and desirable in vitro and in vivo half-lifes. Distribution in the body to sites of complement activity is also desirable, compounds used to treat CNS disorders will preferably penetrate the blood brain barrier, while low brain levels of compounds used to treat periphereal disorders are typically preferred.

Assays may be used to predict these desirable pharmacological properties.

Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Toxicity to cultured hepatocyctes may be used to predict compound toxicity. Penetration of the blood brain barrier of a compound in humans may be predicted from the brain levels of the compound in laboratory animals given the compound intravenously.

Serum protein binding may be predicted from albumin binding assays. Such assays are described in a review by Oravcov6, et al. (Journal of Chromatography B (1996) volume 677, pages 1-27).

Compound half-life is inversely proportional to the frequency of dosage required for the effective administration of a compound. In vivo half-lifes of compounds may be predicted, from assays of microsomal half-life as described by Kuhnz and Gieschen (Drug Metabolism and Disposition, (1998) volume 26, pages 1120-1127).

WO 02/49993 PCT/US00/26816 Preparation of compounds Representative methods for preparing the compounds of the invention are shown in the following Schemes. Schemes 1 and 2 show the preparation of arylimidazole compounds. Scheme 1 illustrates the preparation of arylimidazole compounds where

R

1 is hydrogen or halogen. Scheme 2 represents of the preparation of aryl imidazole compounds where R 1 is alkyl. Within Schemes 1 and 2 the variables Arl, Ar2, R 1

R

2

R

3 and R 4 are defined as above for Formula I.

WO 02/49993 WO 0249993PCT/USOO/26816 Schemel. Synthesis of MeOll, HCl NH RN2NH A -C r <OMe Al-<NHR 2 lo it 12

N-

Ar 1 N )"'CHO

A

1

N

R

2 "2 OH 13 14 N R4 Ar 1 N Ar

R

2 R 3 N

R

Ar 1 N Ar 2

R

2 R 3 As shown in Scheme 1, an appropriately substituted arylnitrile 10O is converted to the imidate 11L via treatment with hydrogen chloride gas in methanol followed by subsequent treatment with base to release the free base. Amidine 12 is prepared from 11 by treatment with a primary amine, 2-Arylimidazole-4-carboxaldehyde 13 is prepared from 12 by one of several methods described in the chemical literature, WO 02/49993 PCT/US00/26816 for instance, by treatment with 2-bromo-3-isopropoxyacrolein in the presence of base. See, for example, J. Org, Chem., 62: 8449 (Shilcrat et al., 1997).

Aldehyde 13 can then be transformed into hydroxymethylimidazole 14 either by reduction (for cases where R 4 is hydrogen) or by treatment with the appropriate organometallic (for cases where R 4 is C1-C6 alkyl). The hydroxy group of 14 is converted to either a halogen or sulfonate ester leaving group. Treatment of this intermediate with an appropriate secondary amine in the presence of base provides 2-aryl-4-aminomethylimidazole 15. Alternatively the aminoalkyl functionality of may be elaborated by sequential amination-acylation-reduction steps. In situations where R 1 is a halogen, it may be prepared from 15 (Ri=H) by treatment with the molecular halogen, a halosuccinimide or the like.

As shown in Scheme 2, an appropriately substituted 2-aryl-4substitutedimidazole 20 can be N-alkylated by treatment with base such as sodium hydride and an alkyl halide or alkylsulfonate ester to provide the trisubstituted imidazole 21. Hydroxymethylation of 21 under the conditions of the Mannich reaction provides hydroxymethylimidazole 22. In examples where R 3 is alkyl, hydroxymethyl derivative 24 is prepared from 22 by oxidation to aldehyde 23 and subsequent treatment with an appropriate organometallic reagent such as an alkyl lithium or Grignard reagent. Conversion of 22 or 24 to the, desired aminomethylimidazoles is carried out by conversion of the hydroxymethyl to a halogen or sulfonate ester leaving group followed by treatment with a secondary amine. Alternatively, the aminoalkyl functionality of the aminomethylimidazole product may be elaborated by sequential aminationacylation-reduction steps.

WO 02/49993 WO 0249993PCT/USOO/26816 Scheme 2. Synthesis of 2-Arvilildazoles Where R 2 is alkyl:

R

Base Am rAr

R

2 X

N

21 )0-b Ar 1 OH, kcetic acid

N

22 Where 1R3 is alkyl: MnO 2 22 r 1 N CHO Where R 3 is hydrogen 222

R

3 Ar 2 The 2-aryl-4-substitutedimidazole 20 may be prepared by methods described in the chemical literature, for instance, via condensation of an arylamidine with a halomethyl or hydroxymethyl ketone.

Cycloalkylimidazoles An illustration of the preparation of compounds of the Cycloalkylimidazole compounds of the present invention is given in Scheme 3. Within Scheme 3 the variables n, Arl, Ar 2

R

2

R

3 R3a, R 4

R

5 R6, R5a,, R6a, R 7 and X are defined previously.

WO 02/49993 WO 0249993PCT/USOO/26816 Scheme 3. Preparation of Cycloalkylimidazoles

R

3 a R NH

R

3 R

(CR

5 aCRC~a)n Arl 1 NH MeO 32 Compound 33 X =1OH Compound 34 X =halogen or suiphonate ester

R

3 a

R

5

R

R3 6

R

3

(CR

5

CR

6 )n

N

N R 7

N

Ar, N \-Ar 2 r 1 I R,

R

2 As shown in Scheme 3, an appropriately substituted arylamidine 30 is condensed with an appropriately substituted 2-halo-3-alkoxyenone 31 to provide a 2-aryl-4,5- WO 02/49993 PCT/US00/26816 cycloalkylimidazole 32. The ketone functionality of 32 can be either reduced (R 7 H) or treated with an appropriate organometallic (for cases where R 7 is alkyl) to give the cyclic alcohol 33. Compounds of general formula 34 can be prepared from 33 by one of several methods described in the chemical literature, for instance, by treatment with thionyl chloride or by treatment with an alkyl or arylsulphonyl chloride in the presence of base.

Compounds of formula 34 can then be transformed into compounds of general Formula 35 by direct treatment with the appropriate secondary amine.

Alternatively, the X functionality of 34 may be transformed into a tertiary amine in a stepwise manner. In this case, 34 would be treated with a primary amine to provide an intermediate secondary amine. This, in turn, could be alkylated to give cycloalkylimidazole compounds of the invention.

Pyridines An illustration of the preparation of pyridine compounds of the present invention is given in Scheme 4. Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention. Within Scheme 4 the variables Ari, Ar 2 R, Ri, R 2

R

3 and R 4 are defined as previously described.

WO 02/49993 PCT/US00/26816 Scheme 4. Preparation of Arvl pyridines Ar R R2

R

HOOC COOH

R

3

-M

R,

RR

N

S OH Ar

IR

2

R

3

RI

Ar R3 R2 Ar 2 As shown in Scheme 4, an appropriately substituted 4-phenyloxazole 40 is condensed with an appropriately substituted maleic acid to provide a 2phenylisonicotinic acid 41. The carboxylic acid functionality of 41 can be reduced directly to the primary alcohol (43, Rs H) or converted by methods known to the art to an intermediate aldehyde 42 and subsequently treated with the appropriate organometallic (for cases where R 3 is alkyl) to give a secondary alcohol 43.

Compounds of general formula 44 can be prepared from 43 by one of several WO 02/49993 PCT/US00/26816 methods described in the chemical literature, for instance, by initial treatment with thionyl chloride or with an alkyl or arylsulphonyl chloride in the presence of base, followed by subsequent condensation with a primary amine. Compounds of formula 44 can then be transformed into compounds of formula 45 by direct treatment with the appropriate alkylating agent or, alternatively, by reductive alkylation.

Alternatively, the tertiary amine functionality of formula 45 may be realized directly from compounds of formula 43 by initial treatment with thionyl chloride or with an alkyl or arylsulphonyl chloride in the presence of base, followed by subsequent condensation with a secondary amine.

Pyrazoles An illustration of the preparation of arylpyrazole compounds of the present invention is given in Scheme 5. Within Scheme 5 the variables Art, Ar2, R 1

R

2

R

3 and R4 are defined as previously described.

WO 02/49993 WO 0249993PCT/USOO/26816 Scheme 5. Preparation of Arylpyrazoles

H

N

Aril

~NR,

00 Alkyl N 0 R2 K>1S0 0 -Alkyl )No Ar 1 512 N 0-H Ar N R 53 N

LG

I

Ar'- N R 3 Ar

R

2 52 N P-H N 0 Ar 1 S56 N~ 0 Ar2 Ar 1

R

2 58 As shown in Scheme 5, an appropriately substituted phenylhydrazine adduct is condensed with an appropriately substituted a-ketoester 51, in the presence of a Lewis acid, preferably ZnC12, with heating at 50 200 oC, preferably at 125 OC to provide a 1-phenylpyrazole ester 52. The carboxylic acid functionality of 52 can be reduced directly to the primary alcohol (53, R 3 H) or converted by methods known WO 02/49993 PCT/US00/26816 to the art to an intermediate aldehyde and subsequently treated with the appropriate the appropriate organometallic (for cases where R 3 is alkyl) to give a secondary alcohol 53. Compounds of general formula 54, where LG represents a leaving group, can be prepared from 53 by one of several methods described in the chemical literature, for instance, by initial treatment with thionyl chloride or with an alkyl or arylsulphonyl chloride in the presence of base, followed by subsequent condensation with a primary amine. Compounds of formula 54 can then be transformed into compounds of formula 58 by sequential treatment with the appropriate primary amine followed by direct alkylation or reductive alkylation of the intermediate secondary amine. Alternatively, the tertiary amine functionality of formula 58 may be realized directly from compounds of formula 53 by initial treatment with thionyl chloride or with an alkyl or arylsulphonyl chloride in the presence of base, followed by subsequent condensation with a secondary amine.

An alternative route to the preparation of compounds of Formula 58 from the 1-phenylpyrazole ester 52 may be realized by hydrolysis of 52 to a carboxylic acid of general structure 56, followed by amide formation to provide 57 and, finally, reduction of the amide functionality to the tertiary amine of 58 (R 3 Scheme 6. Preparation of 2-(1-aryl-1,2,3.4-tetrahydroiso cuinolin-2-vl) acetamides and bicvclics of other ring sizes 1, 2, 3, etc)

R

6 Rs (CH()nC NH X RN 0N

R

6

R

R4 R4 61 62 The 2-(1,2,3,4-tetrahydroisoquinolin-2-yl) acetamides of general formula 62 of the present invention may be prepared according to the procedure described WO 02/49993 PCT/US00/26816 graphically in Scheme 6, wherein a compound of general Formula 60, prepared according to literature procedures, (for example: Scully, Frank Jr.; Schlager, John J. Synthesis of dihydroisoquinolines and 1-substituted tetrahydroisoquinolines. Heterocycles (1982), 19(4), 653-6 or Shinohara, Tatsumi; Takeda, Akira; Toda, Jun; Terasawa, Noriyo; Sano, Takehiro. A highly efficient synthesis of 1-methyl-, 1-benzyl-, and 1-phenyl-1,2,3,4tetrahydroisoquinolines by a modified Pummerer reaction. Heterocycles (1997), 46: 555-566.) is combined (in an appropiate solvent in the presence of an organic or inorganic base) with an appropriately substituted acetamide derivative possessing a leaving group X at its 2 position. For example, X may be halogen, alkyl or aryl sulfonate, or polyfluoroalkylsulfonate. Acetamides of general Formula 61 may be prepared via condensation of the appropriate secondary amine with a 2haloacetylhalide (such as 2-chloroacaetyl chloride) in the presence of base.

Alternatively acetamides of general formula 61 can be prepared by condensation of the appropriate secondary amine with either a 2-(alkylsulfonylester)acetic acid or 2- (arylsulfonylester)acetic acid in the pressence of an coupling agent such as CDI or the like.

Within Scheme 6, R 1

R

2 Ra, R 4 and Rs may be the same or different and are chosen from hydrogen, halogen, C 1

-C

6 alkyl, C 1

-C

6 alkoxy, hydroxy, trifluoromethyl, trifluoromethoxyl, cyano, nitro, hydroxy carbonyl (COOH), aminocarbonyl (CONH 2 mono or dialkylaminocarbonyl, sulfonamido, mono or dialkylsulfonamido, amino, mono- or di-alkylamino, aceto, acetoxy or 3,4-methylenedioxy or ethylenedioxy. The term n refers to an integer from 1 to 3. R 6 may be C1-Cg straight or branched chain alkyl, benzyl (substituted or unsubstituted), phenylethyl (substituted or unsubstituted), phenylpropyl (substituted or unsubstituted), or may be cycloalkyl fused with an aromatic group such as 1,2,3,4-tetrahydronaphthyl, 1- or 2- indanyl or suberanyl.

Scheme 7. Preparation of Ortho Biarvlamides WO 02/49993 PCT/US00/26816 R2 R^^4 1. SOCl 2 or 2 4

CDI

R OH 2. Rs 5 RNH R NR, X X 0 71 Suzuki or Stile

R

3 coupling R2 R4

NR

5

R

6 Ar O 72 The preparation of the ortho biarylamides of the present invention may be carried out via a series of chemical transformations similar to those displayed graphically in Scheme 7. An individual skilled in the art may find modifications of one or several of the synthetic steps described herein without diverting significantly from the overall synthetic scheme.

Thus, as shown, the synthetic route begins with a benzoic acid of general structure 70 possessing a group X at the ortho position. This X group may be iodine, bromine, chlorine, sulfonate ester or polyfluoroalkylsulfonate ester. The benzoic acid may also be substituted by up to four independently chosen substitutents represented by the variables R 1

-R

4 Examples of suitable substituents include hydrogen, chlorine, fluorine, cyano, C 1

-C

6 straight or branched chain alkyl,

C

1

-C

6 straight or branched chain alkoxy, trifluoromethyl, trifluoromethoxy, nitro, amino, mono or dialkyl amino, sulfonamido, mono or dialkylsulfonamido, alkylthio e.g. methylthio, alkylsulfoxide, alkylsulfone, acetyl, acetoxy, alkoxycarbonyl WO 02/49993 PCT/US00/26816 (COOAlkyl) or dialkylaminocarbonyl (CON[alkyl] 2 Additionally, two adjacent groups (i.e Ri and R 2 or R 2 and Rs or R 3 and R 4 may be taken together with a chain of from 3 to 5 methylene carbons to form a alkyl ring of from five to seven carbons fused to the benzoic acid moiety. Additionally, two adjacent groups (i.e R 1 and R 2 or

R

2 and R 3 or R 3 and R 4 may be taken together with an alkyloxy chain, for example or OCH 2

CH

2 0 to form an oxygen-containing moiety (in this example methylenedioxy or ethylenedioxy, respectively) fused to the benzoic acid.

This benzoic acid is then activated by conversion to an acid chloride with thionyl chloride, oxalyl chloride or the like. Alternatively, it may be activated by treatment with carbonyldiimidazole or a similar agent. The activated benzoic acid is then treated with an appropriate secondary amine in the presence of base to provide a tertiary amide of general structure 71.

Amide 71 is then converted to the biaryl structure 72 through the use of aryl coupling reactions know in the chemical literature. Examples of such reactions are the Stille reaction where an aryl trialkyltin reagent is coupled to an appropriate aryl in the presence of a catalyst such as palladium or nickel; or a Suzuki reaction where a arylboronic acid is coupled to an appropriate aryl in the presence of a nickel or palladium catalyst in the presence of base.

The group "Ar" of General structure 72 may be a phenyl which may be substituted with up to five additional independently chosen substitutents, e.g.

hydrogen, halogen, cyano, C1-C 6 straight or branched chain alkyl, C1-C6 straight or branched chain alkoxy, trifluoromethyl, trifluoromethoxy, nitro, amino, mono or dialkyl amino, sulfonamido, mono or dialkylsulfonamido, alkylthio e.g. methylthio, alkylsulfoxide, alkylsulfone, acetyl, acetoxy, hydroxycarbonyl (COOH), alkoxycarbonyl (COOAlkyl), aminocarbonyl (CONH 2 monoalkylaminocarbonyl, dialkylaminocarbonyl (CON[alkyl] 2 methylenedioxy or ethylenedioxy.

The Ar of General Structure 72 may also represent a heteroaryl group such as 1- or 2- thienyl or 1- or 2- furanyl. Such a heteroaryl group which may be additionally substituted by up to three independently chosen substituents, such as hydrogen, halogen, cyano, C 1

-C

6 straight or branched chain alkyl, C 1

-C

6 straight or WO 02/49993 PCT/USOO/26816 branched chain alkoxy, trifluoromethyl, trifluoromethoxy, clialkyl amino, sulfonamido, mono or dialkylsulfonamido, alkylthio e.g. methylthio, alkylsulfoxide, alkylsulfone, acetyl, acetoxy, hydroxycarbonyl (COOH), alkoxycarbonyl (COOAlky1), aminocarbonyl (CONH 2 monoalkylcarbonyl, dialkylaminocarbonyl (CON[alkyl] 2 Scheme 8. General Preparation of Azaarvl benzainides X=F, Cl Acid do The preparation of 2-imidazolyl, 2-pyrrazolyl and 2-(l,2,4)-triazolyl benzamides: begins with an appropriately substituted benzonitrile derivative having a leaving group X at the position ortho to the carboxylic acid functionality. Most WO 02/49993 PCT/US00/26816 commonly this group would be a fluorine or chlorine group. This benzonitrile may be optionally substituted or additionally substituted by up to four substituents (R 1

-R

4 which may be the same or different (examples of such substituents are: hydrogen, halogen, cyano, C 1

-C

6 straight or branched chain alkyl, C1-C straight or branched chain alkoxy, trifluoromethyl, trifluoromethoxy, nitro, amino, mono or dialkyl amino, sulfonamido, mono or dialkylsulfonamido, methylthio, alkylsulfoxide, alkylsulfone, acetyl, acetoxy, alkoxycarbonyl (COOAlkyl) or dialkylaminocarbonyl (CON[alkyl] 2 The benzonitrile 73 is mixed with the azaheterocycle 74 (wherein A and B may be either nitrogen or carbon with the caveat that both A and B not be carbon.

Rs and R 6 may be the same as those groups described for Ri-R4.) This condensation may be carried out either in a single phase system in an appropriate solvent and base, or in a two-phase manner using a phase transfer catalyst.

2-Azaheterocyclicbenzonitrile 75 is the hydrolyzed to the corresponding benzoic acid 76 via means common to the chemical literature, for instance mineral acid.

The benzoic acid 76 is then activated via thionyl chloride, CDI or other means known to the chemical literature and condensed with an appropriately substituted secondary amine toprovide the desired final products 77.

EXAMPLES

The general methods given in Schemes 1 to 8 above for the preparation of compounds of the present invention are further illustrated by the following examples. Specifically, the methods given in Schemes 1 and 2 for the preparation of aryl imidazoles are illustrated by Examples 1-4, shown below. An example of the method shown in Scheme 3 for the preparation of cycloalkylimidazoles is given in example 5, and example of the method shown in Scheme 4 for the preparation of arylpyridines is given in example 6, and an example of the method shown in Scheme for the preparation of arylpyrazoles is given in example 7. The method shown by Scheme 6 for the preparations of 2-(1-Aryl-1,2,3,4-tetrahydroisoquinolin-2yl)acetamides is further illustrated in example 8. The methods shown in Schemes 7 WO 02/49993 PCT/US00/26816 and 8 for the preparation of ortho biarylamides and azaarylamides, respectively, are exemplified in Examples 9 and 10. Unless otherwise specified all starting materials and reagents are of standard commercial grade, and are used without further purification, or are readily prepared from such materials by routine methods. Those skilled in the art of organic synthesis will recognize that starting materials and reaction conditions may be varied to achieve the desired end product.

Example 1. Preparation of an arvlimidazole compound: 1-(l-butvl)-2-phenvl-5-(N,Ndi[3,4-methvlenedioxyphenvl methyll)aminomethylimidazole (Compound 106).

N-(n-butyl)-benzamidine (101). To a solution of methyl benzimidate hydrochloride (12 g, 0.07 mole) in dimethylformamide (DMF, 20 mL) is added 7 ml of triethylamine at 0 After 2 h the reaction is filtered to remove triethylamine hydrochloride. To the filtrate is added 3.68 g of 1-butylamine and the mixture is heated to 60 °C for 6 h. After cooling the mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine, dried over sodium sulfate and concentrated to provide 13.28 g of the amidine as a yellow oil. 1H NMR (400 MHz, CDCs1) 8 7.55 2H), 7.4 3H), 3.37 (bm, 2H), 1.62 2H), 1.42 (m, 2H), 0.95 J 7 Hz, 3H).

1-(1-Butyl)-2-phenylimidazole-5-carboxaldehyde (102). To a solution of 101 (13.28 g) and 2-bromo-3-isopropoxyacrolein (22 g) in chloroform (150 ml) is added potassium carbonate (15.5 g) and water (19 ml). The mixture is stirred at room temperature overnight. The aqueous layer is discarded and the organic layer is washed with water (3X 100 mL), dried (Na 2

SO

4 and concentrated. The residue is purified via flash chromatography MeOH/CHC13) to provide the desired imidazole carboxaldehyde as a pale yellow oil (21.55 1H NMR (400 MHz, CDC 3 8 9.75 1H), 7.90 1H), 7.55 2H), 7.45 3H), 4.38 J 8Hz, 2H), 1.75 (m, 2H), 1.22 2H), 0.91 J 7 Hz, 3H).

WO 02/49993 PCT/USOO/26816 Representative preparation of a I -Alky-2-aryl-4-aminomethylimidazole: 1 -Butyl)-2-phenyl-5-(N,N-di[3,4-methylendioxyphenylmethyl]) aminomethylimidazole) NH N N CH 102

N

104 0"

N

NOH

102 103 1-Butyl)-2-phenyl-5-hydroxymethylimidazole (103). Aldehyde 102 is dissolved in methanol (150 mL). Sodium borohydride (3 g) is added in portions.

After the addition was complete, the reaction is diluted with water and concentrated.

The residue is dissolved in ethyl acetate, washed with brine, dried (Na 2

SO

4 and concentrated. The product is purified by flash chromatography on silica gel MeORICHC13) to give 4.17 g of 103 as a cream colored solid. IH-NMR (400 MHz, WO 02/49993 PCT/US00/26816 CDC3): 5 0.79 (3H, t, 1.18 (2H, m, 1.60 (2H, m, 4.03 (2H, dd, 4.56 (2H, 6.84 (1H, 7.39-7.50 (3H, m),7.50-7.53 (2H, m).

1-(1-Butyl)-2-phenyl-5-(N-[3,4methylenedioxyphenylmethyl]) aminomethylimidazole (104).

Hydroxymethylimidazole 103 (0.82 g) is dissolved in chloroform (10 ml) and treated with thionyl chloride (1 ml). The solution is heated to 50 "C for 30 min, cooled and evaporated. The residue is washed with benzene and evaporated to give the intermediate chloromethyl hydrochloride as a white powder which is taken up in acetonitrile (30 mL). This is added dropwise to a solution of piperonylamine (5 ml) in acetonitrile (10 mL). The reaction is allowed to stand overnight and then evaporated. The residue is taken up in ethyl acetate and washed with water. The organic layer is dried (Na 2S

O

4 and concentrated. Purification on silica gel MeOH/CHCbl) provides the product as a pale yellow oil (0.91 1H NMR (400 MHz, CDC3): 8 0.79 (3H, t, 1.18 (2H, m, 1.56 (2H, m, 3.75 (4H, s), 4.04 (2H, dd, 5.92 (2H, 6.76 (2H, 6.84 6.97 (1H, 7.38-7.44 (3H, 7.53-7.56 (2H, m).

1-(l-Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenyl methyl]-N-(3,4methylenedioxyphenylcarboxy]) aminomethylimidazole (105). Compound 104 (160 mg, 0.44 mmol) is dissolved in chloroform (5 ml, pentene stabilized) and treated sequentially with piperonyloyl chloride (100 mg) and triethylamine (1 ml). The mixture is stirred at room temperature overnight. The solution is concentrated and the residue taken up in ethyl acetate. The organic is washed with water, dried (Na2SO 4 and concentrated. Purification by preparative thin layer chromatography MeOH/CHCla) provides compound 105 as a pale yellow oil (240 mg). 1H-NMR (400 MHz, CDCla): 8 0.75 (3H, br), 1.16 (2H, br), 1.49 (2H, br), 4.01 (2H, br), 4.54 (2H, br), 4.68 (2H, br), 5.97 (2H, 5.99 (2H, 6.66 (2H, d, 6.80 (2H, t, 6.98-7.02 (2H, 7.40-7.47 (3H, 7.56 (2H, d, d=6.8).

1-(1-Butyl)-2-phenyl-5-(N,N-di[3,4-methylenedioxy phenylmethyl])aminomethylimidazole (106). Amide 105 (215 mg) in tetrahydrofuran (THF, 3 ml) is added dropwise to a solution of alane (1 M in THF, 2 ml) and the resulting solution WO 02/49993 WO 0249993PCT/USOO/26816 is stirred for 2.5 h at room temperature. A solution of sodium hydroxide NaOHi, 1 ml) is added and the mixture is extracted with chloroform. The organic extracts are dried (Na 2

SO

4 and concentrated. Purification by preparative thin layer chromatography (10% MeOH /CHC 3 provided compound 106 as a colorless oil (115 mg). IH-NMR (400 MHz, ODCls): 8 0.70 (311, t, 0.98 (2H1, m, 1.30 (211, in), 3.44 (4H, 3.52 (2H1, 3.98 (2H1, dd, 5.92 (4H1, 6.74 (4H1, 6.69 (2H1, 7.02 (1H1, 7.36-7.42 (3H, mn), 7.54 (2H1, dd, d=1.4, The hydrochloride salt 187-190 was prepared in isopropanol.

Exampl~e 2. Pre-paration of 1 -but1l--2--phenvl-5-(1-rN--13.4methylenedioxvphenylmethyl-N-phenvlmeth11amino~ethylimidazole (Compound 108).

1-Butyl-2-phenyl-5-(1-hydroxyethyl)imidazole (107). A solution of aldehyde 102 (230 mg) in diethyl ether (30 mL) is placed in a separatory funnel and treated with a solution of Preparation of 1 -Butyl)-2-phenyl-5-(1 -[N-[{3,4-methylendioxyphenyl methyl])- N-[phenylmethyl]ami noethyl imidazole) OH

N

NN

N

10207 17108

N

0, methyl lithium (1.4 M in THF, 1.5 ml). After 10 min, the solution is washed with ammonium chloride solution (1 M, 20 ml), dried (NagSO 4 and concentrated. The resulting dark oil is purified by preparative TLC (10% MeOH/CHC 3 to provide compound 107 as a colorless oil (180 mng). 111 NMR (400 MHz, CDC 3 3 7.56 J 2 WO 02/49993 PCT/USOO/26816 Hz, 2H), 7.4 (in, 3H), 7.01 1H), 4.86 J 7 Hz, 1Hi), 4.18 (in, 1H), 4.0 (in, 1H), 1.63 J =6.6 Hz, 3H), 1.63 (in, 2H), 1.23 (in, 2H), 0.81 J =7 Hz, 3H).

1-Butyrl-2-phenyl-5-(N-[3,4-methylenedioxyphenyl-Nphenylmethyl)aminoethylimidazole (108). A solution of compound 107 (80 ing) in chloroform (10 ml) is treated with thionyl chloride (1 ml) and heated to 50 0 for min. The solution is then concentrated, diluted with chloroform and reconcentrated to provide the intermediate chloromethyl hydrochloride as an oil. This material is taken up in chloroform (5 ml) and treated sequentially with N-benzylpiperonylamine mng) and triethylamine. After stirring overnight, the reaction is washed with saturated potassium carbonate solution, dried (Na 2

SO

4 and concentrated.

Purification by preparative thin layer chromatography (10% MeON! CHCla) provides compound 108 as a colorless oil (62 ing). 1 H NMR (400 MHz, ODC 3 5 7.46-7.43 (mn, lH), 7.2-7.3 (in, 9H), 6.74-6.86 (in, 4H), 5.94 2H), 4.82 J 6.8 Hz, 1H), 4.33 (in, 2H), 3.78 2H), 3.53 2H), 1.83 J 6.8 H~z, 3H), 1.62-1,68 (in, 21H), 1.21 J =7.8 Hz, 2H), 0.82 J =7.8 Hz, SF1).

Example 3. Preparation of 1 -Butyl-2-phenvl-4-bromo-5-(N-phenvlnethvl-N-r 1butylfamino-methylinidazole (Compound 110).

Preparation of 1 -ButyI)-2-phenyI-4-bromo-5-[N-phenylmethy-N-[l -butyl]) aminomethylimidazole) BrI N

N

N N 102-~- N. N WO 02/49993 WO 0249993PCT/USOO/26816 1-Butyl-2-phenyl-5-(N-benzyl-N-butyl)aminomethyliinidazole (109). A solution of compound 102 (115 mg) and N-butylbenzylamine (85 mg) in toluene ml) is allowed to stand overnight. Treatment of the reaction with sodium borohydride (100 mg) and ethanol (2 mL) followed by aqueous workup and purification on silica gel (10% MeOH/CHCls) provides compound 109 as a colorless oil (35 mg). 1 H NMR (400 MHz, CDC 3 8 7.2-7.5 (in, 10H), 6.98 1H), 4.0 J 8 Hz, 2H), 3.55 2H), 3.52 2H), 2.42 J =8 Hz, 2H), 1.2-1.55 (in, 6 1.05 (in, 2H), 0.84 J 7 Hz, 3H), 0,72 J =7 Hz, 3H1).

l-Butyl-2-phenyl-4-bromo-5-(N-phenylmethyl-Nbutylj)aminomethylimidazole (110). To a solution of 109 (30 mng) in acetonitrile (4 mL) was added N-bromosuccinimide (16 mg). The resulting mixture was heated to and the progress of the reaction followed by TLC. The cooled reaction mixture was diluted with ethyl acetate and washed twice with water. Purification by preparative thin layer chromatography (10% MeOH/C01113) provided compound 110 as a colorless oil (22 mng). 1 H NMR (400 MHz, CDC 3 3 7.2-7.5 (mn, 10 3.98 J= 8 Hz, 2H), 3.55 2H), 3.53 2H1), 2.46 J =7 Hz, 2H), 1.52 (mn, 2H), 1.3 (in, 4H), 0.98 J 7 Hz, 2H), 0.84 J 7 Hz, 3H), 0.70 J =7 Hz, 3H1).

Example 4. Preparation of 1-Butyll-2-phenvl-4-methl-5-(N-[3 .4methylenedioxvphenyl-methvll-N-phenlmethvlaminoniethylimidazole. (Compound 114).

1-Butyl-2-phenyl-4-methylimidazole (112). To a solution of 4-methyl-2phenylimidazole (111, 15.8 g) in diinethylforinainide (100 ml) is added sodium hydride (4.4 g, 60% in mineral oil) in small portions. After the addition is complete, the mixture was stirred for an additional 20 mini and treated with 1 -iodobutane (18.8 The reaction is fitted with a reflux condensor and heated at 100 'C for 12 h. The cooled reaction mixture is partitioned between water (300 ml) and diethyl ether (300 ml). The organic layer is washed with water (3X 200 ml), dried (Na 2

SO

4 and concentrated to provide 20.5 g of N-butylimidazoles. Analysis by 'H-NMR and GC-MS revealed mixture of 1-butyl-2-phenyl-4-inethylimidazole (112) and 1-butyl-2- WO 02/49993 PCT/USOO/26816 in a ratio of 11,5/ 1. The mixture was carried on to the next step without purification, 1 -Butyl-2-phenyl-4-methyl-5-hydroxymethylimidazole (113). A solution of 112 (1 g) in acetic acid (10 mL) and 40% aqueous formaldehyde (2 mL) is refluxed for 14 h. The reaction is then concentrated and dried by repeated reconcentration with toluene. The residue is purified by column chromatography MeOH/ CHC1 3 The fractions are assayed by GC and those fractions uncontaminated by the isomeric hydroxymethylitnidazole combined. Concentration of the combined fractions provides compound 13 (320 mg) as a pale yellow oil. 1 H NMR (400 MHz, ODC13) 8 7.4-7.6 (in, 6H), 4.61 2H, CH 2 OH), 4.02 J 7 Hz, 2H, NCH 2 2.22 (s, 3H, Me), 1.63 (mn, 2H, 1.25 (mn, 2H), 0.81 J =7 Hz, 3H).

Preparation of 1 -Butyl)-2-phenyi-4-methyl-5-(N-13,4-methylenedioxyphenyl]-N-phenylmethyl) aminomethylimidazole

NN

N N H

C

111 112 OH

N

N N 1141 I-Butyl-2-phenyl-4-methyl-5-(N-benzyl-N-butyl)aminomethylimidazole (114), Compound 114 (23 mg) is prepared from 113 (50 mg) in a method similar to that used to obtain compound 108. 'H NMR (400 MHz, CDC13) 5 7.5-7.55 (in,2H), 7.38- 7.42 (in, 3H), 7.23-7.30 (in, 5H), 3.95 J 7.5 Hz, 2Hf), 3.55 2Hf), 3.53 2Hf), WO 02/49993 PCT/US00/26816 2.40 J 7 Hz, 2H), 2.22 3H), 1.25-1.40 6H), 1.05 2H), 0.82 J 7 Hz, 3H). 0.70 J 7 Hz, 3H); MS (LCMS) m/e 390 Example 5. Preparation of a cvcloalkvlimidazole compound: 4-i{butvl(1-butvl-2phenvl(4,5,6-trihydrocyclopenta[3,2-dlimidazol-6-vl))aminolmethyll-3-chlorophenol N-(n-butyl)-benzamidine (120). To a solution of methyl benzimidate hydrochloride (12 g, 0.07 mole) in dimethylformamide (DMF, 20 mL) is added 7 ml of triethylamine at 0 After 2 h the reaction is filtered to remove triethylamine hydrochloride. To the filtrate is added 3.68 g of 1-butylamine and the mixture is heated to 60 OC for 6 h. After cooling the mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine, dried over sodium sulfate and concentrated to provide 13.28 g of the amidine as a yellow oil. IH NMR (CDC1a) 7.55 2H), 7.4 3H), 3.37 (bm, 2H), 1.62 2H), 1.42 2H), 0.95 (t, J 7 Hz, 3H).

2-Bromo-3-methoxycyclopentenone (131) is prepared via the method of Curran et al JACS, vol 112, page 5601. To a suspension of 1,3-cyclopentanedione g) in chloroform (700 ml) is added a N-bromosuccinimide (18.2 The mixture is refluxed for 2 h, cooled and concentrated. Methanol (700 mL) and p-toluenesulfonic acid (1 g) are added and the solution is refluxed overnight. The mixture is concentrated to 100 ml, diluted with methylene chloride (500 mL) and poured into water. The aqueous layer is discarded and the organic layer is washed with water (3 X 100 mL), dried (Na2SO 4 and concentrated. The residue is crystallized from ethyl acetate to give 131 as tan crystals (1.67 g).

1-Butyl-2-phenyl-4,5-dihydrocyclopenty[1,2-d]imidazol-6-one (Compound 132), To a mixture of amidine 130 (3.52 g, 20 mmol) and enone 13 (4.58 g, 24 mmol) in chloroform (40 mL) and water (5 mL) was added solid potassium carbonate (3.32 g, 24 mmol). The resulting mixture is refluxed overnight. After cooling, the mixture is washed with water, dried (Na 2 S0 4 and concentrated. Purification on silica gel eluting with 25% ethyl acetate/hexane gives the desired product 132 (3.0 g) LC-MS WO 02/49993 PCT/US00/26816 255. IH-NMR CDC13): 0.84 J 7.6 Hz, 3H), 1.23 (dt, J 7.0, 7.6 Hz, 2H), 1.81 2H), 2.95 4H), 4.13 J 7.6 Hz, 2H) 7.5-7.45 3H), 7.76-7.6 2H) ppm.

1-Butyl-2-phenyl-4,5-dihydrocyclopenty[1,2-d]imidazol-6-ol (Compound 133). To a solution of 132 (2.68 g) in methanol (20 mL) is added sodium borohydride equiv) and the mixture stirred overnight. The mixture is concentrated, diluted with chloroform and washed with 0.5 N NH 4 C1 solution. The organic layer is dried (Na 2

SO

4 and concentrated to provide the desired product 133. LC-MS (M 1) 257.

Butyl(l-butyl-2-phenyl-4,5,6-trihydrocyclopentyl[3,2-d]imidazol-6-yl))amine (Compound 135). Compound 133 (2 g) is dissolved in chloroform (20 mL) and thionyl chloride (5 mL) and the resulting solution is stirred at room temperature overnight. The solvent and excess thionyl chloride are evaporated and the crude chloride 134 was dissolved in n-butylamine (10 mL). After 2 h, the excess butylamine was evaporated, the residue dissolved in ethyl acetate and the organic solution washed with 5% NaOH solution and water. The organic layer was dried and concentrated. The organic residue is purified by column chromatography on silaica gel eluting with 10% CH 3 OH in CHC1a to provide the desired secondary amine 135 in 82% yield. LC-MS 312 IH-NMR (chemical shift, CDC13): 0.83 J 7.2 Hz, 3H), 0.9 J 7.2 Hz, 3H), 1.23 J 7.2 Hz, 2H), 1.35 J 7.2 Hz, 2H), 1.46 2H), 1.70 2H), 2.24 1H), 2.55-2.66 4H), 2.73-2.80 2H), 3.97-4.04 2H), 4.30 J 5.6 Hz, 1H), 7.37-7.44 3H), 7.55-7.57 2H).

4-{[Butyl( 1 -butyl-2-phenyl(4,5,6-trihydrocyclopenta[3,2-d]imidazol-6yl))amino]methyl}-3-chlorophenol (Compound 5, Table To a solution of compound 135 (50 mg) in 1,2-dichloroethane (2 mL) and 2-chloro-4hydroxybenzaldehyde (30 mg) is added sodium triacetoxyborohydride (100 mg). The resulting mixture is allowed to stir overnight. After washing with 0.5 ammonium chloride solution, the organic layer is dried (NaaSO 4 and concentrated. Purification WO 02/49993 PCT/USOO/26816 using preparative thin layer chromatography eluting with 5% CH3OH/CHCIa3 provides the desired product 136 as an oil (21 mg). LC-MS 452, 450.

1 H-NMR (chemical shift, CDC13): 0.74 J 7.2 Hz, 314), 0.83 J 7.2 Hz, 314), 1.11 J 7.2 Hz, 2H1), 1.21-1.33 (mn, 2H), 1.41-1.51 (in, 4H), 2.34-2.44 (in, 3H1), 2.51-2.57 (mn, 1H), 2.60-2.67 (in, 11H), 2.69-2.75 (mn, 111), 3.38 J =7.6 Hz, PH1), 3.47 J =13.6 Hz, 3.65 J 13.6 Hz, 3.78-3.96 (in, 1H), 6.62 (dd, J= 8,2 Hz, 11H), 6.78 J 2 Hz, 1H), 7.07 J 8 Hz, 1H1), 7.35-7.41 (in, 3H), 7.45- 7.48 [mn, 214).

WO 02/49993 WO 0249993PCT/USOO/26816 Preparation of 4-{[Butyl(1 -butyl-2-phenyl(4.5,6-tri hydrocyclopenta F3,2-dl im idazol .6-vI)am 1nol meth-vil-3-ch lorop heno0l MeO a Br Compound 133 X OH Compound 134 X CI Compound 135 X HNBu Compound 136 WO 02/49993 WO 0249993PCT/USOO/26816 Examtile 6. Preparation of 2-iphenvl-4-(N,N-dil2H-Benzof3,4-d -1 vlmethivllamino)methvl-3-butvlpvridine 4-Phenyl-S-butyloxazole (140). A mixture of a-bromohexanophenone (25.5 g, 0.1 mole), amnmonium formate (22 g, 0.35 mole) and formic acid (110 mL) was refluxed with stirring for 3 h. The reaction mixture was poured onto ice and made basic with 10 N NaOH- and extracted with ether. The organic layer was washed with water, dried ever sodium sulfate and concentrated. The crude product was purified by flash chromatography on silica gel eluting with 20% ethyl acetate in hexane. To provide the desired compound as an oil (8.3 g, 41 1H NMR CDCla, 400 MHz) 7.55 (in, 2H), 7.40 1H), 7.34 (dd, J 7,7 Hz, 2H), 7.22 (dcl, J 7, 7 Hz, 114), 2.74 (in, 2H1), 1.6 (in, 2H), 1.30 (in, 2H), 0.84 J 7 Hz, 3H) ppm.

2-Phenyl-3-butylisonicotinic acid (141). A mixture of (12, 5 g, 25 inmol) and inaleic acid (3.5 g, 30 minol) is heated at 100 OC for 30 min.

After cooling, the semisolid mass is triturated with ether and the solid collected by filtration. 'H NMR CDC13, 400 MHz) 11,68 (brs, 1H), 8.72 J=6.0 Hz,l11), 7.73 J= 5.6 Hz, 1H), 7.48-7.51 (in, 2H1), 7.42-7.44 (in, 2H), 6.25 1H), 2.86 (d, J= 7.6 Hz, 2H), 1.36 (in,2H), 1.11 (dt, J= 7.6, 7.2 Hz,211), 0.68 J= 7.6 Hz,311).

MS 256, (M 1) 254.

2-Phenyl-4-hydroxymethyl-3-butylpyridine (142). 4 mL of a 1M solution of lithium aluminum hydride in tetrahydrofuran is added to a solution of 2-phenyl- 3-butylisonicotinic acid (13, 510 mng, 2 mmol) in tetrahydrofuran (20 mL). The reaction is stirred overnight and then quenched with 5 mL of 15% aqueous NaOH.

The resulting mixture is extracted with ether, dried (Na2SO4) and concentrated to provide the desired hydroxyinethylpyridine as an oil (470 mg). LC-MS 242; 'H NMR CDCL3) 8.35 (1H, d, J 5.2 Hz), 7.30-7.39 (6H, in), 4.59 (211, 2.43 (211, t, J 8.0 Hz), 1.23 (2H, in), 1. 13 (211, in), 0.70 t, J =7.2 Hz).

2-Phenyl-4-(N-{2H-benzo[3,4-d]-1,3-dioxolan-5-ylmethyl})aminomethyl-3butylpyridine (143). Thionyl chloride (200 mg, 1.67 mmol) is added to a solution of 2-phenyl-4-hydroxymethyl-3-butylpyridine (400 mng, 1.66 inmol) in pentene stabilized chloroform (8 mL) and the mixture is heated to 50 oC for 2 h. The resulting WO 02/49993 PCT/US00/26816 mixture is cooled, washed with saturated sodium bicarbonate solution, dried (Na 2

SO

4 and concentrated. The resulting crude chloride is taken up in dimethylformamide (10 mL) and added dropwise to a refluxing solution of piperonylamine (1.0 g, 4 equiv) in dimethylformamide (30 mL) containing 3 g of powdered potassium carbonate. After the addition is complete, the resulting mixture is refluxed for an additional 3 h, cooled and partitioned between water (200 mL) and ether (100 mL). The ethereal layer is washed 2 times with water, dried (Na 2 S0 4 and concentrated. The resulting material is purified by chromatography on silica eluting with 10% CHsOH/CHC1s to give the desired secondary amine 15. LC- MS 375.3; 1H-NMR CDCls): 0.73 (3H, t, J 7.2 Hz), 1.15 (2H, m J 7.2 Hz), 1.30 (2H, 2.58 (2H, t, J 8.0 Hz), 3.79 (2H, 3.83 (2H, 5.93 (2H, s), 6.75-6.82 (2H, 6.89 (1H, d, J 1.2 Hz), 7.36-7.42 (6H, 8.45 (1H, d, J 4.8 Hz) ppm.

2-Phenyl-4-(N,N-di{2H-benzo[3,4-d]-1,3-dioxolan-5-ylmethyl})aminomethyl-3butylpyridine (144). To a solution of 14 (38 mg) in dichloroethane (5 mL) was added piperonal (30 mg). The resulting mixture was stirred for 3 h after which time sodium triacetoxyborohydride (150 mg) is added in one portion and the resulting mixture is stirred overnight. The reaction mixture was quenched with ammonium hydroxide solution (5 ml). The organic layer is washed with water and extracted with IN HC1 solution. The acidic extract is made basic with 1N NaOH solution and extracted with chloroform. The organic extract is dried (NaSO0 4 and concentrated. The resulting oil is purified on preparative thin layer chromatography eluting with 10% CHO 3 H/CHC1l to give the desired tertiary amine 144 as an oil (18 mg). LC-MS 509.4; 1 H-NMR CDC13): 0.71 (3H, t, J 7.2 Hz), 1.10 (2H, m, J 7.2 Hz), 2.60 (2H, t, J 8.0 Hz), 3.48 (4H, 3.58 (2H, 5.94 (4H, 6.75 (1H, d, J 8.0 Hz),6.80 (1H, dd, J 0.8, 8.0 Hz), 6.91 (1H, d, J 0.8 Hz), 7.36-7.43 7.56 (1H, d, J 5.2 Hz), 8.47 (1H, d, J 5.2 Hz) ppm.

WO 02/49993 PCT/USOO/26816 Preparation of 2-Phenyl-4-(N,N-di{211-benzop[,4-di-1,3-dioxolan-5-ylmethyl}) aminomethyl-3-butylpyridine 0\ NH 1.thionyl chloride 2. piperonylamine

K

2 C0 3 reduction Example 7. Prenaration of an Arvi-pyrazole: WO 02/49993 PCT/US00/26816 1,3-diphenvl-4-(N-f2H-benzo[3,4-di-1,3-dioxolan-5-vlmethvll-N-butvlamino)methyl- N'-Phenyl-N-phenylhydrazone (150). Benzaldehyde (9.81 g, 9.25 mmol) is added at 0-5 oC to a solution of phenyl hydrazine (10 g, 9.25 mmol) in ethanol (100 mL). A cream colored solid forms and the reaction mixture is allowed to stand for 2h. The solid is collected by filtration, washed with ice-cold ethanol and dried under vacuum to provide the desired compound, compound 150 (14.92 g);LC-MS m/z 197.2, IH NMR CDCls, 400 MHz) ppm.

Ethyl 1,3-diphenyl-5-propylpyrazole-4-carboxylate (152). A mixture of 150 (5 g, 25.5 mmol) and ethyl butyrylacetate (20.2 g, 128 mmol) and a catalytic amount of zinc chloride is heated at 125 oC under an air atmosphere for 3h, The reaction vessel is fitted with a short path distillation head and excess ethyl butyrylacetate iss distilled away under vacuum. The resulting material is purified by column chromatography on silica eluting with 10% ethyl acetate in hexanes to provide the desired ester 152 as a yellow oil (6.39 g) which crystallizes upon standing. Recrystallization from diisopropyl ether provides a white solid. 1H NMR CDC1L, 400 MHz) MS 335.2 1,3-Diphenyl-4-hydroxymethyl-5-propylpyrazole (153). To a solution of ester 153 (670 mg, 2 mmol) in tetrahydrofuran (20 mL) is added 4 mL of a 1M solution of lithium aluminum hydride in tetrahydrofuran. The reaction is stirred overnight and then quenched with 5 mL of 15% aqueous NaOH. The resulting mixture is extracted with ether, dried (Na 2

SO

4 and concentrated to provide the desired hydroxymethylpyrazole as an oil (505 mg). LC-MS 293.3; 'H NMR

CDCL

3 7.86 (dd, J= 8.4 Hz, 2H), 7.34-7.52 8H), 4.65 2H), 2.72 J= 8.0 Hz, 2H), 1.52 2H), 0.87 J= 7.6 Hz, 3H).

[(1,3-Diphenyl-5-propylpyrazol-4-yl)methyl]butylamine (154). To a solution of 18 (289 mg) in pentene stabilized chloroform (8 mL) is added thionyl chloride (1 mL) and the mixture heated to 60 oC for 2 h. The resulting mixture is cooled, washed with saturated sodium bicarbonate solution, dried (Na 2

SO

4 and concentrated. The resulting crude chloride is taken up in dimethylformamide (3 mL) WO 02/49993 PCT/US00/26816 and added dropwise to a solution of butylamine (1.0 g) in dimethylformamide mL) containing 2 g of powdered potassium carbonate. After the addition is complete, the resulting mixture is stirred for an additional 3 h and partitioned between water (20 mL) and ether (10 mL). The ethereal layer is washed 2 times with water, dried (Na 2

SO

4 and concentrated. The resulting material is purified by chromatography on silica eluting with 10% CHaOH/CHC13 to give the desired secondary amine 155 (190 mg). LC-MS 348.3; IH-NMR CDC1 3 7.87 (dd, J= 8.0, 1.6 Hz, 2H), 7.32-7.48 8H), 3.77 2H), 2.70 4H), 1.48 4H), 1.34 2H), 0.91 J= 7.6 Hz, 3H), 0.87 J= 7.6 Hz, 3H) ppm.

1,3-Diphenyl-4-(N-{2H-benzo[3,4-d]-1,3-dioxolan-5-ylmethyl}-N- (Compound 155). To a solution of 154 mg) in dichloroethane (5 mL) is added piperonal (30 mg). The resulting mixture is stirred for 3 h after which time sodium triacetoxyborohydride (150 mg) is added in one portion and the resulting mixture is stirred overnight. The reaction mixture is quenched with 10% ammonium hydroxide solution (5 ml). The organic layer is washed with water and extracted with 1N HC1 solution. The acidic extract is made basic with 1N NaOH solution and extracted with chloroform. The organic extract is dried (Na 2

SO

4 and concentrated. The resulting oil is purified on preparative thin layer chromatography eluting with 10% CH 30 H/CHC1s to give the desired tertiary amine (Compound 155) as an oil (24 mg). LC-MS 482.5; 1H-NMR CDCl1): 7.87 J 7.2 Hz, 2H), 7.47 J 4.4 Hz, 4H), 7.33-7.43 4H), 6.77 1H), 6.70 2H), 5.92 2H), 3.56 2H), 3.42 2H), 2.74 J 8.0 Hz, 2H), 2.37 J 7.2 Hz, 2H), 1.42 4H), 1.21 2H), 0.83 J 7.6 Hz, 3H), 0.81 J 7.2 Hz, 3H) ppm.

WO 02/49993 WO 0249993PCT/USOO/26816 Preparation of 1,3-Diphenyl-4-(N4(2H-benzo[3,4-dl-1 -N -butylamino)methyl-5-propyl pyrazole

H

NN N

P

150 0 0 +Pr11 p 151 '-Et 152 154 155 WO 02/49993 PCT/US00/26816 Example 8. Synthesis of N-(1-fluorobenzvl)-N-indan-2-vl-2-(6. 7-dimethoxy-1phenvl-1.2,3,4-tetrahvdroisoauinolin-l-vl) acetamide (162). A mixture of 6, 7dimethoxy-l-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (160, 153 mg, mmol), N-(1-fluorobenzyl)-N-indan-2-yl-2-bromoacetamide (161, 180 mg, 0.5 mmol) and potassium carbonate (500 mg) in acetonitrile is heated at 80 oC overnight. After cooling, the mixture is filtered and concentrated. The resulting residue is purified by column chromatography eluting with 5% methanol in chloroform to provide the title product (162) as a thick oil (215 mg, 1 H NMR (CDCls) 6.8-7.3 14H), 6.60(s, 1H), 6.05 1H), Meo Me o F 0 MeO N N MOON N

HCI

160 161 162 Example 9. Preparation of 4 Trifluoromethvl-biphenvl-2-carboxvlic acid benzoll ,3ldioxol-5-vlmethyl-benzvl-amide (174). 1,1'-carbonyldiimidazole (175 mg) is added to a solution of 2-iodobenzoic acid (248 mg, 1 mmol)(170) in tetrahydrofuran (THF, 5 ml). The resulting mixture is stirred overnight at room temperature. A solution of N-3,4-methylenedioxybenzyl-N-benzylamine (241 mg, 1 equiv)(171) in THF (2 mL) is added and the resulting solution is stirred for 1 h, quenched with water and extracted with diethyl ether. The organic extracts are dried (Na 2

SO

4 and concentrated. The residual material is taken up in dimethoxyethane (10 mL) and a catalytic amount (20 mg) of tetrakis(triphenylphosphine)palladium(0) is added. The resulting mixture is stirred under an argon atmosphere for 10 min and solid 4-trifluoromethyllphenylboronic acid (150 mg) is added in one portion. A second phase of lN aqueous Na 2

SO

4 is added and the mixture is warmed to 80 oC for 6 h under a argon atmosphere. The solution is cooled, diluted with water and ethyl acetate and filtered through a pad of WO 02/49993 WO 0249993PCT/USOO/26816 celite. The organic phase is dried over sodium sulfate and concentrated.

Purification on silica eluting with 20% ethyl acetate in hexane provided the desired biphenylamide product (1'74)(410 mg). The proton NMR displays a doubled pattern commonly observed for amnides which possess some rotational restriction about the amide nitrogen at room temperature. The ratio of the rotomers is approximately equal. 1 H NMR (CDCl3) '3.50 and 3.62 (two doublets, J =X Hz, 1H), 3.72 and 3.83 (two doublets, J X Hz, 1iH), 4. 10 and 4.18 (two doublets, J X Hz, 1 5.09 and 5.16 (two doublets, J x Hz, 1H4), 5.95 J X Hz, 214, OCH 2 6.30 (in, 1.5 H), 6.46 J =1 Hz, 0.5 Hz), 6.60 and 6.66 (two doublets, J =X Hz, 111), 6.80 (bd, J X Hz, 1 6.86 (in, 1 7.16-7.62 (in, 11 H).

OH

I0 170 1. CDI, THF 2.

NH

01 171

K

0

O

B(OH)

2 0-

CF

3 2. Pd(rPb 3 4 3. NaZCO 3 dimethoxyethane 4'-Trifluorometiyl-biphenyl-2-carboxylic acid benzo(1,3]dioxol-5-ylmethyl-benzyl-amide WO 02/49993 PCT/US00/26816 Example 10. Preparation of N-Benzo[l,3]dioxol-5-lmethl-N-benz-2-pyrazol-2l-1benzamide 2-Pvrazol-l-vl-benzonitrile, Compound 177. A solution of 20 mmol of 2fluorobezonitrile and 40 mmol of pyrrazole is mixed together in dimethylformaide with 1 equivalent of potassium hydroxide and a catalytic amount of 18-crown-6.

The mixture is stirred at room temperature overnight, quenched with water and ethyl acetate and extracted with ethyl acetate. The organic extract is washed repeatedly with 1 N NaOH solution. The organic layer is then diluted with ether and washed with IN HCI solution, dried and concentrated. 1H NMR (CDCl 3 6.55 J 2 Hz, 1H), 7.42 1H), 7.65-7.82 m, 4H), 8.15 J 1 Hz, 1H).

2-Pyrazol-l-yl-benzoic acid, Compound 178. A solution of compound 177 in cone HC1 is refluxed overnight, cooled and concentrated. The product is precipitated by addition of 1 N NaOH until pH of 5-6, filtered and dried. 1H (CDC13) 6.52 J 3 Hz, 1H), 7.40 J 8 Hz, 1H), 7.50 J 8 Hz, 1H) 7.62 J 8 hz, 1H), 7.81 (m, 2H), 8.12 J 8 Hz, 1H).

N-Benzo 1 ,3ldioxol-5-vlmethvl-N-benzyl-2-pyrazol-1-yl-benzamide, Compound 179. 1.1 equiv of carbonyl diimidazole is added to a solution of benzoic acid 178 (200 mg) in tetrahydrofuran (5 mL); the reaction is stirred at room temperaturte for 3 h. After this time N-piperonyl-N-benzylamine (0.25 g) is added in one portion.

After 30 min, the reaction is filtered, diluted with ether and washed with water. The organic layer is dried (Na2S04) and purified over column chromatography to provide the desired product (390 mg). The proton NMR displays a typically doubled pattern.

1H (CDC1s) 3.83 and 4.32 (two doublets, J 16 Hz, 1H), 3.91 (two doublets, J 8 Hz, 1H), 4.18 two doublets (J 6 Hz, 1H), 5.0 and 5.1 (two doublets, J 14 Hz, 1H), 5.93 and 5.98 (s and doublet, J 2 Hz, 2H, OCH20), 6.35-6.40 2H), 6.51 J 4 Hz, 0.5 6.4 1.5 7.0-7.88 m, 15H). LC-MS 412.3 WO 02/49993 WO 0249993PCT/USOO/26816

H

N

176

HCI

179 /178 Example 11. Preparation of N-benzovl-N-(4-methoxybenzvl)-N-(l1-propyl-2methyleno-7-azabenzimidazole 2-aminopropyl-3-nitropyridine N C1 180 CH3CN ayN0 2 N N 181 2-chloro-3-nitroaminopyridine (180) (5.5 g, 35 mmol) is dissolved in 150 mL acetonitrile at room temperature. Propylamine (21 g, 350 mmol) is added dropwise and the reaction mixture is stirred for 5 hours at room temperature. The solvent and excess propylamine are removed in vacuo. The residue is dissolved in 150 mL ethyl acetate and washed once with 100 mL saturated NaHCO3 solution and once WO 02/49993 WO 0249993PCT/USOO/26816 with 100 mL brine. The organic layer is dried over MgSO 4 filtered, and the solvent removed in vacuo, to afford 6.3 g of 2-aminopropyl-3-nitropyridine (18 1).

2-aminopropyl-3-aminopyridine.

H2 qN0 2 Pd/C H N H 40 psi N H 181 182 2-aminopropyl-3-nitropyridine (171)(6.3 g, 35 mmol) is dissolved in 100 mL 1/1 ethyl acetate ethanol in a Parr shaker bottle. Nitrogen is bubbled through the solution for 2 minutes followed by the addition of 10% Pd/C (500 mg). The suspension is hydrogenated on a Parr apparatus under 40 psi of H4 2 until hydrogen uptake ceased. The suspension is filtered through Celite and the solvent evaporated in t'acuo to afford 5.3 g of the 2-aminopropyl-3-aminopyridine (182).

1-propyl-2-chloromethyl-7-azabenzimidazole

NH

2 NH HIN C K KH EtO' N"C[C .N i N N' N N 182 183 2-aminopropyl-3-aminopyridine (172) (5.3 g, 35 mmol) is dissolved in 100 mL CHC1 3 at room temperature. Ethyl chloromethylimidate hydrochloride (14 g, 89 mmol) is added followed by K 2 CO3 (25 g, 180 mmol). The suspension was stirred vigorously at room temperature for 3 hours. The reaction mixture is filtered through Celite and the solvent removed in vacuo. The residue is passed through a short plug of silica gel eluting with ethyl acetate to afford 3.7 g of 1-propyl-2-chloromethyl-7azabenzimidazole (183).

1-propyl-2-(4-methoixybenzylamino)methy1-7-azabenzimidazole.

WO 02/49993 PCT/US00/26816 N C NI N H V ,F MeO HO, N 18 CH3CN

N

183 184 OMe 4-Methoxybenzylamine (3.8 g, 27 mmol) is dissolved in 20 mL dry acetonitrile. 1propyl-2-chloromethyl-7-azabenzimidazole (173)(940 mg, 4.5 mmol) dissolved in mL acetonitrile is added dropwise. The mixture is stirred 10 hours at room temperature. The solvent is removed in vacuo and the residue dissolved in 20 mL ethyl acetate. This solution is washed once with 20 mL 1 N NaOH, once with 20 mL water, once with 20 mL 5% HOAc in water, then once with 5 N NaOH. The organic phase was dried over MgSO4, filtered, then concentrated in vacuo. The product mixture is purified by flash chromatography eluting with ethyl acetate followed by 95/5/1 ethyl acetate methanol triethylamine to afford 850 mg of the 1-propyl-2- (4-methoxybenzylamino)methyl-7-azabenzimidazole (184).

N-benzoyl-N-(4-methoxybenzyl)-N-( -propyl-2-methyleno-7-azabenzimidazole Cal HN C NNN N N 184 OMe OMe 185 1-propyl-2-(4-methoxybenzylamino)methyl-7-azabenzimidazole (174)(19 mg, 0.06 mmol) is dissolved in 0.6 mL toluene. Saturated sodium bicarbonate solution in water (0.3 mL) is added followed by benzoyl chloride (11 mg, 0.08 mmol). The reaction mixture is stirred at room temperature for 10 hours. It is then diluted with mL ethyl acetate and transferred to a separatory funnel. The aqueous layer is removed and the organic phase washed once with 1N NaOH, once with 5 mL water, then and once with mL brine. The organic phase is dried over MgSO 4 filtered and the solvent removed in vacuo. The product is purified by preparatory tic eluting with WO 02/49993 PCT/US00/26816 1/1 ethyl acetate hexanes to afford 20 mg of the desired compound (185). NMR 400 MHz (CDC13) 8.39 ppm (br d, 1 8.15 ppm (br d, 1 7.52 ppm 1.5 H), 7.40 ppm 1.5 7.22 1 7.18 ppm (br d, 1 6.83 ppm, J 4 Hz, 2 4.93 ppm (br s, 2 4.71 ppm br s, 1 4.39 ppm (br s, 1 3.79 ppm 3 1.89 ppm (br m, 2 0.98 pp, (br t, 3 H).

Example 12 Assay for C5a Receptor Mediated Chemotaxis This assay is a standard assay of C5a receptor mediated chemotaxis.

Human promonocytic U937 cells or purified human or non-human neutrophilis are treated with dibutyryl cAMP for 48 hours prior to performing the assay. Human neutrophils or those from another mammalian species are used directly after isolation. The cells are pelleted and resuspended in culture media containing 0.1% fetal bovine serum (FBS) and 10 ug/ml calcein AM (a fluorescent dye). This suspension is then incubated at 37 °C for 30 minutes such that the cells take up the fluorescent dye. The suspension is then centrifuged briefly to pellet the cells, which are then resuspended in culture media containing 0.1% FBS at a concentration of approximately 3 x 106 cells/mL. Aliquots of this cell suspension are transferred to clean test tubes, which contain vehicle DMSO) or varying concentrations of a compound of interest, and incubated at room temperature for at least 30 minutes. The chemotaxis assay is performed in ChemoTx T M 101-8, 96 well plates (Neuro Probe, Inc. Gaitherburg, MD). The bottom wells of the plate are filled with medium containing 0-10 nM of C5a, preferably derived from the same species of mammal as are the neutrophils or other cells human C5a for the human U937 cells). The top wells of the plate are filled with cell suspensions (compound or vehicle-treated). The plate is then placed in a tissue culture incubator for minutes. The top surface of the plate is washed with PBS to remove excess cell suspension. The number of cells that have migrated into the bottom well is then determined using a fluorescence reader. Chemotaxis index (the ratio of migrated cells to total number of cells loaded) is then calculated for each compound concentration to determine an ICso value.

WO 02/49993 PCT/US00/26816 As a control to ensure that cells retain chemotactic ability in the presence of the compound of interest, the bottom wells of the plate may be filled with varying concentrations chemo-attractants that do not mediate chemotaxis via the receptor, e.g. zymosan-activated serum (ZAS), N-formylmethionyl-leucylphenylalanine (FMLP) or leukotriene B4 (LTB4), rather than C5a, under which conditions the compounds of the invention preferably do not inhibit chemotaxis.

Preferred compounds of the invention exhibit IC5o values of less than 1 pM in the above assay for C5a mediated chemotaxis.

Example 13 Determination of dopamine D 4 receptor binding activity The following assay is a standard assay for determining the binding affinity of compounds to dopamine D 4 receptors.

Pellets of Chinese hamster ovary (CHO) cells containing recombinantly expressing primate dopamine D4 receptors are used for the assays. The dopamine

D

4 receptor expression vector may be the pCD-PS vector described by Van Tol et al.

(Nature (1991) 358: 149-152). The sample is homogenized in 100 volumes (w/vol) of 0.05 M Tris HC1 buffer containing 120 mM NaC1, 5 mM MgC12 and 1 mM EDTA at 4°C and pH 7.4. The sample is then centrifuged at 30,000 x g and resuspended and rehomogenized. The sample is then centrifuged as described and the final tissue sample is frozen until use. The tissue is resuspended 1:20 (wt/vol) in 0.05 M Tris HC1 buffer containing 120 mM NaC1.

Incubations for dopaminergic binding are carried out at 25°C and contain 0.4 ml of tissue sample, 0.1 nM 3 H-YM 09151-2 (Nemonapride, cis-5-Chloro-2methoxy-4-(methylamino)-N-(2-methyl-2-(phenylmethyl)-3-pyrrolidinyl)benzamide) and the compound of interest in a total incubation of 1.0 ml. Nonspecific binding is defined as that binding found in the presence of 1 uM spiperone; without further additions, nonspecific binding is less than 20% of total binding.

Example 14. Preparation of radiolabeled probe compounds of the invention The compounds of the invention are prepared as radiolabeled probes by WO 02/49993 PCT/US00/26816 carrying out their synthesis using precursors comprising at least one atom that is a radioisotope. The radioisotope is preferably selected from of at least one of carbon (preferably hydrogen (preferably 3 sulfur (preferably 35S), or iodine (preferably 1251). Such radiolabeled probes are conveniently synthesized by a radioisotope supplier specializing in custom synthesis of radiolabeled probe compounds. Such suppliers include Amersham Corporation, Arlington Heights, IL; Cambridge Isotope Laboratories, Inc. Andover, MA; SRI International, Menlo Park, CA; Wizard Laboratories, West Sacramento, CA; ChemSyn Laboratories, Lexena, KS; American Radiolabeled Chemicals, Inc., St. Louis, MO; and Moravek Biochemicals Inc., Brea,

CA.

Tritium labeled probe compounds are also conveniently prepared catalytically via platinum-catalyzed exchange in tritiated acetic acid, acid-catalyzed exchange in tritiated trifluoroacetic acid, or heterogeneous-catalyzed exchange with tritium gas.

Such preparations are also conveniently carried out as a custom radiolabeling by any of the suppliers listed in the preceding paragraph using the compound of the invention as substrate. In addition, certain precursors may be subjected to tritiumhalogen exchange with tritium gas, tritium gas reduction of unsaturated bonds, or reduction using sodium borotritide, as appropriate.

Example 15: Baculoviral Preparations (For C5a Expression) The human C5a (hC5a) receptor baculoviral expression vector was cotransfected along with BACULOGOLD DNA (BD PharMingen, San Diego, CA) into SJ9 cells. The Sf9 cell culture supernatant was harvested three days post-transfection.

The recombinant virus-containing supernatant was serially diluted in Hink' s TNM- FH insect medium (JRH Biosciences, Kansas City) supplemented Grace's salts and with 4.1mM L-Gln, 3.3 g/L LAH, 3.3 g/L ultrafiltered yeastolate and 10% heatinactivated fetal bovine serum (hereinafter "insect medium") and plaque assayed for recombinant plaques. After four days, recombinant plaques were selected and harvested into 1 ml of insect medium for amplification. Each 1 ml volume of recombinant baculovirus (at passage 0) was used to infect a separate T25 flask WO 02/49993 PCT/US00/26816 containing 2 x 106 S]9 cells in 5 mis of insect medium. After five days of incubation at 27 0 C, supernatant medium was harvested from each of the T25 infections for use as passage 1 inoculum.

Two of seven recombinant baculoviral clones were then chosen for a second round of amplification, using 1 ml of passage 1 stock to infect 1 x 108 cells in 100 ml of insect medium divided into 2 T175 flasks. Forty-eight hours post infection, passage 2 medium from each 100ml prep was harvested and plaque assayed for titer. The cell pellets from the second round of amplification were assayed by affinity binding as described below to verify recombinant receptor expression. A third round of amplification was then initiated using a multiplicity of infection of 0. 1 to infect a liter of SJ9 cells. Forty hours post-infection the supernatant medium was harvested to yield passage 3 baculoviral stock.

The remaining cell pellet is assayed for affinity binding using the "Binding Assays" described by DeMartino et al., 1994, J. Biol. Chem. 269 #20, pp.

1 4 4 4 6 14 4 5 0 at page 14447, adapted as follows. Radioligand is 0.005-0.500nM 12 5 I]C5a (human recombinant), New England Nuclear Corp., Boston, MA; the hC5a receptorexpressing baculoviral cells are used instead of 293 cells; the assay buffer contains mM Hepes pH. 7.6, 1 mM CaC1 2 5 mM MgCl 2 0.1% BSA, pH 7.4, 0.1 mM bacitracin, and 100 KIU/ml aprotinin; filtration is carried out using GF/C WHATMAN filters (presoaked in 1.0% polyethyeneimine for 2 hours prior to use); and the filters are washed twice with 5 mLs cold binding buffer without BSA, bacitracin, or aprotinin.

Titer of the passage 3 baculoviral stock is determined by plaque assay and a multiplicity of infection, incubation time course, binding assay experiment is carried out to determine conditions for optimal receptor expression.

A multiplicity of infection of 0.1 and a 72-hour incubation were the best infection parameters found for hC5a receptor expression in up to 1-liter SJ9 cell infection cultures.

WO 02/49993 PCT/US00/26816 Example 16: Baculoviral Infections Log-phase Sj9 cells (INVITROGEN Corp., Carlsbad CA), are infected with one or more stocks of recombinant baculovirus followed by culturing in insect medium at 270C. Infections are carried out either only with virus directing the expression of the hC5a receptor or with this virus in combination with three G-protein subunitexpression virus stocks: 1) rat Gai2 G-protein-encoding virus stock (BIOSIGNAL #V5J008), 2) bovine bl G-protein-encoding virus stock (BIOSIGNAL #V5H012), and 3) human g2 G-protein-encoding virus stock (BIOSIGNAL #V6B003), which may be obtained from BIOSIGNAL Inc., Montreal.

The infections are conveniently carried out at a multiplicity of infection of 0.1:1.0:0.5:0.5. At 72 hours post-infection, a sample of cell suspension is analyzed for viability by trypan blue dye exclusion, and the remaining S]9 cells are harvested via centrifugation (3000 rpm/ 10 minutes/ Example 17: Purified Recombinant Insect Cell Membranes SJ9 cell pellets are resuspended in homogenization buffer (10 mM HEPES, 250 mM sucrose, 0.5 jyg/ml leupeptin, 2 jg/ml Aprotinin, 200 jM PMSF, and 2.5 mM EDTA, pH 7.4) and homogenized using a POLYTRON homogenizer (setting 5 for 30 seconds). The homogenate is centrifuged (536 x g/ 10 minutes/ 4 0 C) to pellet the nuclei. The supernatant containing isolated membranes is decanted to a clean centrifuge tube, centrifuged (48,000 X g/ 30 minutes, 40C) and the resulting pellet resuspended in 30 ml homogenization buffer. This centrifugation and resuspension step is repeated twice. The final pellet is resuspended in ice cold Dulbecco's PBS containing 5 mM EDTA and stored in frozen aliquots at -800C until needed. The protein concentration of the resulting membrane preparation (hereinafter "P2 membranes") is conveniently measured using a Bradford protein assay (Bio-Rad Laboratories, Hercules, CA). By this measure, a 1-liter culture of cells typically yields 100-150 mg of total membrane protein.

WO 02/49993 PCT/US00/26816 Example 18: Agonist-Induced GTP Binding Agonist-stimulated GTP-gamma 3 5 S binding ("GTP binding") activity can be used to identify agonist and antagonist compounds and to differentiate neutral antagonist compounds from those that possess inverse agonist activity. This activity can also be used to detect partial agonism mediated by antagonist compounds. A compound being analyzed in this assay is referred to herein as a "test compound." Agonist-stimulated GTP binding activity is measured as follows: Four independent baculoviral stocks (one directing the expression of the hC5a receptor and three directing the expression of each of the three subunits of a heterotrimeric G-protein) are used to infect a culture of SJ9 cells as described in Example 16.

Agonist-stimulated GTP binding on purified membranes (prepared as described in Example 17) is assessed using hC5a (Sigma Chemical Co., St. Louis, Missouri, USA) as agonist in order to ascertain that the receptor/ G-protein-alphabeta-gamma combination(s) yield a functional response as measured by GTP binding.

P2 membranes are resuspended by Dounce homogenization (tight pestle) in GTP binding assay buffer (50 mM Tris pH 7.0, 120 mM NaC1, 2 mM MgC12, 2 mM EGTA, 0.1% BSA, 0.1 mM bacitracin, 100KIU/mL aprotinin, 5 pM GDP) and added to reaction tubes at a concentration of 30 ug protein/reaction tube. After adding increasing doses of the agonist hC5a at concentrations ranging from 10- 1 2 M to 10- 6 M, reactions are initiated by the addition of 100 pM GTP gamma 35 S. In competition experiments, non-radiolabeled test compounds compounds of the invention) are added to separate assays at concentrations ranging from 10-10 M to 10s M along with 10 nM hC5a to yield a final volume of 0.25 mL.

Neutral antagonists are those test compounds that reduce the stimulated GTP binding activity towards, but not below, baseline (the level of GTP bound by membranes in this assay in the absence of added C5a or other agonist and in the further absence of any test compound).

WO 02/49993 PCT/US00/26816 In contrast, in the absence of added C5a certain preferred compounds of the invention will reduce the GTP binding activity of the receptor-containing membranes below baseline, and are thus characterized as inverse agonists. If a test compound that displays antagonist activity does not reduce the GTP binding activity below baseline in the absence of the C5a agonist, it is characterized as a neutral antagonist.

An antagonist test compound elevates GTP binding activity above baseline in the absence of added hC5a in this GTP binding assay is characterized as having partial agonist activity. Preferred antagonist compounds of the invention do not elevate GTP binding activity under such conditions more than 10% above baseline, preferably not more than 5% above baseline, and most preferably not more than 2% above baseline.

Following a 60-minute incubation at room temperature, the reactions are terminated by vacuum filtration over GF/C filters (pre-soaked in wash buffer, 0.1% BSA) followed by washing with ice-cold wash buffer (50 mM Tris pH 7.0, 120mM NaC1). The amount of receptor-bound (and thereby membrane-bound) GTP gamma 3 5 S is determined by measuring the bound radioactivity, preferably by liquid scintillation spectrometry of the washed filters. Non-specific binding is determined using 10 mM GTP gamma 35 S and typically represents less than percent of total binding. Data is expressed as percent above basal (baseline). The results of these GTP binding experiments may be conveniently analyzed using SIGMAPLOT software (SPSS Inc., Chicago, Illinois, USA).

EXAMPLE 19 Calcium Mobilization Assays A. Response to U937 cells are grown in differentiation media (1 mM dibutyrl cAMP in RPMI 1640 medium containing 10% fetal bovine serum) for 48 hrs at 37 C then reseeded onto 96-well plates suitable for use in a FLIPRTM Plate Reader (Molecular Devices Corp., Sunnyvale CA). Cells are grown an additional 24 hours (to 70-90% WO 02/49993 PCT/USOO/26816 confluence) before the assay. The cells are then washed once with Krebs Ringer solution. Fluo-3 calcium sensitive dye (Molecular Probes, Inc. Eugene, OR) is added to 10 ug/mL and incubated with the cells at room temperature for 1 to 2 hours. The 96 well plates are then washed to remove excess dye. Fluorescence responses, measured by excitation at 480 nM and emission at 530 nM, are monitored upon the addition of human C5a to the cells to a final concentration of 0.01-30.0 nM, using the FLIPR T M device (Molecular Devices). Differentiated U937 cells typically exhibit signals of 5,000-50,000 Arbitrary Fluorescent Light Units in response to agonist stimulation.

B. Assays for Determination of ATP Responses Differentiated U937 cells (prepared and tested as described above under "A.

Response to C5a") are stimulated by the addition of ATP (rather than C5a) to a final concentration of 0.01 to 30 uM. This stimulation typically triggers a signal of 1,000 to 12,000 arbitrary fluorescence light units. Certain preferred compounds of the invention produce less than a 10%, preferably less than a and most preferably less than a 2% alteration of this calcium mobilization signal when this control assay is carried out in the presence or absence of the compounds.

C. Assays for the Identification of Receptor Modulatory Agents: Antagonists and Agonists Those of skill in the art will recognize that the calcium mobilization assay described above may be readily adapted for identifying test compounds as having agonist or antagonist activity, at the human C5a receptor.

For example, in order to identify antagonist compounds, differentiated U937 cells are washed and incubated with Fluo-3 dye as described above. One hour prior to measuring the fluorescence signal, a subset of the cells is incubated with a 1 M concentration of at least one compound to be tested. The fluorescence response upon the subsequent addition of 0.3 nM (final concentration) human recombinant WO 02/49993 PCT/US00/26816 is monitored using the FLIPRTM plate reader. Antagonist compounds elicit at least a 2-fold decrease in the fluorescence response relative to that measured in the presence of human C5a alone. Preferred antagonist compounds elicit at least a fold, preferably at least a 10-fold, and more preferably at least a 20-fold decrease in the fluorescence response relative to that measured in the presence of human alone. Agonist compounds elicit an increase in fluorescence without the addition of which increase will be at least partially blocked by a known C5a receptor antagonist.

Example 20. Assays to evaluate agonist activity of small molecule C5a receptor antagonists Preferred compounds of the invention are C5a receptor antagonists that do not possess significant greater than agonist activity in any of the mediated functional assays discussed herein. Specifically, this undesired agonist activity can be evaluated, for example, in the GTP binding assay of Example 18, by measuring small molecule mediated GTP binding in the absence of the natural agonist, C5a. Similarly, in a calcium mobilization assay that of Example 19, a small molecule compound can be directly assayed for the ability of the compound to stimulate calcium levels in the absence of the natural agonist, C5a. The preferred extent of C5a agonist activity exhibited by compounds of the invention is less than more preferably less than 5% and most preferably less than 2% of the response elicited by the natural agonist, EXAMPLE 21. Expression of a C5a receptor A human C5a receptor cDNA was obtained by PCR using 1) a forward primer adding a Kozak ribosome binding site and 2) a reverse primer that added no additional sequence, and 3) an aliquot of a Stratagene Human Fetal Brain cDNA library as template. The sequence of the resulting PCR product is set forth as SEQ ID NO: 1. The PCR product was subcloned into the cloning vector pCR-Script AMP (STRATAGENE, La Jolla,CA) at the Srf I site. It was then excised using the restriction enzymes EcoRI and NotI and subcloned in the appropriate orientation for WO 02/49993 PCT/US00/26816 expression into the baculoviral expression vector pBacPAK 9 (CLONTECH, Palo Alto, CA) that had been digested with EcoRI and Notl.

As set forth in the tables appended hereto, R groups do not necessarily correlate with those R groups shown in the text of the specification or in the claims.

The following table 1 (204-313) is a list of preferred 1,2,5 substituted imidazoles of the present invention; The following table 2 (314-419) is a list of preferred 1,2,4,5 substituted imidazoles of the present invention; The following table 3 (420-421) is a list of preferred pyrazoles of the present invention; The following table 4 (422-423) is another list of preferred 1,2,4,5 substituted imidazoles of the present invention; The following table 5 (424-456) is a list of preferred amides of the present invention; and The following table 6 (457-458) is a list of preferred amides of the present invention.

Additional Aspects of Preferred Compounds of the Invention The most preferred compounds of the invention are suitable for pharmaceutical use in treating human patients. Accordingly, such preferred compounds do not exhibit single or multiple dose acute or long-term toxicity, mutagenicity as determined in a bacterial reverse mutation assay such as an Ames test), teratogenicity, tumorogenicity, or the like, and rarely trigger adverse effects (side effects) when administered at therapeutically effective dosages. For example, preferred compounds of the invention will not prolong heart QT intervals as determined by electrocardiography, in guinea pigs, minipigs or dogs).

Therapeutically effective doses or concentrations of such compounds do not cause liver enlargement when fed to or injected into laboratory animals mice or rats) and do not promote the release of liver enzymes ALT, LDH, or AST) from hepatocytes in vitro or in vivo.

WO 02/49993 PCT/US00/26816 Because side effects are often due to undesirable receptor activation or antagonism, preferred compounds of the invention exert their receptor-modulatory effects with high specificity. This means that they only bind to, activate, or inhibit the activity of certain receptors other than C5a receptors with affinity constants of greater than 100 nanomolar, preferably greater than 1 micromolar, more preferably greater than 10 micromolar and most preferably greater than 100 micromolar. Such receptors preferably are selected from neurotransmitter receptors such as alpha- or beta-adrenergic receptors, muscarinic receptors (particularly ml, m2, or m3 receptors), dopamine receptors, and metabotropic glutamate receptors; and also include histamine receptors and cytokine receptors, interleukin receptors, particularly IL-8 receptors. Such receptors may also include GABAA receptors, bioactive peptide receptors (other than C5a receptors, including NPY or VIP receptors), neurokinin receptors, bradykinin receptors, hormone receptors CRF receptors, thyrotropin releasing hormone receptors, or melanocyte-concentrating hormone receptors).

Additionally, preferred compounds of the invention do not inhibit or induce microsomal cytochrome P450 enzyme activities, such as CYP1A2 activity, CYP2A6 activity, CYP2C9 activity, CYP2C19 activity, CYP2D6 activity, CYP2E1 activity, or CYP3A4 activity. Preferred compounds of the invention also do not exhibit cytotoxicity in vitro or in vivo, are not clastogenic, as determined using a mouse erythrocyte precursor cell micronucleus assay, an Ames micronucleus assay, a spiral micronucleus assay, or the like and do not induce sister chromatid exchange, in Chinese hamster ovary cells.

Highly preferred C5a receptor antagonist compounds of the invention also inhibit the occurrence of C5a-induced oxidative burst (OB) in inflammatory cells, neutrophil, as can be conveniently determined using an in vitro neutrophil OB assay.

Initial characterization of preferred compounds of the invention can be conveniently carried out using a C5a receptor binding assay or functional assay, such as set forth in the Examples, and may be expedited by applying such assays in WO 02/49993 PCT/US00/26816 a high throughput screening setting.

The following Tables depict further preferred compounds of the invention. In those Tables, the vriable X indicates the pouint of attachment of the specified moiety to the structure shown at the top of the Table.

LU

-J

LU

-I-

LU

I-

D-

U-

-J

I-

L(U

C/)

C14 -i

I-

F-

P-

C,,

C14 -i

F-

P:~

cj, 222 223 224 226 227 -~x

'I-

x CN x

I

K

Gl-I 3 CH 3

GH

3 x 4 X, )CH: O a ci i~q. f'~62.29'1(4S3.33O6 2O 1459.2136 16 034 x 1

H

3

C

x 4 1.99 459.1981 !40.226 C14 -i

I-

cj, wU 1.19 495.2416 40A6.268O4 2.08 1 521.16371I522.2009 C14 -i

I-

F-

P-

C,,

C14 -i cj, wi C14 -i cj, wi C14 -i cj, wi C14 -i cj, wi C14 -i cj, wi C14 -i cj, wi C14 -i cj, wi C14 -i cj, wi C14 -i cj, wi C14 -i cj, wi C14 -i

I-

F-

P-

C,,

C14 -i cj, wi Ir I I I 306 307 -308

F

Nxi

F

K1 xi cSYX s~I CH 3 x 2 x 2

CH

3 x 2 CH 3 xz x 4

X

4 9"X 4 0 0

X

4

X'I

It

)-N

9X"I -1.99 491.214 j_492.2_7483 1.91 1425.2234 1426.2757 C14 -i

I-

cj, wU

W-

I 1.069 1 425.2579 426.3054 310 0x- 1.96 1.98 603.1879 459.1981 50d.2485 all__ 459ANI

I

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

F-

P:~

cj, WO 02/49993 WO 0249993PCT/USOO/26816 .1 228 SUBSTITUTE SHEET (RULE 26) C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i cj, wi C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

F-

P:~

cj, C14 -i

I-

F-

P-

C,,

WO 02/49993 WO 0249993PCT/USOO/26816

C)

239 SUBSTITUTE SHEET (RULE 26) WO 02/49993 WO 0249993PCT/USOO/26816 240 SUBSTITUTE SHEET (RULE 26) C14 -i cj, wi -r r 424 426 427 R2 R4 Ri

F-

X1

F

X1 X1 H 3

C

H 3 X H 3 2

H

3 c2 TAB LE ]A R3 P3 is I-Iunless olh hrwisspeclifie~d.- R4 R5 6CH 3 ii.

Crnd Mass I-I+ Ion Obs -2.02 2.06 427.2424 1428.2541 4 x 4 x 4 x 5

H

3 0

CH,

CH

3 x cl-I 441.258~ 455,2 737.

442.2744 456,2899 C14 -i

I-

cj, wU

W-

2.1 2.08 455.2737 1456.2953 469.2893 2.1 ~1 47fl!~i A .3 ___2.13 4703137 429 -433_ 434 X1

I-CH

xl X1 H3(C

H

3

C

H

3

C

2

H

3 2

X

4 x 4

H

3

C

X4 i-I 4 -485.24.79 I x 5 -CH3

H

3

C

x 5 0 0 x 2.02 2:t5~ 486.2833 481.3093 1 482.332 C14 -i

I-

cj, wU

W-

1_420.285.6 1.91 1431.2573 432.2898 A'IA ~f A 123 1371fl i no' I. fJ:.I~~ T 1 1 T 435 43.6- -437 Xf xl 9, 91 H 3

H

3

C

H 3 c H3 X,2

X

4 Il

C--

P CH 3 X4

FOH

3

~CH

3 I-4 x s x

X

5 x 5 0 0

J

0 1 1433.2729 1434.3078 434.3079. 2.04j 433.2729 2.0_4_ 1401.:28311j402.3126 C14 -i

I-

cj, wU

W-

2.01 1446.3118 439 4140 1.99 _IA,7.2886] 448.329 448.3293 1.98 1 447.2886 J. L 441.._.

442 443

K

X1 X1

X

11 3 C2

H

3 0 x2 H 3

C

H

3

C

H a rx 4

CH

OCH

3 3H 0113C)--/ CH 3 0 0 1.95 447.2886 448.3331 2.06 447.2886 1448.3315 2.09143.291.404.3406.

-r C14 -i

I-

cj, to

I-

W-

444' 2.07 1447.2886 1448.3385 X

X

445) 4146 xa 1.99 459.2886 460.3416 AV-n 13A'37 2.07 r t x 4 449 450 xi xi

X,

I1 xl X1

K-

X1 Fix 2 H 3

G

H

3

C

H

3

C

H

3

C

X

4 x 4 0-

X,

0 x 6 0 0-J 0 x x 2.04- 461.042 62.362 2.04 473.3042 474.3634 2.12 47.444.60 C14 -i

I-

cj, wU

W-

4511-- 452 2.05_ 2.09 2.09 473.3042 475.3199 529.2729 474.3627 476.3831 530.334 I -1 1 J 1 4 4 T I T -r t i r 453 451 456 459 X1

X

2

H

3

C

H

3

C

H3( x 2 x 2

H

3 c H 3c 2 0 ~x 4

X

4 4 x

X

5

X

XX

Xi

H

3 2.09 545 j.2678.1546.3349 2.02 2.07 423.2675 459.2675 424.3183 410.3021 460.326 C14 -i

I-

rW

X

4 .2 1453.2416 1454.3023 2.06 1437.2831_ p 424.318 2.05 423.2675 2.05 1 423.2675 424.318 1 1 r 7 460-..

462 463 464 4165

K

xi x .xi p, x 2 I-I x 4 x 2 I-I C 3

IH

3 c Z/x 2

H

3

C

x 4

CH

3 x 5 CH 3

X

0* 2.1-1- -2.04- 2.06 438.3386 437.2831 C14 -i

I-

cj, wU

W-

i 473.2831 474.3436 467.2573 468.3186 113C 2.11 473.2831 474.3485 2.03 467.2573 468,3192 I I. 1 1 1 1 7 r 468 xl x 9, x 91 -x

K

x, 91 X 2

H

3 0 H 3 c H 3 0 H 3 cx

X

4 x 4 x 4 x

F

4 x 0 x 6 x 0 Xg 5 bF 2.04 2.1 2.02 423.2675 473.2831 424.3211 47-4.3.467- 467.2573 1_Aqp3 2 -469-.

-470 471 472 1.99 1471,2322 1472.3021 C14 -i

I-

cj, wU 2.02 1441.258 442.3175 472.3026 1.98 2.03 471.2322 441.258) 442.3105 C14 -i

~LU

F-

P-

C,,

C14 -i

~LU

F-

P-

C,,

C14 -i

~LU

F-

P-

C,,

C14 -i

~LU

F-

P-

C,,

V I I r I V 499 __501 X1 xi xi 9,

H

3

C

H3x 2

H

3

C

Z- x 2 13c

X

4

X

4 I C, x 0 x 5 0 H3C

X

X,

I~

3 2.06.~ 1 48.7 19 32 .1 484..3?- 2 -2.06 1.97 453.278 454.3479 -440,.32 C14 -i

~LU

cj, wU

W-

.50.3-.

-489.278_1 9037 4B4.3253 483.2522 I r r 505 H 3 c 2 2 3-c 0 5J06_J.

t13c~ 4 11 C x 1.96 1.99 439.2624 454.3445 440.3253 -490.3457. -5071 2.07 1489,278.

x 2 H 3 C14 -i

~LU

cj, to

I-

W-

H

3 0

X

509

X

CH

3

F

H 3 1__.97 48j~3.25 22 4_ 84.3227 11523 5538

H

3

C

2

X

4 441,258 442.3267 J 4 r I I I T I 515 516

X

xi Ci x 2

H

3 c

H

3 c2

H

3 c x 0/

X

2.11- X7- I %C

F

x 4 02C x 2.04' j 8j.2 79 1_486.3185 o 0

X

2.04 441.258 442.3253 2.03 1485.2479 486.3174 491.2737.[49.3441 C14 -i

~LU

cj, wU

W-

2.05j 1i! 2737.1 4566M 2M4 44 1.258 491.2737 442.325 492.3412 C14 -i

~LU

F-

P-

C,,

I

Yx -526 530 531

X,

xi

X,

H3 H 3c 2

F

x 4

F

Fi- 0-0 0 2. 49221490.2792 445.2329 2.02 446.2807 2.06 __495.2486 1496.2982 0 490..2744 2 1489.2228 C14 -i

~LU

cj, wU

W-

2.01 445.2329 446.282 2.496.2984 490.2794 1.99 I 489.2228 I

I

C14 -i

~LU

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

547 549- 651 552 9 x X1 9

K,

Z x 2 F3C

H

3

C

H

3 C

X

-x 2

H

3

C

H

3

C

0xib x 4

XX

4 0 0xx 0 503.2937 2.1 2.01 504.3604 497.26791j 498.336 2.02 1467.2937 1468.3528 2.01 497T.2679 498.3345J C14 -i

I-

-w cj, 1.99 467.2573 468.3251 2.05_ 503.2573q 1 504.3299 497.2314 1.97 498.303 I I I I j C14 -i

I-

F-

P-

C,,

x I r 559 560

K

xl

K

xl xf 9

X,

HSG

H3 HGc

X

4 x 4 Fj ,0 0

X

0 x 5

CH

X

'0 1.98.

2.05 45-7.2629 1.458.3177 507.2680 508.3424 1.96 1501.242i 1502.3192 2.1 C14

-I

I-

Cj, wU W- 457,2285 F 458.2933 2J14 507.2441_1_503.3201 -2.086- 2.04 501.2183 505.1932 502.2952 506.2737 I

T

665 5-666 563 5-69.

570 671 x 1 X1

H

3

C

Z I-X2

H

3

C

H3C

X

2

H

3

C

Z'/x 2

H

3 0 'Ix 2 H1 3

C

x 4 x 4

X

4

CH

3 0

HCH

CH

H 3C

CH

3 C x 5 2 46,..3144 1466.3809 2.15 509.304215 .38 2.15 479.33 1480.3981 C14 -j cj, 465.31.44 14_ 466.3795 510.383 2.13 -109.3042

X,

X1 .285 6233 2.06 1 467.2937 1 468.3609 L L 1 1 1 7 1 F 672 574 575 577 xi xi X1 l

X,

-X

2 H 3

C

H 3 C2 x 2

H

3

C

X

4

CH~

11,, 0II x 4 x 4 4

M

3 x 2.12 517.3093 518.3871 -2.04 511.2835 512.3613

CH,

x 5

CH

3 (0 2.1 483.2708 2.08 (6.2 2 484.3423 470.3222 520.3477 514.3214 C14 -i

I-

cj, wU

W-

519.2708 513.245 C14 -i

I-

F-

P-

C,,

C14 -i

F-

P:~

cj, C14 -i

I-

F-

P-

C,,

596

X

HGc 598 X1

H

3 C2 600 X 601 1i H93c 602 X, tyI~ H 3

G

603 x 4 r~

F

4o 4 Cl4 0] 3 x1r 1 0113 0 0 0- x 5 -dOH 3

S-C]

3 2.09- -2.0.8, -50-1..17.79. 502.2556 546.2542 2.04 553.2496 554.1792 2.07 545.1678 546.1213 2.05 555.1901__556.1432 2.5 597.991 598.16 C14 -i

I-

cj, wU

W-

2.04 4.55..239.5 2.01 499.2293 .456..2075.

-500.2002 0 C14 -i

I-

F-

P-

C,,

C14 -i cj, wi C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

F-

P:~

cj, C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

F-

P:W

cj, C14 -i

P:W

cj, C14 -i

F-

P:W

cj, C14 -i

F-

P:W

cj, C14 -i

F-

P:W

cj, C14 -i

F-

P:W

cj, C14 -i

F-

P:W

cj, 1-707.

1708 710 711 712.xl x

F

K

x

F

X1 I- 3 x 2 3 x 2 3 X 2 0) 3 c I~~G

X

4 13c

X,

xrc 0 xs -601-.4194- 602.24 xrc 0 x 5 -4 x 6 x 6 0 C14 -i 3W 19 1437.2479 43B.2715 438.2693 450.2746 x 2 4 1

C

1.9 1.91 44.9.2479 71.3 I 4~9 9QIR 451 2635 1462 2936 C14 -i

F-

P:W

cj, 720 722 723 x 2

H

3

C

H3C

H

3

G

1'x 2

HGC

H

3

C

(l

I

S CH 3 2,051465,791 466.31 466.309 465.2791 cf-j xz 4 r-l

X,

11O 2.06 1.99 2.00 2.03 477.2 7 9! 478.3101

CD

-i

I-

LeW cj, 477.2791 478.3092 724 479.2948 1480.3289

F

Y

xb /0 x ~491~~i 491.29481 A~?L 2.1 491,2948 1492,3293 2.1 491.29481 492.3293

I

1041 -104,2 1044 1046 1048

OX,

N. X, cx

X,

H-IC3 xz

H,C?

xl H3C

X,

C"3 X2 oil

XF

X,

Oil 0 pl,

'C

X,

CH,

X"

1 1.74 497.3042 1498.3471I 5 ,38.3746.

.9 1 3.35 1.11 572,27871 730 1.88 1.91 494.3046 495R.3434 C14 -j

I-

572.2821 1573.3249 C

C.

0

F

X,

595.2,777 59G.3219 I I .I I1 I1 I I 1 C14 -i cj, wi C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

l0ss 1087 1089 1093 0 ox OX1.

H

3 C xl 14,C 2 xl

HGC

x 3 HGc 13 x 3 xp x 3 9, X,1

'S

0 H C

CI

oil it 0 -n

OH,

'1 0 0 xl 6 6

X,

-0L I 1_J_ .93 511.3199 512.2905 X.e oil 2.06 2.07 565.24965 66.2386 1559.2835 580.2629 1.99 559.28351562 8 C14 -j

I-

ci, wU

I-)

2.02 )5334 529.3398 2 593.2348 1 694.2117 1.95 J59.2835 1660.2643 693.2445 594.2274 I 593.2445 1 I I I C14 -i

F-

P:~

cj, 1103 1103 1105 Qxi 0< x 2 Hoc

HC

x 2

H

3 x 3 X ~Ott

I

6 Oil 01-i

C)

11O6~ 1107 1100 1109 x x 2 ",Cy xi

X,

X 9

X,

I IL 1.95 1.89 1.98 646.3042 545.3042 551.3512 1.83 1.W7 531.2886 1532.2817 558.3029 1 5.25 1.93 16G5.2496 5066.240 546,2853 540.2955 C14 -i

I-

U-

H

3

C

552.3348 595.2273 1.83 1594.2301 2.01 1 531.2653 1 532.2531

I

C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

C14 -i cj, wi WO 02/49993 WO 0249993PCT/USOO/26816 302 SUBSTITUTE SHEET (RULE 26) WO 02/49993 WO 0249993PCT/USOO/26816 303 SUBSTITUTE SHEET (RULE 26)

U,

c i cn m

-I

C

qni C14 -i

I-

F-

P-

C,,

C14 -i

I-

F-

P-

C,,

r-

I

1164 1166 1167 I 16.4

X,

He

J

ill

'C'

113 113C* 3)

X,

CC

R-c I,1

IX,

3

U'I~

a a

I

L

I

2.

UTi. .J 1F It70-A15 C14 -i cj, 1160 X, 1171

X,

1172 iI~X 1 If

'S

iir

'S

I."

'S

Q L~ 7 i3 1 1173 1174 .I 7 11)8 Iia? 110 I 181i xl X1

X,

xl Ii C

I

xl xl 0313 xl

III

xa I 1$' xl (4 11 3

C

2

D

Xi

X,

f1r 'ic cI's xl e.5,3jvy 1w. VAR I C? 11i'm qv? rio. Iet ,6-1 401 C14 -j cj, 1.08 402.4177 2.07 It.Opgj§1942PI 2.05 1545.3042 1 .540.425WJ

I'

2.12 2.11 j6i1.3406 619.281 622.4504 520-40121

I

Xr 1182 X F 2.15320 554.3001 irxFI

X

5 _i -32 0 1183 X

I

r X, 2.7 5 31 118 0- Xe I I -5 .1 1165 1 496,.. A. 399-~2.9 5 93 99 5 04 cj, 118 Xx 2 /l k 1c37 x 2.15 51.200 52.3397 p 1191 1192 1193 1195 x

X,

X X2

X

2

X

2 X2

X

3 X3

ON

3 i7,,

CR

al, 30

'CS

$6

CII'

'C

XC

Xe

N

x

S

Gil 2.26 559.2621 560.3600 Si1,.3199 15242 2.05 545.3042 546.4219 2.04 575.3140 676.4052.

2.09 551.3512 552.4758t C14 -i

I-

-w cj, -1.91.

1191I 1198 1 200 2.05_ 545.3042,15549A!7 _2.05-1 575.3140 570.4329 552.351? 552.4604 2.09 529.2093 530.33 1201 1202 1203 1204 1205 1206 1207

I?

X,

I-Ic 2

'IC

3 x 2 1130

H

3

X

2

'C,

1130 X2 1130 113 x 2

Y.

x.

'Jr F Y~k ~,X 3

III

2 CI

C'

f

\'CG

(33

XI..

SI

C"

XIS

sq Cl!3 'Co

C,

rq I QfA6 5 6432a 2.11 g 1H .2042(5 4 3 2 2.05 4619.2893 I 470.3277 1303.2737 j.343~ C14 -i

I-

-w -w 2.14 509.30 1510.368 2.0 465.25983 lip,

Y

2.19 549.2547 '100.3074 550.3127 I V'f I I I- 3

Y

12.12 9X,

X,

x2 I I I IC lip X3 0.

I

CI

IaC, xa 0CII, 2.19 I525.2 1 126.3676 465.3144 00.3585 20-1_9.2907 1500.364 1214 1215 1216 X3b 3 b 2.04 2.1.3 2.13 2.22 505.3467 160.02 C14 -i

I-

-w cj,

W

479.33 513.3144 543.325 48.3647 5d4.3829 5 19.3013 1 520,4305 t I 1219 1220 122)- 1222 1223 1224 1225

X,

Ha' '<a 1130 '<a "ac '<2 110 3

I~I

xl '<2 'lao xl 140 a '<a 110 a l1~ xl

X,

0 lb 0

'IC

"a 0

IIC

S.

cit (at,

II~:-.J

1.91 4181.30931 482.3035

XIS

I.

0

I

"C

XIS

~x 4 (:55, '<6 x t2

X

Cl I, 2.06 1 515.2936 1.97 2.00 545.3042 546.3696 521.310G 522.'1055 G20.3003 43.*3~76 530.3716 C14 -i

I-

-w cj, wi 2.00 1 9Q9 2.17 535.3563 j A1 3 5~'1.43fl5 5~fl.J563 .1 0 -I I 1228.

1230 1231 1232 1233 1235 1236

X,

Ilp~ jIC 3l~

X,

x

X,

X3 X'6xa 0

F

<A

x 01 r II r Hp O X.

XI

Gil

XII

2.17 0;57.3406 564227 607.3512 500.4426 2.26 1563.3873 1564.4906 2.00 519.206A 520.36.91 554.355 2_.09 J_5.2705 C14 -j

I-

-w cj, 2.08 6.21 56'4.3691 2.07 2.17 659.3174 1.5041261 493.3457 4194.4268 527.3301 520.4103

I

1237 12-38 1239 I 240 12A 1 __124.2__ -124.3 1244 124

X,

I 1,IC x 2

X

2 x x II C Cs I, Sc.

£2 0

XI

)~I

557,3'l06

CII,

X

6

CII,

Xl 528.4191 2.15 527.3301 591.325 592.42721 C14 -i

F-

220~5O1.3D13~ 50.403 1.04 2-04 495.20136 49311 -529-.2729 1 30.3501.

559.20351 500.3097 I. I I I. I 1246 1247 _1248.

1249 126U 1251 1252 1253 1254

I?

xl

'IC

a

H

3 x 2 1130 x 2 1130 x 2 1130 113 x 2 Ho 3 x 2

C"

1 Xi 0/ 0' xrl

'CJ

j 0 0 C/ X Gil, 0 \xn x l 1 cl 1 ,i 2.13 1 .94 2.05 2.04 2.13 535.3,99 63G.4042 509,3042 j 0l.37gG 643.2B00 I 1'1.3738 573.2991 574,3901 549.33rr, 6,50.4245 C14 -i

I-

-w 0, 2.1 54.2 .544,4181 2.24_ 603.3503 [584.4531 541.3304 2.02 575.3140 1 576.4094 ~1 1255 1256 1257 1258 XI

XI

y

X,

p

XI

p

X,

y

X,

y xi

X,

X,.

I lI ltl

CIIC

X

2

X,

I1G 0 0

X,

ou Iv P0

-CD

1II;k x"0 OI I 1.97 2 605.3254 .60642G1 501.3010 582.4799 2.25 597.3719 598.4060 20 1558.415(6 1260 1261 1262 1263 2.15 2.24 2.02 2.09 2.16 621.3355 597.3719 567.3512 621.3355 027.3025 622.A58 590.4362 68.4137 C14 w

-J

I-

r~W -w

SI

W-

C

622.41490 620.4063 L L 1 I -I- 1265

X

Y_

1267 1260 1269 1270 1271 1272

X,

x 9

XI

p

XI

x, x

X,

H3(; CI 13

X

xe xl

X

3 0 0

II-O

"C

54-'t cil Xf

XI

C"

3 620.485 2.18 627.3825 C14 c_,

LU

W

I-

I

W

1 .9 LI ALI 512.4009 b45.3012 5i7.3140 551.35121 546.34BI 576.4091 552.14 7 1273 1274 1275 127 1277 127 1279 -1280 1281 9K,

X

K9

X,

9K pK' IIJc

X

2

X

Y?

K

2 2 'IC3-~X x 2 ei X3

X

3

X

3 'a X3 0 7

O-P

vii '3, Cl 0 i;,

K

0-Eli, fll 8 5 1 51.3 199 545.3042 1546.3782 1.97 575.314E3] 8 '098 512.394 2.07 1 .3512 52.4422 2.02 1 60.2787 2 526.2944 2.00 1 506.3257 527.3639 567.4181 531.3361 C14 1

I-

-w cj,

SI

C

53qO:2449 594.2397 1 595.334 9__ 128 1203 I ,284 1285 1286 1287 1988 1289- 129) xl x

X,

9

'(I

p_ xl p, xl 'i- X,, X 2 \IC 13

X,

rlGil CI~a '11

X.,

xl x 1

K:,

11,0 (i t 2.12 j570.2.7? 0 7 t71.3751 O- .Cii il, x 2.07 ~1594,2397 tr~p :3354 2.00 2.14 2.13 479.33 543.3254 543.325 4BU.4 123 514.3954 544.4046 C14 -j

I-

cj,

LU

w

SI

C

2.05 497.2799 I_ 021 120_?3 522.3414 552.3583 2.05 551.2749 .1 1 1 r

I

1291 1292 1293 1294 1295 1296 1297 1290 1299

K'

K

Xp_

XI

K,p px

X

2 I I C 2 X2

X

2 I'4 x~l X3

X,,

X,

F

r

C

'I;

CII,

x 8 527.3112 5 20A1017

I

520.312 2,14 2.13 519.2200 p03.2157 652.3798 488.3528D C14 -i

I-

-w cj,

SI

C

C,

2.14- 651.2604 2.06 2.05 407.2799 1 521.2643 1522.341 L I I.

I--

l3(k) 1301 13U3 1304 1305 -1306- 1307 1308 9

X,

K?

IlaC

'IC

a

K

2

K

2 II 0 a

JIG

3

I-I

a x 2 1-I 3

K

2

II

a

K

2 3lie

K

2

X,

K

3 r Cl 02 t 0 -X D-

X

2.06 2.14 2113_ 551,2740 552.3575 527.3112 521U1.39104 510.2208 1520,3009

X,

5192208.

553.205t 583.2157 584.3103 C14 -i

I-

cj, wU 520.3032 554.2903 .584.3069 ~I p Xe 1307 I 310 1311 9 y

XI

9

X,

9

X,

y

XI

I 2 3 lie t"lC X2.

X

2

X,

x

XI

Jo$ 1313 1314 1315 1316, 1317 r

C

CI

F F Fj

F

-cl',

I

CI'

2.09 567.221 563,3202 2.10 2.05 2.00 543.20!771 644.722 -17.2799 521.2643 551.2740 100.351, 522.3360 552.3557 2.11 503.2504 504.3281 C14 -i

I-

cj, LU

W

SI

0,

C,

537.,2347-1 2.1 2 3112j5203931 48n.349 2.07 17.2790 I. 1. 1 1318 1319 1320 1321 1322 1323 1324' 1326 1326

Y

XI

p

X,

X, X,

X,

XI

p8 xI tI' x 2

X,

'<2 r/X2 lIx 2 x ksI

X

3 xa

I

F

F-

F

r

K,

2.05 2.06 521.2613 52.3353 551.2748 552.356I1 2.14 127112 52.30' 417.2799 -480.352 2.06 2.0 p04S21.2643 522.34111, C14 -i

I-

cj,

LU

W

I-

SI

C

2:01156!3I.7 4 1 p 2, 17 1...527.3 112 1528.3907 2.13 53I5.28t I ~336.3B 570.3573 2.12 509.2654 I I 1 -I 1327 1320 1329, 1330 1331 1332 1333 1331 1335

IP

X,

x,

X,

9

XI

px

XZ

llx 2 1130 x 2

-~X

xl x.

'4.

Xrj 6 "yr O-c r 0-" Qio x, 01j IIt~ cl 1 I1C /k X 2.11 2.01 ?.O1i 2.05- 2.04 5754 600.31 5 17,2905 58.3644 551-2740 581.2354 562.3729 C14 -i

I-

cj,

LU

W

I-

fi)

SI

C

C,

2.12 557.3210 65.4104 2.1 535.2011 530.3071 'b

U-

Ipo 2.11 2.11 569.2654 599.2759 570.3599 600.3765 I I .1 1 WO 02/49993 PCT/USOO/26816 1, 1; I x. x x x Nhx 97 K- 326 SUBSTITUTE SHEET (RULE 26) 1345 1349 -1351 1352

X,

XI

X,

/X2 X2 x

X

Xe Xe

K.'

'2, xi r

F

r r r r

'C,

r r rQ Hr /~Ui

X.

/--flv r /I3~

'IC.

U

flr

'C.

~e iI~Ck 0 j.

XE

CI'3 Xe It r'

X,

x6 Cl' .3 2.09_ 537,2767 1 30.3624I 57.2.3517 602.369 2.08 2.16 601.2716 577.30U 2.11- 2, 1 6.1.1042.

[570.404 546.2905 502.29-0 G 12.3 5g5.34 560.31 C14 -i

I-

r.U cj, 2.10 1 597.2311 559.2 19B 2A35 2.05 -1354- 1359- 1360 1301 1362

X,

Xe 1~C x 7

'IC

"'C

Hr 3 Xe

C

3

C

3 Xe 110 3 H C a Xe Xe H C 3

X,

.1 )(3 X,6 02

VI

X6 2:98 023.2.147 624.31 2.02 50.40j5042 2.14 5*13,325.

5-74.4336- C14 -j

I-

P-

C,,

2.?11i-- 2.19 507.3614 1.SOO.4463 541.3457 5412.43131 1:163 136(1 1165 1:166 1:167

X,

9

X

xz, 1~1 C .1 1130

'IC

3 x2

'IC

3 '<2 tic 3 ItO a 1130 113 x 2

'I

3 x

X"

ni, ni

RG~

r

C'

"p

I'

tr a x

I~

r-v-Ixc 2.10. 571,3503 572.447 2.04 !P3.2042 563.2948 34.366 C14 -i

I-

cj, wU 1:169 1371 1.07 423.2675_1424.3263 1.97 437.2831 438,3482 451,29037 1 452.3079 1.372 1:174 1.177 1.)76 1;17D

X,

y

X,

9

X,

9

K,

9K,

K

I I C

X

2

X,

X2

X

2

X

2 xl xi

K'C

Drx, Ur a I X, Os>

I:X,

SX

5 I I 3

IG

5 x o ull i.2.03 501,1779 515.1936 502.2537 516.27 2.12 1 529.2093 530.29 i. 442.3157 C14 -i

I-

0,

LU

w

SI

0,

C,

2.01 455.237145U.335L 470.3576 2.05 1 f46392093 2.02 4 57.22835 14513.3003 2.07_1 47?.241 1472.3165 Ilne7r~nn 06.3203 _05 I I 2 C14

LU

U)

LU

F-

LU

F-

LU

1409 1411 1412 1413

X,

X1

X,

p

X,

K

p

XI

X

2 H A X2 Ill'3

K

2 jX I ~x 2 Xi x 3 X3

X,

r

P

F

lip3-0P1 CI-o X6

I~-

.PI,

X.

Cl 4 2.08 195 505.?705 150G.2041I 519.2861 520.2950 Xe ~e I 13 cl 1z CI7u 467.2937 46.8..1446 401.3093 482.2171 457.2205 450.1470 C4

LU

SI

F-3

F-

U-

C

m

D,

2,04_ 4~71244I1471?71 i' 1415 14lti 2.0-9 2.05 405.25960 486.1973 516.2304 1 515,2930 L 1 (Ii? 1418 1419 1421 1422 1423 -14124 1425

Y

XI

p x 9

XI

)(2

X

2

X

2 I1lC'

X.,

Xfl

X'

2.09 529.3093 G.1 .326-5 -f r.rQJ9 4 rj~i x 4

C

4 Or Q l cIl 0113 2.12 630.2510 644.2772 2 5U53.2304 504.027

X,-

2.06 2.00 617.2541 618.2202 531.2097 532.241

CD

U'

m

SI

C

LU

C,

107,1623 I~?pll: 1Ii73

K

1(3

'I)

i.Utlj 501.1770* 602.1747 2.04 5~l.93j 56.17C' 2.001 529.2093 1 530.21 I I

LU

F-

LU

8LoWve ZLf6l9I "I I I i5~

I

Ix -0 -A llI CI

J

Ix iAI) cn.' 999C001' CUGLI' CO~ c 1 V6 99 1 Wl c-fiibv xfl IZ6 :k'V j'lc*&Zc''V* 61 11144 X

XI

1445

X,

_14-16 x3 -14 1 X2 b 11

J

14,10

X,

r -xi

X,

405.325 431.3093 1.05 1.07 2.03 14,19

X,

p

X

2

X

2 ll~x X3 II c

II

XiCl 509.3400 496.3600 482.356 4G.3740 510,4019 524.4143

C

F-

SI

C

LU

m

C,

D,

J2-05 523.3563j 2.05 505.2705.1 J OG.3 mOq I '1!O -4- .00~ j519.206I 520.3441 I 4f,2 Xr, x X 1.95 451.2987 452.3453 1.97 465.3144 460.3562 1454 X 14545

XS

xI 2.03 479.31 '00.3@830 .2.07- 493.57 19.U73 i .C I 2 .0 7 5 13 .3 14 4 5 1 4 .3 7 1'156

X,

.1.93 481.279 402.3010 1459 036 -1460

-LJ

LU

S LU

LU

I-

I-I

D,

C,,

II xI XI 162 14A63 1465 -1 468- 1 469 1

X,

tic x o Cl o o

C!

(2~ oil

'CI

71.93 5139.3042 503iJ .2.1~!9:93~j516.35412 529.3093 543.325j 154.32 'C3 1.913 2.02 529.309353.10 C4

LU

F-

D-

I-

D,

C,,

64,35 1 4.307 (1~ 2.05 1557.3406 15513.4091 1.97 573.3355' 57.439PG1 1 5137.3512 1580.4052 I I I. .1 1 Y a- I 1471 1412 1473 M474 1470 1476 1478 14179 I 600 9

X,

9 xo X-i-

XO

x 1

K

x 1 x 2 I I

XI

I

cI I, x 3 0? 0, 0, 1 F- 9"

X'

x x,

XG

sxc i

K.

cl.3

X

cl I 2 r37.35i2 58.4127 1.07 1497.3042 498.34713? 1.81 511,3199 512.3705

C

F-

L

SI

U)

m

LU

I Ios~~~~sll 3199 512.T367 .93_ 2.09 2.14 437.2831 438.3286 465.3144 4060 516.2552 515.1936 543.2249 1 544.29 t I. 1403 X.10 1405 x

X,

1487 1490 1 X2 Vil i 0 -x- -3x 6 Gi, 2.08 a, 2.06 2.1

X,

C, 1.93 Gi, 2.07 xx 2 455.2737 457.2205.

471.2441 505.275 481.3093 404.3603 468.2746 472.2985 500.33221 460.330 .49.3770 506.2[14 482.32600 C"4

LU

I-

D-

I-

GI1 2Z 509,3406 1 510.0073 J- r -149 2 I 493..

S1494 1495 19611 .1491- 1490 1499 Ian( xro\ x-o xt Xe ifii Gl, G1 I: CHt

X

3

X

xe rAx 110 3 1.81 dlDl.

3 0 4 2 i xrci's -cl Cl Xa 1l:G

C

0x 011a 1.94- -2.05- -2.02- 2.00 2.05 525.3355 4197.30412 -455.2737 451.2987 470.33 467.2037 495,325 471.244'1 515.1936 520.3015r 493.333 6243.3023 452.3412 4800.3812 496.3726 .472.2934 516.24

C

5 4

SLU

LU

I-

D-

I-

2.12 543.2249 544.2B _1.9 455--*~.2737 450.315 1505 x 1 1 X2 .1DIG 2.04 483,305 4034.3472 ~X .c .4 471.2441 4722_0

CIA

LU

7 1 499.274 500.3232 x aLU 1 0 8 /I 3

LU

,c, 13 1.93 437.2031 430.3264

U

X2\

LU

1509 x 1 \cI ~110

C--

9 4 5 1 2 9 87 4 5 2 2U 20 47 .3 480.3131 3 36 1512 x .II 4 29137 452.3448 1513 X, /i 13 2 46.14 0003 44 46I363 7 7 r 7 C 7 1514 x 1515 X1 1516 xr- 15)7 .10\ 1522 x, N0 1 523 1524 oil 1 x Cl 1, x 2 l x..

Ii, x 6 "C6 xi .1l x c -1.87-4.7.2937.

'190.3754 1.9- _I 407.29376.340 1.2 4811.3093 482.358

F-

LU

510.3994 509.3400

F-

I)

2,12 2.01 470.33 54.3674 2.04 2.04 1 1525 xo CA X3 1528 x 1 \.1 -X-2 1529 li r- x 1531 CILo X3 1532 cii 1533 1 X 1535 ly'Q cixn

XI'

x ic Xe x x0 I-i C 1.08 1.91 1.99 1.80 4607.273 46.20001 482.3t537 509.3042 510.3197 481.2729 482.31521 1.00 13.2006 1 jq.3308

CD

U)l

LU

1.97 523.3199 524.3652 2.4 60 1,36003 -29 525.33: 02. 1 Ua iC x yx 2 137 x XX2 i3t a yS 1540 1542.

X,

p

X,

1130

I.,

3

H

3

'SI

"a 3 Fl 3

X

2 X3 Gii r r

X

cCI cfl2.1 405.2590 (Xe1 485.306 1_483-~:286 14437 xe I I 4178.3447 497.3042

I

2.02 2.07 2.114 511.3199 512.3699 515.1936 510.24

F-

I-

D,

c,, 529.209 530.27 44 ~27~

I.

441.258 442 P997 1.99 455.2737 456.321 I- IXi4 156 9 I rA7 9, 1540- 1550 1551 1553 Xe p p p_ 9 9 ii C 3

H

a

H

3 x 2

'IC

3 113 "ac x 2 "Sc Hf II 3 x 2 x b

'I)

'<3 x '<a '<3 x Fp rpr 11C 0 11C0Q1 Irc( x.

a 1 465.3144. IA 6 6 2.04~ P~ 451.20071423o 2.01 4191.254i0 492.3076 2.06 505.2705 506.3239 2.09 109.2861 152U.3427

CD

Lu ~c Lu m 1.00145327 454.32 -1.95.

407.2937 1168.3404 1.91 1 481.3093 1402.3591 Cooi *Wrj' S UZ 5 1, COWOLPl~ C19269 L1V pJL i8; 39' 'Ito Ix Yjz2.ioos ~uo~o~g 6O~ 9ki'F 1919 orjaft6 CTi4, 1 10 oil

SX

sx

ID

Q

ILX

Ix Ix x Ix Ji-'

CX

V

ii

CX

V

Ji'

C

x x 6

IX

6

X

91L ox x t9I9 ZX x .6.I I4'6~LI'.~ 171;~ 666pl~1i, 1 A 1564 1665 1567 1 569.

1670 1571

X,

Y

X,

e

X,

XI

9

XI

X

X2

X

2 IlaC 11,c'-

X

X a

X

3

X,

03 "0- "C0- 203 4.71.2441. l1. 47,2929 2.07 485.25l r10:q4 lip Ic 1,

CII

I1. 95 1 -451,2907 452.340? 1.99 1.94 2 465.3144- I i(p:213G94 4.51.2907_1f 46,2.482

CD

C

U.

m

U)

.1 405.3144 479.33 453.2711 407.2937 40.3705 460.3148 4 64.3195 468.3429 I.e1 WO 02/49993 PCT/USOO/26816 IM i :0 i 0 IF 0 l 0 K 0 351 SUBSTITUTE SHEET (RULE 26) x, 2_ 151 X, 51 -3 4 5( 14.333 3 20 262 0 6 73

K-U

2.00 554.0 52.323 L I S O 1, X 6 2.00 554.29873 55.3 7. 'J

U)

X,'

1 3 2.12 493.3457 494.4006

X

2 7 oil, 2.03 47.63 474.2992

X..

7 x 21 5 12 56 5 23 7 CI

X

2.1 491.1095 492.2394 -1i Xl- X x 11692 X, 13 2 1/ 2.11 505.2051. 500.2584 I .10 533.2365 534.3019 1543 2.06 -475.2191 476.2581

C

2.00 .489.2347 490.2056 S Lii Cu 3 *13 2.14 517.266 51.31013 I

W

I-

1591 I 2.04 4173.2643 474.3057 X,

U)

1598 CAI 011 2.1 Gil,95 502.3344 159 II. 013 r~ /113 2 -J 45.2329 446.2716 .2.02 459.2406 46U.2065 1 10 2.05, 473.24347.37 16U2- -l C 501.295G 502.3315 x-

X

1603 x it C X i 52.3 47. 247.3059

F--J

r cl13 2.3 450.2956.. 3305to.

x

LU

2 5 1 3 .3 .1 5 0 5 1 4 3 5 2 3 LU PI yf

D

f~X 2L cii ,LZ

U)

1609...~ 1.63l 3 li 555.34481 550.3D21) 2. i .A06 509.3042 510.3471 1611 S~19 407.293741832 1612 X CII t31.92 41.3093 42. 35 Ix: 9 Z l IaI x I~x 'la 0191 1191 x 113 019X m x ql Ox-. X- I 3- OCI V 1191 Oxx Oal~ig 6W1 x fit;' x 164 1 2.14 517.206 518.3209 x 1 1.7 525.3355 526.3B39 .1.813 511.3190 5 12.3085S 1.8 407.3042 498.3402

ND

Lii Lii l 1.85 5 11.3199 51.70U)

F-

16:10 .l .2.03 5B9.2304 590.29 1 6 1 I I 3 8 5 4 7 2 9 3 7 4 6 8 3 3 4 x' 16313 0u xaicC (VOliCi 1.97 495.325 408.37800 C I 9 0 .77 453 278 454.3 150 (2 14'91 i 8L C t VI. m E -I Ix

IO

11.0,

I'I

-I )I.fI) qC91 "I la: C Xo G9 I- I WO 02/49993 WO 0249993PCT/USOO/26816 SUBSTITUTE SHEET (RULE 26)

LU

F-

LU

U)

I

XC,

rn Il

NI

LU

F-

L

m

LU

F-

LU

WO 02/49993 WO 0249993PCT/USOO/26816 363 SUBSTITUTE SHEET (RULE 26)

LU

F-

LU

F-

LU

U)

I

XC,

rn Il

NI

U)

I

X C rn-~ Il

NI

U)

I

XC,

rn Il

NI

LU

F-

LU

x. 1 x 2 1$

K

X1 I726-.

X,

0IKI 10- IlO- 113C 0 xe 13 1.0- !!497.3042 4j90.313291 1727 1.03 405.2042 '100,.3419 2.04

F-

CI)

LU

515.2940 J 519.2452 1 520.3127

LU

F-

LU

F-

LU

F-

LU

F-

LU

WO 02/49993 WO 0249993PCT/USOO/26816 SUBSTITUTE SHEET (RULE 26)

LU

F-

LU

F-

LU

F-

LU

v 10~1)6 Ir 10177 1816 8s 1010 1821 1822 IW xl 1823 i IllO

CICH

it ~iCII xl J *1 2.05 2.030 2.02 2.01 2.05 1.99 521.3042 493.260 459.325 '159.325 527.2703 4o. 3199 '187.3199 622.3520 194.3401 460,3719 160.3700 520.3164 PA8. 3 1-3 48.314B

CD

c"4

U.

m

D

U)

LU

C,

LU

F-

LU

F-

L

LU

F-

LU

F-

LU

F-

LU

WO 02/49993 WO 0249993PCT/USOO/26816 385 SUBSTITUTE SHEET (RULE 26)

LU

Ic LU

LU

F-

m,

D,

LU

F-

LU

WO 02/49993 WO 0249993PCT/USOO/26816 388 SUBSTITUTE SHEET (RULE 26)

LU

F-

LU

F-

LU

F-

L

m

LU

F-

LU

F-

LU

F-

LU

r I- I 1920 449.2216 1 450.2622 1921 1922 1923 1924 1925 0 FNx' 1 2.11 467.2121 1468.2447 467.2121 468.2424

LU

I-

D-

U-

479.2321 j 480.2583 C 3 81'0 400.2515 401.2748 412.2515 413.2805

LU

F-

LU

U)

I

-I

rn-~ Il

NI

LU

F-

LU

F-

LU

F-

LU

C14

LU

-J

LU

U

U'

LU

F-

LU

F-

LU

F-

LU

F-

LU

F-

LU

F-

LU

F-

LU

F-

LU

F-

I

LU

F-

I

LU

WO 02/49993 WO 0249993PCT/USOO/26816 SUBSTITUTE SHEET (RULE 26) t T CMP 1824 1825 1826 1827 1828 R3

R

H

H NR1 R2 R6 Rl or Riand R2 R3

X

X,-

TABLE

R~4 4113 4 CH3 4 CH 3 R5 /0 0 f0 0 0- R6 X1.

0 X-0 x 6

XG

Riri. time 1.91 2.17 2.2 2.09 2.1 Cmp. Mass 424.2151 514.252 508.2362 H+I ton Obs.

425.2364 5.2742 515.2186 509.2629 -j

I-

LU

SLU

LU

F-

C,,

M,

X

3 464.2464 1 465.2729

U)

I

I,

Ni

LU

F-

I

LU

I. I I I .733.

734 737 738 -739- 740

F,,

F

X,

X

X,

H

3

C

2 x 2 11 3 c 2

X

4 i-I x 4 CH 3 -01 0-X 0 0 0

X

0 1.99 471.2322 1472.2518 2.03-_1485.2.479. 486.2677 2.05 2.12 485.2479 486.2654

CIA

LU

S LU

LU

I-

D-

U-

204j 1.2948 1 48 0 323 447.305

H

3

C

H

3

C

0- 0 xi-

CH

3 .(0 1:991489.2228 448.31991 490.2399 z-l x 2 2.05 499.26351I500.2832 J J

LU

F-

I

LU

748 749_

H

3

C

H

3 c

H

3 0 Gi 3 x 4 x 4 1-1

CC

CH 3 x 4 It

C-

CH 3 d2l.2893 1 422.306 2.11 447.305 1448.3214 H 3 c

CH

3 H c

X

CH

3 ~1.9 4 35.305 1436.3263

LU

~c LU

LU

I-

D-

U-

2.05_ 46.29 1464.3266 x 2 2.05 1 449.3206 1 450.3442 .1

LU

F-

I

LU

F-

LU

F-

L

m

LU

F-

LU

F-

LU

WO 02/49993 WO 0249993PCT/USOO/26816 SUBSTITUTE SHEET (RULE 26)

LU

F-

LU

F-

LU

-r r -r r 800 801 803 804 805 Fq xi xf xf

F

X

H3 c

X

2

H

3

G

[IC

H

3

G

HaC H X2

H

3 C Z1

-X

x 2 X 4 x 4 0

X

4 (7 0r~ 0-

X

x X- _CH, NH2 0 rX 5

S-CH,

F

0 1.97 462=3159_ 463.4108 462.3159 46.3.4136 507.2133 508.3045

CD

U.'

r- L

D

cI) 2.01 1517.2199 5 .1 1 2.02j _1§52415634 2.02 1 667.22B1 1 668.3466 563.1584 1 564.27 L .L I.

806 1307 808 809 811

X,

F,

X1 Fq xi H I3 C2

H

3 Gc

H

3 c2

H

3 C2 C) 4 0 0 X, 0 O~e-)x 4 0 0 x 4 H 3 0 OH 3 x 4 x 5 S -CH, 0 CH 3 xs c 110 1.55-1,18-1- 2.03_ 2.03 2.02 2.01 521.2479 1522.3456 559.2635 473.2301 552.2875 560.3663 474.313 CD U' 517.21991f518.3132 501.2558 502.358 2.09 I 527.27151I528.381 r *1 T 817 818

F

X1

F

Kt

F

XI

x 2

H

3 0 H3 c H 3 c

O-\X

4 0 x-

C

CH 3 xa4 3H x 4

CH

0

X

x cl CH 0 0 X 6 0 2.05_ 521.2479 5237 2.09 1455.2504 456.3523

CD

U'

CI)

-2.,07 5_§q 198 520.3145 1.85 449.2841450.3776 513.2428 1.95 514.3442 I 4

I

-819-- 823

F

1

F

X,

x1 xi F

'N

X1 X1 H3C

H

3 c H 3 0

H

3 c2

H

3 c2 H 3 C0 x 4 x4

H

3 0

CH

3 0 4 0 2.04 1475.29 1 1 T 7 x x 5 CH 3 476.4023 538.3297 1.98 2.04 537.2239 457.2693 1458.3844

LU

I-

D-

U-

x 0 824 1 or, gi'3 OAl3n r4 A IIA L j j ~)I9..Jti)

LU

F-

L

m

LU

F-

LU

F-

LU

F-

LU

F-

LU

WO 02/49993 WO 0249993PCT/USOO/26816

-O

SUBSTITUTE SHEET (RULE 26)

LU

F-

LU

WO 02/49993 WO 0249993PCT/USOO/26816 SUBSTITUTE SHEET (RULE 26)

LU

F-

LU

F-

LU

F-

L

m

LU

F-

LU

F-

LU

F-

LU

F-

LU

F-

LU

F-

LU

F-

LU

F-

LU

F-

LU

(0

-J

I

p' -1*

U)

(0

-J

I-

w w) m

D'

U).

(0

-J

I-

w w) m

D'

U).

(0

-J

-I.

p' -t.

m-

D-

U-

(0

-J

I-

w w) mt

D'

U).

(0

-J

I-

w w) m

D'

U).

1 27 1028 1030 rxI

QX,

x 2 fHc' x 3 x 3 xp xp 0 O-Cfl oil

CH,

2.03 544.2872 543,2886 1544.3122 545.3313 2.03 J(jou&4 1 1,3I (0 -j zU

I-

-I-

w) m-

D-

U-

1031 1.98 1 529.2729 530.2999.

xi 1032 1033 Hic xz "3c 1.97 515.2936 16(.3203 (0

-J

I-

w w) m

D'

U).

Claims

24. JUN. 2008 15:25 NO. 016 8 P. 00 1. A compound of the formula: O ;Z N Ar N 0 Ii R RA RRA Sor a pharmaceutically acceptable salt thereof, wherein: m is 0, 1, or2; R 1 is chosen from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; R 2 is chosen from optionally substituted C 1 -Ca alkyl, optionally substituted C 3 Ca cycloalkyl, optionally substituted C 3 -Ca cycloalkyl(Ci -Cs)alkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -Ce alkynyl, haloalkyl, aminoalkyl, each of which may be unsubstituted or substituted with one or more substituents selected from oxo, hydroxy, alkoxy, amide, ester, cyano, acetoxy or nitro; R 3 RSA, R 5 and Re are independently selected from hydrogen, hydroxy, halogen, amino, cyano, nitro, haloalkyl, alkoxy, mono- or dialkylamino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted (cycloalkyl)alkyl; R4 is alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl each of which may be optionally substituted; or R4 is optionally substituted carbocyclic aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or heteroalicyclic group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 459 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:25 N~~6 .2 NO. 0168 P. 00 heteroatoms; Ar 1 is optionally substituted carbocyclic aryl or optionally substituted arylalkyl; and RA represents 0 to 3 groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Ce alkyl, C 2 -C 6 alkenyl, 02 -05, alkynyl, C, -CO alkocy, amino, and mono- or cii(C.sub. I -C.sub.B)akylamino. 2. A compound that is: c- 1 -butyl)-2-phenyl-5-(N,N-di[3,4-methylenedioxypheny methyl]) IND aminomethylimidazole; 1 -butyl)-2-phenyl-5-(1 -[N-{3,4-methylenedioxyphenylmethyl}-N- phenylmethy Q] amino) ethylimidazole; Nl 1 -uty)2-phenyl-4-methy-5-(N-[3,4-methylenedioxypheny-methylU-N- phenylmethyl) aminomethylimidazole; I -(1-Butyl)-2-(4-fluorophenyl)-5-(N-[3,4-.methylenedioxyphenylmethyl]-N- phenylmethyl) aminomethylimidazole; I -(lVButyI)-2-(4-fluorophenyl)-5-(N-[3 ,4-methylenedioxyphenymethyl]-N- phenylmethyl) aminomethylimidazole; 1 -Butyl)-2-(2-methoxyphenyl)-5-(N-[3,4-methylenedioxyphenyfmethyll-N- phenylmethyl) aminomethylimidazole 1 -Butyl)-2-(2-methoxyphenyl)-5-(N ,N-dif3,4-methylenedioxyphenylmethylj) aminometh-ylimidazole; 1 -Butyl)-2-(2-methylphenyl)-5-(N-13,4-methylenedioxyphenylmethyl]-N- phenylmethyl) aminomethylimidazole; 1 -Butyl)-2-(4-fluorophenyl)-5-(N,N-dj[3,4-methylenedioxyphenylmethyl]) aminomethylimidazole; 1 -Butyl)-2-(2-methylphenyl)-5-(N,N-dil3,4-methylenedioxyphenylmethyl]) amino-methylimidazole; 1 -Butyl)-2-(3-fluorophenyl)-5-(N ,N-di[3,4-methylenedioxyphenylmethyl) aminomethylimidazole; 1 -Butyl)-2-(3-methoxypheny9-5-(N-[3,4..methylenedioxyphenylmethyl]-N- phenylmethyl)-aminomethylimidazoie; 1 -Butyl)-2-phenyl-5-{1 -(N-[3,4-methylenedioxyphenylmethyll-N- phenylmethy 1) amino) ethylimidazole; 460 COMS ID No: ARCS-195737 Received by IP Australia: ime 15:18 Date 2008-06-24 24. JUN. 2008 15:25 N.U6 .2 NO. 0168 P. 22 o0 1 -Btl--hnl5(-34mtylndoyhnlehl--3 o d iohlorophenylj methyl) aminomethylimidazole; I-Cl -Butyl)--2-phenyl-5-(N, N-di(3,4-methylenedioxYPhelymethYl]) aminomethylimidazole; 1 uy)2peyl5(-34mthlndoyhnymty--34 methoxyphenylmethylfl-aminomethylimidaZOle, ci propyl}phenylmethylj)aminomethylimidazole; 1 .Butyl)-2-phenyl-5-N-[3,4-methylenedioxyphelylmetlyl]-N-L3,4- dichlorophenylethyl]) aminomethylimidazole; o) 1 -ButyI)-2-phenyl-5-(N-[3,4-methylenedioxypheny]mthyl-N-4-litrOPhelYl ci methyl]) aminomethylimidazole; 1-(l -Butyl)-2-phenyl-5-(N[3 ,4-methylenedioxyphenylnethyj-N-[4-{1 propyloxy) phenylmethyl]) aniriomethylimidazole; 1 -ButyI)-2-phenyl-5-(N-(3,4-methylenedioxyphenymethyl-N-quinol-6- ylmethylfl-aminomethylimidazole; 1 -Rutyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl]-N-12, 3- dic-hlorophenylmethyl])-aminomothylimidazole; 1 -Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl]4'J-[3,4- dimethylphenylmethyl])-aminomethylimidazole; I -(1-Buty)-2-phenyl-5-(N4[3,4-methyienedioxyphenyl]methyl-N-findan-2-ylD- aminomethylimidazolo; 1 -Butyl)-2-phenyl-5-(N-[3,4-methylenodioxyphenylmethyl]-N-[2-phenylethyl]) aminumethyfimidazole; 1 -Butyl)-2-phenyl-5-(N-[3,4-methyenedioxyphonylmethyl]-N-phenylmethyl) aminomethyk-imidazole; 1 -Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyJ-N- ethyl)aminomethylimidazole; 1 -Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenymethy -propyl]) aminomethyl-imidazole; 1 -8utyfY-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl-N-[1 -butyl]) am inomethyl-imidazole; 1 -BuWIl)-2-phenyks5-(N4[3,4-methylenedioxyphenylmethyq]-N- cycloheptylmethyl) amino-methylimidazole; 461 COMS ID No: ARCS-i 95737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:26 NO. 0168 P. 23 oo 1<-1 -ButyI)2-pheny5(N-434methylnedixyphenylmthy-N- o isobutyl)aminomethyl-imidazole; 1-(1 -Butyl)y2-phenyl-5-(N4S3,4-methylenedioxyphenylmethyl]-N-[2- ;Z cyclopontylethyl]) 2mino-methylimidazole; 1 -Butyl)-2-phonyk-5-(N-[3.4-methylenedioxyphelylmethyl]-N-(3- cyclopentypropy]) amino-methylimidazols; 1 -Butyl)-2 -phenyl-5-(N-[3,4-methylenedioxyphnylmethyl-N-[1 -n-octYlj) Ci aminomethyl-imidazole; IND1 -Butyl)-2-phenyI-5-(N-[3,4-methylenedioxyphenylmethy]-N- 0 cyclopropylmethyl) amino-methylimidazole; o1 -Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylmethyl]-N- 0 cycloperitylmethyl) amino-metliylimidazole; 1 -Butyl)-2-phenyl-5-N-[3,4-methylenedioxyphenymethyl]-N- cyclohexylmethyl) amino-methylimidazole; 1 -Butyl)y2-phenyl-5-(N413 1 4-mnethylenedioxyphenylmethyl]-N-t-amyl]) aminomethylimidazole; 1 -Butyl)-2-phenyl-5-(N-[3,4-methylenedioxypheny[methyl-N-1 -{3-methyl)b utyl)]amino-methylimidazole; 1 -Butyl)-2-phenyl-5-(N-f3 1 4-methylenedioxyphenylmethyl]-N-[l-{2,2- dimethyl}buty[]) aminomethylimidazole; 1 -Butyl)-2-phenyl-5-(N-[34-methylenedioxyphenylmethyl]-N-methyl) aminomethylimidazole; 1 -Butyl)-2-phenyl-5-(N-[3,4-methylenedioxyphenylnethylp-N-(2- thiophenylmethyl]) amino-methylimidaole; 1 -Butyl)-2-phenyl-5-.(N-[3,4-methylenedioxyphenylmethy-N-pindo-s.. ylmethyl]) amino-methylimidazole; 1-(l -Butyl)-2-phenyl--5-(N-[3,4-methylendioxyphenylmethyl]-N-[{i -methylindol- aminomethylimidazole; 1 -Dutyl)-2-phenyl-5-(N-[3,4-methylened ioxyphenyljmethyl-N-[4-hydroxy-2- Ghlorophenyl]-methyl) aminoniethylimidazole; 1 -Butyl)-2-(3-fluorophenyl)-5-(1 -[N-{2-ohloro-4-hydroxyphenyllmethy[-N- pheny~methy]) aminoethylimidazole; 1-.(1-Butyl)-2-phenyl-5-(N4[3,4..methylenedioxyphenyqmethyl-N-[2 ,3- methyl) aminomethylimidazole; 462 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:26 NO. 0168 P. 24 00 -uy--4furpey)6( [-,4mtyeeixpeymeh-N 0 Btl2(-loohnl-- [~34mtyeeix~e~~ehlN o phenylmethyll-amino) ethylimidazole; Ni 1 uy)2peyl5(-hnlehy--34dmtoxpeymty] ;Z aminomethylimidazole; 1 uy)2pey--N-6clr-,-ehlneixpeymty]N phenylmethyl)-aminomethylimidazole; Bis-benzo[1 ,3]dioxol-5-ylmethyl-(3-butyl-2,5-diphenyl-3H-imidazol-4-ylmethY 1)- ci amine; INDBenzo[1l,3]dioxol-5-ylmethyl-benzy-3-butyl--(4-methoxy-PheYl)-2-PhenflY-3 H-imidazol-4-ylmethyLJ-amine; o Benzo[1 ,3]dioxol-S-ylmethyl-benzyl-[3-b utyl-2-(2--methoxy-pheflyl)-5-phely-3 0 H-imidazol-4-ylmethyl)]-amine; Benzol ,3]dioxol-5-ylmethyl-benzyl-(I -(3-butyl-2,5-diphenyl-3H-imidazol-4-y Q)- pentyll-amine; Benzo[l ,3]dioxol-5-ylmethyl-benzyl-[1 -(3-butyl-2, 5-diphenyi-3H-imidazol-4-y I)- ethyl]-amine; Benzo(1 ,3]dioxol-5-ylmethyl-benzyl-[3-butyl-5-(4-fluoro-phenyQ-2-phenyl-3H imidazol-4-ylmethyl]-amine; ,3Jdioxol-5-ylmethyl-amino)-methyl)-2,4-dipheny-imidazo I -yl}-butan-1-ol; 1 -Butyl)-2-(4-fluorophenyl)-5-(1I NN-di[3,4-methylenedioxyphenylmethylla mino)ethylimidazole; or a pharmaceutically acceptable salt, prodrug or hydrate thereof. 3. A compound according to claim I of the formula: RR4 TN RRA 0 463 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:26 NO. 0168 P. wherein RA, Arl, RI, R 2 R 3 and R 4 are as defined in clam 1. 4. A compound according to claim 1 of the formula; wherein: Ri is hydrogen, C, -Cy alkyl, halogen or phenyl optionally substituted with Ci -Cs alkyl, C1 -Ce alkoxy, halogen, hydroxy, amino, or mono- or di(Ci C6) alkylamino; Rz is C, -Cs alkyl or C3 -Ca cycloalkyl; and R 3 is hydrogen or C 1 -C 7 alkyl. A compound according to claim 1 of the formula: wherein: Ar 1 is phenyl which is optionally substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, 464 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:27 NO.0168 P. o trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci -C alkyl, C 2 -C alkenyl, C 2 o Cc alkynyl, Ci -C 6 alkoxy, amino, and mono- or di(Ci -Ce) alkylamino; SR1 is hydrogen, C1 -CT alkyl, halogen or phenyl optionally substituted with Cl h Ce alkyl, C, -Ce alkoxy, halogen, hydroxy, amino, or mono- or di(Ci C 6 )alkylamino; R 2 is Ci -Ce alkyl or C 3 -C8 cycloalkyl; and ifl R 3 is hydrogen or C 1 -C 7 alkyl; and N R4 is C, -Cs alkyl, C 3 -Ca cycloalkyl, or (C 3 -Ce cycloalkyl) C 1 -C 3 alkyl, each of I which is unsubstituted or substituted with one or more substituents selected C from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, Shydroxy, acetoxy, C 1 -Ce alkyl, C 2 -C 6 alkenyl, C 2 -Cs alkynyl, C -C 6 alkoxy, C amino, and mono- or di(C 1 alkylamino. 6. A compound according to claim 1 of the formula: R1 NT /-R4 Ar N N I R2 R3 wherein: Art is phenyl which is optionally substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Cc alkyl, C 2 -C 6 alkenyl, C 2 C 6 alkynyl, C 1 -Cs alkoxy, amino, and mono- or di(Cl -Cs)alkylamino; R 1 is hydrogen, C1 -C 7 alkyl, halogen or phenyl optionally substituted with Ci C 6 alkyl, C1 -C 6 alkoxy, halogen, hydroxy, amino, or mono- or di(CI -C 6 alkylamino; R 2 is C1 -CS alkyl or C 3 -Cs cycloalkyl; and R 3 is hydrogen or C, -C 7 alkyl; and 465 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:27 NO. 0168 P. 27 R4 is phenyl, phenyl(Cl -C 4 )alkyl, thienyl, pyridyl, or pyrimidyl, each of which is optionally substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci -C 6 alkyl, C2 -Cs alkenyl, C2 -Cs alkynyl, C, -Ce alkoxy, amino, and mono- or di(Cl -C 6 alkylamino; or R 4 is a bicyclic oxygen-containing group of the formula wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C1 -C6 alkyl, C 2 alkenyl, Cz -Cs alkynyl, Ci -C 6 alkoxy, amino, and mono- or di(Ci -C6) alkylamino. 7. A compound according to claim 1 of the formula: wherein: Arl is phenyl which is optionally substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Cs alkyl, C 2 -Cs alkenyl, C2- Ce alkynyI, C, -Ca alkoxy, amino, and mono- or di(C 1 -Ce) alkylamino; Ri is hydrogen, methyl, ethyl, or phenyl; 466 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:27 NO, 0168 P. 28 o R 2 is C 3 -Ca alkyl or C3 -C 8 cycloalkyl; and o R3 is hydrogen or methyl; and SR 4 is C 1 -CB alkyl, Cs -Ca cycloalkyl, or (C 3 -C 8 cycloalkyl) C1 -C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents 1 selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, cil haloalkyl, hydroxy, acetoxy, C 1 -C 6 alkyl, C2 -Ce alkenyl, C 2 -Cs alkynyl, C, -Cs iV alkoxy, amino, and mono- or di(Ci -Cs) alkylamino. o N ArN N R2 R3 0 0 wherein: Ar is phenyl which is optionally substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Cs alkyl, C2 -C alkenyl, C2 Cg alkynyl, Ci -CB alkoxy, amino, and mono- or di(Ci -Ce) alkylamino; R 1 is hydrogen, methyl, ethyl, or phenyl; R 2 is Ca -Cs alkyl or C3 -Ca cycloalkyl; and R 3 is hydrogen or methyl: and R 4 is phenyl, phenyl(C, -C. 4 )alkyl, thienyl, pyridyl, or pyrimidyl each of which is optionally substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, Ci -Cs alkyl, C.2 -CG alkenyl, Cz -Ce alkynyl, C11 -Co alkoxy, amino, and mono- or di(CI -C 6 )alkylamino; or R 4 is a bicyclic oxygen-containing group of the formula: 467 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:27 NO. 0168 P. 29 00 00 N o c or RA wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, I trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Ce alkyl, C 2 C6 alkenyl, C 2 -C6 alkynyl. C1 -C6 alkoxy, amino, and mono- or di(Cj -C6) alkylamino. 9. A compound according to claim I of the formula: N~ R, N- Ar N N I R2 R3 0 0 or a pharmaceutically acceptable salt, prodrug or hydrate thereof, wherein: Ar, is phenyl which is optionally substituted or substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Cs alkyl, C2 -CB alkenyl, C2 CG alkynyl, C, -Cc alkoxy, amino, and mono- or di(Cl -Ca) alkylamino; R, is selected from i) hydrogen, halogen, hydroxy, amino, Ci -Cc alkoxy, mono- or di(C, -Ce)alkylamino, cyano, nitro, haloalkyl, and ii) C 1 -Ca alkyl, C2 C 8 alkenyl, C2 -Cs alkynyl, 03 -C3 cycloalkyl, and (C3 -C 8 )cycloalkyl) C, -C 3 alkyl, each of which may be unsubstituted or substituted by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, alkoxy, amino, and mono- or di(Cl -C 8 )alkylamino; or R, is selected from pheny), pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyrazinyl, each of which may be optionally substituted or 468 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:28 NO. 0168 P. 00substituted with up to four groups independently selected from halogen, nitro, o cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Ca alkyl, C2 -C 6 alkenyl, C2 -Ce alkynyl, C, -Cs alkoxy, amino, and mono- or di(C, Ce) alkylamino; R 2 and R 3 are independently selected from i) hydrogen, halogen, hydroxy, amino, Ci -Cc alkoxy, mono- or di(Cj -Cs)alkylamino, cyano, nitro, haloalkyl, and ii) Ci -C 6 alkyl, C2 -Ce alkenyl, C 2 -Cs alkynyl, C 3 -Cs cycloalkyl, and (C3 Ca cycloalkyl) C 1 -Cs alkyl, each of which may be unsubstituted or substituted IN by one or more of halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, N~ haloalkyl, hydroxy, acetoxy, C, -C6 alkoxy, amino, and mono- or di(C, -Ce) alkylamino; and 0 R 4 is C, -Ca alkyl, C 2 -C 6 alkenyl, C2 -C 6 alkynyl, Ca -C cycloalkyl, (Cs -Ca cycloalkyl) Ci -C3 alkyl, each of which may be unsubstituted or substituted with one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Cs alkyl, C2 -Cs alkenyl, C2 C6 alkynyl, C 2 -C 6 alkoxy, amino, and mono- or di(, C, -Cs alkylamino; or R 4 is phenyl, thienyl, pyridyl, or pyrimidyl, each of which is optionally substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Ce alkyl, C2 -Cs alkenyl, C2 -Ce alkynyl, C 1 -Cs alkoxy, amino, mono- or di(Cj -Cs) alkylamino, carboxylic acid, esters of carboxylic acids, aminocarbonyl, mono or di(Ci -Cs )alkylaminocarbonyl, N-(C 1 -C e )alkylsulfonylaminocarbonyl, 1- azetidinyl, 1-pyrrolidinyl, and 1-piperidyl; or R4 is a bicyclic oxygen-containing group of the formula: o o/ RA wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Cs alkyl, C2 -Cs alkenyl, C2 alkynyl, C, -Cs alkoxy, amino, and mono- or di(C, Ce)alkylamino. 469 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:28 NO. 0168 P. 31 00 0 o 10. A compound according to claim 9, wherein the compound exhibits an IC.so of 1 SuM or less in an assay of C5a mediated chemotaxis or calcium mobilization. 11. A compound according to claim 9 wherein: R1 is hydrogen, methyl, ethyl, or phenyl; I R is C3 -CB alkyl or C3 -Ca cycloalkyl; Rs is hydrogen or methyl; and ID R4 is Ci -Ca alkyl, C2 -CG alkenyl, C 2 -Cs alkynyl, Cz -CB cycloalkyl, and (C 3 -C8 cycloalkyl) C 1 -C3 alkyl, each of which may be unsubstituted or substituted with o one or more substituents selected from halogen, nitro, cyano, trifluoromethyl, Ci trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -Cs alkyl, C2 -Ce alkenyl, C 2 C6 alkynyl, Ci -C 6 alkoxy, amino, and mono- or di(C 1 -C 6 )alkylamino. 12. A compound according to claim 9, wherein; R 1 is hydrogen, methyl, ethyl, or phenyl; R 2 is C 3 -C8 alkyl or C 3 -Cs cycloalkyl; R 3 is hydrogen or methyl; and Fq is phenyl, phenyl(Ci -C4)alkyl, thienyl, pyridyl, or pyrimidyl, each of which is optionally substituted with up to four groups independently selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -C 6 alkyl, C2 -Ce alkenyl, C2 -C 6 alkynyl, Ci -Cs alkoxy, amino, and mono- or di(Ci -Ce) alkylamino. 13. A compound according to claim 9, wherein: R is hydrogen, methyl, ethyl, or phenyl; R 2 is C 3 -C 8 alkyl or C3 -Cs cycloalkyl; R 3 is hydrogen or methyl; and R4 is a bicyclic oxygen-containing group of the formula: 470 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 JUN. 2008 16:10 O 27 P NO. 0227 P. 4 00 wherein RA represents 0 to 3 groups selected from halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, haloalkyl, hydroxy, acetoxy, C, -C 6 alkyl, C 2 IND C 6 alkenyl, C 2 -C 6 alkynyl, C, -Cs alkoxy, amino, and mono- or di(C., Cs)alkylamino. 14. A compound according to claim 9 in which Ar 1 is phenyl, R, is hydrogen, R 2 is phenyl, R 3 is hydrogen, R4 is phenyl, and Ar 2 is benzo[1 A compound according to claim I which has the formula N 0 wherein R 2 and R 4 are defined as follows: Ar, R 2 R phenyl -petyl benzy] phenyl butyl benzyl phenyl butyl -benzo[1I,3]d oxyl-57ylmeth I penyl butyl 3-cyclopentyl-methyl phenyl buty! cyclopentyl-methyl 2-fluoro-phenyl butyl benzy[ phenyl butyl cyclohenylmethyl Phanyl butyl thionhen-2-ylety phenyl butIyl butyl phenyl butyl propyl phenyl butyl 13-4-dichloro-benzyL pheniyl butyl I3-4-dimethoxy-benzyl COMS ID No: ARCS-195916 Received by IP Australia: Time 15:57 Date 2008-06-25 24. JUN 2008 15:29 N.~6 .3 i NO. 0 16 8 P. 113 ph nyl phenyl butvl 2-(3,4,dichoro-phenl)-ethyl -butyl b utvl 4-propy- Isobutyl 4-proyI- benzyl benzyl phenyl butl 2-methoxy-ohenl Iyy 7-methoxv-DheflVI butvl -meh-Dhenyl-~.*t 7 4-methoxy-pheflyl bu!yi butyl 4-fluoro-phenyl benzyI benzo[1 benzy] enzol 1 31dloxql-5-ylmethyl BenzvI benzo[1 benzytl benzo I 5 9~mpthvI-nhenvI buM 2-methyl-phenvI butyl 2-methyl-pheny 3-fluoro-phenyl butyl butVl 1 hntvl 1 2-methox-phenyl butyl benzyl Naphyl butyl benzyl phenyl butyl quinoline-7-yi-methyl pheny1 butyl in an-2-Yl henyl buy 2,2-dimethylpropyl -phenyl butyl 3-methyl-butl 4-chloro-phenyl Butyl benzyl phenyl buityl 2-cyclopentyl-ethyl phenyl butyl _2 2-ImethyI-bul -phenyl butyl 3,4-dimethyl-beflzyl phenyl butyl o Iy phenyl butyl cycloheptyl-methyl phenyl bu Il cyclopropyl-methyl phenyl butyl Cylcopropyl-methyl Phenyl 3-methyl-butyl Benzyl Phenyl Butyl 2-chloro-4-hydrwxybenzyl 2-methyl-3-fluoro- Butyl Bny phenyl Phenyl Butyl 4-hudrqxynetyl-belzyl; and 4-fluoro-phenyl Butyl Phej y-ehyl 16. A compound according to claim I which has the formula: 472 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 2008 15:29 N.06 .3 NO, 0168 P. 34 00 wherein oR 4 is cyclobutyl-methyl, pentyl, hexyl, 4-methyl-.pentyl, 3,3-dimethyl-butyl, 2- ethyl-butyl, heptyl, cyclohexyl-ethyl, 2-phenyl-benzyl, 3-methyl-benzyl, 4- methyl-benzyl, 2-methyl-benzyl, 3-fluoro-benzyl, 4-fluoro-benzyl, 2-fluora- benzyl, 4-ethyl-benzyl, 3,5-dimethyl-benzyl, 2,3-dimethyl-benzyl, 2, benzyl, 2,4-dimethyl-benzyl, 3-methoxy-benzyl, 4-methoxy-benzyl, 2-methoxy- benzyl, 3-fluoro-4-methyl-benzyl, 2-methyl-3-fluoro-benzyl, N benzyl. 3-chioro-benryl, 4-chloro-benzyl, 2-chloro-benzyl, 3,4-difluoro.-benzyl, 2,3-dmfuoro-benzyl, 2, 5-difluoro-benzyl, 2,4-difluoro-benzyl, 4-isopropyl-benzyl, 3-ethoxy-benzyl, 4-ethoxy-benzyl, 2-ethoxy-benzyl, phenyl-ethyl, naphth-1 -yl- 0 methyl, 4-methylsulfanyl-benzyl, 3-fluoro-4-methoxy-benzyl, 3-methyl-4-chloro- Ci benzyl, 3-chloro-4-fluoro-benzyl, 4-butyl-benzyl, 4-tert-butyl-benzyl, 4-propoxy- benzyl, 4-isopropoxy..benzyl, 4-ethylsulfanyl-benzyl, 2,3,5,6-tetrafluoro-benzyl, 2,4,6-trilluoro-benzyl, 2,3,6-trifluoro-benzyl, 2-chloro--fluoro-benzyl, 2,4- dimethoxy-phenyl-ethyl, 2,6-difluoro-phenyl-ethyl, 4-rnethylsulfanyl-phenyl- ethyl, benzo[1 ,3]dioxol-5-ylethyl, 2-chloro-5-methylsulfanyl-benzyl, nethyl-benzyl, 2-bromno-3-methyl-benzyl, 2-chloro-5-trifluoromethyl-benzyl, 2- methylsulfanyl-benzyl, 2-bromo-3,4-dimethoxy-phenyl-ethyl, bromo-phenyl-ethyl, 2,3-dimethoxy-phonyl-ethyl, 2,3-difluoro-phenyl-ethyl, 3- iodo-4-methyl-benzyl, 4-lodo-phenyl-ethyl, thiophen-2-yl-rnethyl, 4-methyl- phenyl-ethyl, 2-methyl-phenyl-ethyl, 2-phenyl-propyl, 2-fluoro-phenyl-ethyl, 2- phenyl-butyl, 2-o-tolyl-propyl, 3-methoxy-phenyl-ethyl, 4-methoxy-phenyl-ethyl, 4-ethoxy-phenyl-ethyl, 2-ethoxy-phenyl-ethyl, 3-chioro-phenyl-ethyl, 2-(4- methoxy-phenyl)butyl, 2,5-dimethoxy-phenyl-ethyl, 4-trifluoromethyl-phenyl- ethyl, 2,4-dichioro-phenyl-ethyl, 3-bromo-phenyl-ethyl, 4-bromo-phenyl-ethyl, 2-bromo-phenyl-ethyl, 2,3-dimethoxy-benzyl, 2,5-dimethoxy-benzyl, 2- methoxy-4-chloro-benzyl, 3-bromno-4-methyl-benzyl, 3-bromo-4-fiuoro-benzyl, 3-iodo-benzyl, or 4-iodo-benzyl, or 2-iodo-benzyl. 17. A compound according to claim I which has the formula 473 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN-2008 15:29NOU6 2. NO. 0 16 8 P. 35 00 N 1 R N 0 wherein R 4 is butyl, iso-butyl, cyclobuty-methyl, 3-methyl-butyl, 2,2-dimethyl- o propyl, cyclopentyl-methyl, hexyl, 2--methyl-pentyl, 3,3-dimethyl-butyl, 2-ethyl- o butyl, 2,2-dimethyl-butyl, cyclopentyl-ethyl, cyclohexyl-methyl, heptanyl, cyclohexyl-ethyl, cycloheptyl-methyl, cyclopentyl-propyl, octul, 3-methyl- benzyl, 4-methyl-benzyl, 2-fluoro-phenyl, 3,4-dimethyl-benzyl, 2,3-dimethyl- benzyl, benzo[1 ,3]dioxol-5-ylmethyl, methyl-sulfanyl-benryl, benzyl, 2,5-dimeth oxy-benzyl, 2,5-d ichloro-benzyl, 3-bromo-benzyl, 4-bromo- benryl, 2-bromo-benzyl, 2-phenyl-ethyl-benzyl, 2,4,O-trifluoro-benzyl, 2,3,6- trifluoro-benzy, 3 ,4-dimethoxy-pheny-ethyl, benzo[1 naphtha-2-y-ethy, 4-rrethyl-phenyl-ethyl, 3-rnethoxy-phenyl-ethyl, 4-methoxy- phenyl-ethyl, 4-chloro-phenyl-ethyl, 4-lodo-phenyl-ethyl, 4-bromo-pheny-ethyl, 4-methylsulfanyl-pheny-ethyl, 2, 6-difluoro-benzy, 2-methylsulfanyl-benzyl, 2- trifluoromethoxy-benzyl, 2,5-di-(2,2,2-trifluoro-ethoxy)-benzyl, 2-bromo-3- methyl-benzyl, 2-chloro-5-methylsulfanyl-benzyl, napth-1 -yl-methyl, or 9H- fluoren-3-yl-methyl. 18S. A compound according to claim I which has the formula 474 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN. 203 15:30 O 16 .3 NO. 0168 P. 36 00 N 1 R Cl FN 0 IN0 ciwherein R 4 is 2-ethyl-butyl, 2,2-dimethyl-butyl, cyclopentylethyl, o cyclohexyLmethyl. heptariyl, 3-methyl-butyl, benzo[l ,3]dioxol-5-ylmethyl, 4- o methylsulfanyl-benyl, 2,5-dimethoxy-benzy, 2,4-dimethoxy-benzyl, 3-methoxy- pheryl-ethyl, 4-methoxy-phenyl-ethyl, 4-iodo-phenyl-ethyl, 4-methylsulfanyl- ethyl, 2-methylsulfanyl-benzyl, 2,3-dihydro-benzofuran-5-ylmethyl, 3,4- dimethoxy-phenyl-ethyl, 3-methoxy-4-ethoxy-pheny-ethyl, or napth-2-yl-ethyl- 19. A compound according to claim I which has the formula N 0 0- wherein R 4 is naphth-2-yI-methyl, 3-chloro-4-methyl-benzyl, 2,3-dihydro- 4-difluoromethoxy-benzyl, 2-fluoro-phenyl-ehyl, 2- methoxy-phenyl-ethyl, 2-ethoxy-pheny-othyl, 2-bromo-pheny-ethyl, dimethoxy-phenyl-ethyl, 2,3-riimethoxy-phenyl-ethyl, 2,4-dimethoxy-phenyl- ethyl, or 2-allylsulfanyl-pyrid in-3-ylmethyl. A compound according to claim 1 which has the formula 475 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 24. JUN-200 15:30 O 16 .3 NO. 0 16 8 P. Ij 7 wherein Arl, R, and R4 are defined, as follows: Arl iR phenyl 4-cyano-phenyl butyl 3-methoxy-phenyl phenyl butyl 3-methoxy-phenyl phenyl benzyl 2-methoxy-phenyl pheriYl butyl 2-methoxy-phenyl phenyl Benzyl 4-methoxy-phenyl 4-(cooh)-benzyl phnlphenyl benzyl phenyl 4-methoxy-benzyl phenyl .cyclohexyl-methyl phenyl methyl phnlphenyl ethyl phenyl______ [phenyl propyl; and phenyl_______I phenyl butyl 21. A compound according to claim 1 which has the formula 476 COMS ID No: ARCS-195737 Received by IP Australia: Time (l1:m) 15:18 Date 2008-06-24 JUN.2008 16:11NO 27 NO. 0227 P. wherein Ar 1 R- 3 and R 4 are defined, as follows: Arl R R 4 phenyl methyl benzyl 4-fluoro-phenyl methyl benzo[1 4-fluoro-phenyl methyl bny 4-fluoro-phenyl methyl cyclopentyl-methyl 4-lurpIenl methyl 2-chloro-4-hydroxy-benzyl phenyl I methyl benzo[1 ,31dioxol-5-ylmethyl phenyl methyl 2-chloro-4-hydroxy-benzyl phenyl buyj cycloh xymethyl phenyl methyl 4-hyd oybenzyl phenyl btlbenzyl; and Lphenyl Ibutyl [bu! I 22. A compound according to claim 6 wherein Ar, is phenyl, R, is phenyl, R 2 is butyl, R 3 is hydrogen, and R 4 is propyl. 23. A compound according to claim 6 wherein Ar, is phenyl, R, is phenyl, R 2 is butyl, R 3 is hydrogen, and R 4 is phenyl. 24. A compound according to claim 6 wherein Ar, is phenyl, III is tert-butyl, R 2 is butyl, R 3 is hydrogen, and R 4 is phenyl. A compound according to claim 6 wherein Ar, is phenyl, R1, is tert-butyl, R 2 is butyl, R 3 is hydrogen, and R 4 is benzo[1 477 COMS ID No: ARCS-195916 Received by IP Australia: Time 15:57 Date 2008-06-25 24. JUN. 2008 15:30 NO. 0168 P. 39 0 0
26. A compound according to claim 6 wherein Arn is phenyl, R1 is tert-butyl, R, 2 is O butyl, Rs is hydrogen, and R 4 is 2-chloro-4-hydroxy-phenyl. S27. A compound according to claim 6 wherein Art is phenyl Ri is tert-butyl, R 2 is butyl, R 3 is hydrogen, and R 4 is 3-chloro-4-hydroxy-phenyl.
28. A compound according to claim 6wherein Ar, is phenyl, R 1 is 4-methoxy- C phenyl, R 2 is butyl, R 3 is hydrogen, and R4 is propyl. C" 29. A compound according to claim 6 wherein Arl is phenyl, R 1 is 4-fluoro-phenyl, o R 2 is butyl, Ra is hydrogen, and R 4 is propyl. 0 A compound according to claim6 wherein Arl is phenyl, Ri is 4-fluoro-phenyl, R 2 is butyl, R3 is hydrogen, and R 4 is phenyl.
31. A compound according to claim 6 wherein Ar is phenyl, R.sub.1 is phenyl, Rz is butyl, Ra is hydrogen, and R 4 is benzo[1,3]dioxol-5-yl.
32. A compound according to claim 6 wherein Ari is phenyl, Ri is phenyl, R2 is butyl, R3 is hydrogen, and R 4 is 4-acetoxy-phenyl.
33. A compound according to claim 6 wherein Ar is phenyl, Ri is phenyl, R 2 is butyl, R 3 is hydrogen, and 4-carboxy-phenyl.
34. A compound according to claim 6 wherein Ar is phenyl, R, is phenyl, R2 is butyl, R 3 is butyl, and R 4 is phenyl. A compound according to claim 6 wherein Arl is phenyl, R 1 is phenyl, Rz is butyl, R a is methyl and R 4 is phenyl.
36. A compound of the formula 478 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 JUN.2008 16:11NO 27 .6 NO. 022) P. 6 wherein Arn, R. 1 R 2 and R 4 are defined, as follows: Arl R___R2__F4 phenyl hydrogen bu 4-acetoxy-benKyl phenyl hydrogen buy 2-phenoxy-benzyl phenyl hydrogen butyl 4-benzyioxy-phenyl- ___ethyl phenyl hydrogen buy 2-phenoxy- henyi-ethyI phenyl -hydrogen buy Phenoxy-ethyl phenyl hydrogen buy 3.-(2-fluoro-phenyl)-allyI phenyl hydrogen buy 3-methyf-phenoxy-ethyl phenyl hydrogen butyl 3-methoxy-phenoxy- ethyl phenyl hydrogen buty'l 3-(2-5-dimethoxy- phenyl hydrogen butyl 3-(3,5-dimethoxy- phenyl)- Ilyl phenyl hydrogen butyl 3-(3-trifluoromethyl- pheny)-allyl phenyl hydrogen butyl 3-(2 allyl phenyl hydrogen butyl 3-(3-bromo-phenyl)-allyl pheny h hdrogen buy 3-thiophen-3-yl-altyl phenyl hyd :ogen buy 3-furan-2-y-ally phenyl hydrogen butyl 3-(44-sopropyl-phenyl)- ____allyl phenyl hydrogen butyl 2-phenyl- cyclopropylmethyl phenyl hydrogen buy 2- ,fluoro-3-phenyl-alyL_ phenyl hydrogen butyl 2-cyclopentyf-2-phenyI- _y d ro g e e th y l phen hdrognutyl 2,2-diphenyi-ethyl phenyl hydrogen butyl 2-cyclohenxyr-2-phenyl- ethyl phenyl hydrogen buX 2-phenyU-ethyl-benzyl phenyl hydrogen butyl 3-(2-fluoro-5-bromo- I Rhenyl) allyl 479 COMS ID No: ARCS-195916 Received by IP Australia: Time 15:57 Date 2008-06-25 24. JUN. 208 15:31 O 16 .4 NO, 0168 P. 41 phenyl)-ajjyl phenyl hydrogen butyl 3-(2-fluoro-4-brorfo- phenyl hydrogen butyll 3(-lo4lor phenyl hydrogen butyl 3-(2-flucro-4-chloro- phenyl hydrogen butyl 3-(2-fthoro--bhlro- _________phenyl)-allyl pheloo hydrogen butyl 2-(4-ethylphenoxy)-- 4-fluoro- hydrogen butyl 2-phenoxy-phyi-eyl phenyl phenyl jphenyl 4-aminocarboxy-benzyl phenyl 4-dimethylamino-ethoxy- butyl bultyl phenyl phenyl butyl z phenyl phenyl butyl H N 0 phenyl butyl butyl phenyl butyl butyl phenyl 4-d imethylaminoethyl- but-yl butyl phenyl 480 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 JUN 2008 16:11NO 27 .7 NO. 022) P. phenyl Butyl butyl phenyl phenyl butyl 4-methyl-phenyl- pheny] phenyl 3-4-acetoxy-berizyl ethoxycarbon yi-proyl~ phenyl phenyl 3- benzo[1 ethoxycarbon ylmethyl xy2-PYLpy_ phenyl phenyl 3- 2-chloro-4-hydroxy- ethoxycarbon benzyl phenyl phenyl 3- 4-methoxy-benzyl ethoxycarbon phenyl phenyl 3- 4-dimethylamino-benzyl ethoxycarbon phenyl phenyl pheyl pheyl4-hydroxy- 4-hydroxymethyl-benzy phenyl pheny pheyl pheyl4-hydroxy- Benzo[1 ,31dioxol-5- phenyly phenyll ylet pheyl pheyl4-hydroxy- 2-chloro-4-hydroxy- pheny pheyl l benzvl pheyl pheyl4-hydroxy- 4-methoxy-benzyl phenyl bhtny phel heyl4-hydroxy- 4-dimethyl-benzyl phenyl phenyl; Benzo[1 OH ylmethyl 0 henyl 4-fluoro-phenyl butyl butyl phenyl 4-chioro-phenylbuy _henyI 4-methoxy-phenyl buyluy and Phenyl 2-methoxy-phenyl Buy pyl]
37. A compound according to claim 6 wherein Ar, is phenyl, RI is phenyl, R 2 is butyl, R 3 is methyl, and R 4 is 4-carboxy-phenyl. 481 COMS ID No: ARCS-195916 Received by IP Australia: Time 15:57 Date 2008-06-25 24. JUN. 2008 15:31 NO. 0168 P. 43
38. A compound according to claim 6 wherein Arl is phenyl, Ri is phenyl, RP is propyl, Rs is hydrogen, and R 4 is 4-amino-sulfonyl-phenyl,
39. A compound according to claim 1 which is represented by the formula: A compound of the formula wherein R 4 is ethyl, propyl, or butyl.
41. A compound according to claim 1 which has the formula 482 COMS ID No: ARCS-195737 Received by IP Australia: Time 15:18 Date 2008-06-24 JUN. 2008 16:12 NO. 0)227 P. 8 00 O R, N n R 0 o 0 wherein Ri is phenyl; R 2 is ethyl, propyl, or pentyl, and R4 is butyl.
42. A pharmaceutical composition comprising a compound of any one of claims 1 to 40 or a prodrug or hydrate thereof and a pharmaceutically acceptable carrier therefor.
43. A method for treating a patient suffering from rheumatoid arthritis, psoriasis or bronchial asthma comprising administering to the patient an effective amount of a compound or composition of any one of claims 1 to
44. A method for treating a patient suffering from Alzheimer's disease, myocardial infarction or artherosclerosis comprising administering to the patient an effective amount of a compound or composition of any one of claims 1 to 483 COMS ID No: ARCS-195916 Received by IP Australia: Time 15:57 Date 2008-06-25